# 2025年11月14日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 减量Enfortumab Vedotin、治疗连续性与尿路上皮癌患者的生存

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231504](https://pubmed.ncbi.nlm.nih.gov/41231504)
**期刊：** JAMA oncology
**PMID：** 41231504
**DOI：** 10.1001/jamaoncol.2025.4566

### 第一部分 原文与翻译

**英文原标题：** Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究基于其标题判断，旨在探讨在尿路上皮癌治疗中，采用剂量减少的Enfortumab Vedotin策略对维持治疗连续性及患者生存结局的影响。研究的核心价值在于解决了临床实践中的一个重要问题：如何在管理Enfortumab Vedotin相关毒副反应的同时，最大化其治疗效益。该研究可能揭示了通过适当的剂量调整，患者能够更长时间地接受治疗，从而可能改善其总体生存率，为临床医生提供了优化治疗方案、平衡疗效与安全性的重要参考。由于缺乏摘要，本研究的具体设计和结果尚不明确，但其提出的临床问题具有高度的现实指导意义。

---

## 2. 纳武利尤单抗联合伊匹木单抗治疗晚期错配修复缺陷/高微卫星不稳定性非结直肠癌：一项非随机临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231502](https://pubmed.ncbi.nlm.nih.gov/41231502)
**期刊：** JAMA oncology
**PMID：** 41231502
**DOI：** 10.1001/jamaoncol.2025.4721

### 第一部分 原文与翻译

**英文原标题：** Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial.

**英文摘要原文：**
IMPORTANCE: Mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) cancers constitute one of the most immunogenic tumors. Anti-programmed cell death 1 (PD-1) monotherapy provides durable responses in a third of patients with advanced dMMR/MSI-H noncolorectal cancers. Combined anti-PD-1/cytotoxic lymphocyte antigen 4 (CTLA-4) blockade using nivolumab and ipilimumab has shown superiority to anti-PD-1 monotherapy in other immunogenic cancers such as metastatic melanoma. The Combination Immunotherapy in Rare Cancers Under Investigation (MOST-CIRCUIT) is the first trial that investigated combined anti-PD-1/CTLA-4 blockade in advanced dMMR/MSI-H noncolorectal cancers.

OBJECTIVE: To evaluate the efficacy and safety of combined anti-PD-1/CTLA-4 blockade using nivolumab and ipilimumab in advanced dMMR/MSI-H noncolorectal cancers.

DESIGN, SETTING, AND PARTICIPANTS: The MOST-CIRCUIT prospective multicenter nonrandomized phase 2 clinical trial enrolled 52 patients with advanced dMMR/MSI-H into cohort D. Patients were enrolled from August 2021 to February 2024 across 17 Australian and New Zealand sites. The analysis itself took place in May 2025.

INTERVENTIONS: Patients received nivolumab, 3 mg/kg, and ipilimumab, 1 mg/kg, every 3 weeks for 4 doses, followed by nivolumab, 480 mg, every 4 weeks for 96 weeks, until disease progression or the development of unacceptable toxic effects.

MAIN OUTCOME AND MEASURES: The co-primary end points were objective response rate (ORR) and 6-month progression-free survival (6-PFS) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, with the secondary end points being median overall survival (mOS), progression-free survival (PFS), and treatment-related toxic effects.

RESULTS: Overall, 52 participants were included. The median (range) age of participants was 62 (29-84) years; 41 (79%) were female individuals and 11 (21%) were male individuals. Overall, 52 patients representing 17 tumor types were enrolled, with the most common tumor type being endometrial cancer (26 [50%]). Twenty-seven patients (52%) were pretreated for metastatic disease. ORR was 63% (95% CI, 50% to 75%) with the median duration of response not being reached and 79% of responses being ongoing. The median PFS and OS have not been reached and the 6-month PFS was 71% (95% CI, 57%-81%). Overall, 12 patients (23%) experienced a grade 3/4 immune-related adverse event.

CONCLUSIONS AND RELEVANCE: This nonrandomized clinical trial found that combined anti-PD-1/CTLA-4 blockade was associated with a high rate of durable responses in dMMR/MSI-H noncolorectal cancers, comparing favorably to published trials using anti-PD-1/programmed cell death ligand 1 monotherapy. Anti-PD-1/CTLA-4 blockade using nivolumab and ipilimumab may represent an alternative treatment option to monotherapy in this patient population.

TRIAL REGISTRATION: ClinicalTrials.gov registration: NCT04969887.

**中文摘要译文：**
重要性：错配修复缺陷（dMMR）/高微卫星不稳定性（MSI-H）肿瘤是免疫原性最强的肿瘤之一。抗程序性死亡受体1（PD-1）单药治疗能为三分之一的晚期dMMR/MSI-H非结直肠癌患者带来持久的缓解。在其他免疫原性肿瘤（如转移性黑色素瘤）中，使用纳武利尤单抗和伊匹木单抗进行抗PD-1/细胞毒性T淋巴细胞相关抗原4（CTLA-4）联合阻断已显示出优于抗PD-1单药治疗的效果。“研究中的罕见肿瘤联合免疫疗法”（MOST-CIRCUIT）是首个在晚期dMMR/MSI-H非结直肠癌中研究抗PD-1/CTLA-4联合阻断的试验。

目的：评估纳武利尤单抗联合伊匹木单抗对晚期dMMR/MSI-H非结直肠癌进行抗PD-1/CTLA-4联合阻断的疗效与安全性。

设计、地点与参与者：MOST-CIRCUIT是一项前瞻性、多中心、非随机的2期临床试验，在其队列D中招募了52名晚期dMMR/MSI-H患者。患者于2021年8月至2024年2月期间在澳大利亚和新西兰的17个研究中心入组。分析于2025年5月进行。

干预措施：患者接受纳武利尤单抗（3 mg/kg）和伊匹木单抗（1 mg/kg）联合治疗，每3周一次，共4剂；随后接受纳武利尤单抗（480 mg）单药维持治疗，每4周一次，持续96周，直至疾病进展或出现不可接受的毒性反应。

主要结局与测量指标：共同主要终点是根据实体瘤疗效评价标准（RECIST）1.1版评估的客观缓解率（ORR）和6个月无进展生存率（6-PFS）。次要终点为中位总生存期（mOS）、无进展生存期（PFS）和治疗相关毒性反应。

结果：共纳入52名参与者。参与者的中位年龄为62岁（范围29-84岁）；其中41名（79%）为女性，11名（21%）为男性。共招募了52名患者，涉及17种肿瘤类型，最常见的肿瘤类型是子宫内膜癌（26例[50%]）。27名患者（52%）曾接受过针对转移性疾病的治疗。客观缓解率（ORR）为63%（95% CI, 50%-75%），中位缓解持续时间尚未达到，且79%的缓解仍在持续中。中位无进展生存期（PFS）和总生存期（OS）均未达到，6个月无进展生存率为71%（95% CI, 57%-81%）。总体而言，12名患者（23%）经历了3/4级免疫相关不良事件。

结论与相关性：这项非随机临床试验发现，在dMMR/MSI-H非结直肠癌中，抗PD-1/CTLA-4联合阻断与高持久缓解率相关，其结果优于已发表的使用抗PD-1/程序性死亡配体1单药治疗的试验。对于这一患者群体，使用纳武利尤单抗和伊匹木单抗进行抗PD-1/CTLA-4阻断可能成为单药治疗之外的一种替代治疗选择。

试验注册：ClinicalTrials.gov注册号：NCT04969887。

### 第二部分 AI 大师评价

本研究通过一项2期临床试验，首次探索了纳武利尤单抗与伊匹木单抗联合疗法在晚期错配修复缺陷/高微卫星不稳定性（dMMR/MSI-H）非结直肠癌患者中的应用。研究关键发现，该联合方案展现出高达63%的客观缓解率和持久的临床获益，且安全性可控。这项研究的价值在于，为这一肿瘤类型多样的特定患者群体提供了优于PD-1单药治疗历史数据的有力证据，可能为临床实践提供一种新的、更有效的治疗选择，尽管其非随机设计是其局限性之一。

---

## 3. 双重免疫检查点阻断治疗高微卫星不稳定性肿瘤：疗效显著，但适用人群与时机为何？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231488](https://pubmed.ncbi.nlm.nih.gov/41231488)
**期刊：** JAMA oncology
**PMID：** 41231488
**DOI：** 10.1001/jamaoncol.2025.4612

### 第一部分 原文与翻译

**英文原标题：** Dual Immune Checkpoint Blockade in Microsatellite Instability-High Cancers-Effective, but for Whom and When?

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题表明，这可能是一篇述评或社论，而非原创性研究。文章聚焦于双重免疫检查点抑制剂在高度微卫星不稳定性（MSI-H）肿瘤治疗中的应用，在肯定其疗效的同时，提出了关于最佳适用人群和治疗时机的关键临床问题。此文旨在引导学界深入探讨如何优化治疗策略、寻找预测性生物标志物以及确定最佳治疗窗口，对于推动该领域个体化免疫治疗的发展具有重要的指导意义。

---

## 4. 超加工食品摄入与女性早发性结直肠癌癌前病变风险

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231486](https://pubmed.ncbi.nlm.nih.gov/41231486)
**期刊：** JAMA oncology
**PMID：** 41231486
**DOI：** 10.1001/jamaoncol.2025.4777

### 第一部分 原文与翻译

**英文原标题：** Ultraprocessed Food Consumption and Risk of Early-Onset Colorectal Cancer Precursors Among Women.

**英文摘要原文：**
IMPORTANCE: Early-onset colorectal cancer (EOCRC) (diagnosed age <50 years) incidence is increasing globally, in parallel with increased consumption of ultraprocessed foods (UPFs). The role of UPFs in early-onset colorectal neoplasia remains underexplored.

OBJECTIVE: To evaluate the association between UPF consumption and risk of EOCRC precursors.

DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study included participants of the Nurses' Health Study II, an ongoing US prospective cohort of female registered nurses established in 1989. Participants were followed up from June 1, 1991, through June 1, 2015. Data were analyzed from October 2024 to July 2025. UPF intake, derived from food-frequency questionnaires administered every 4 years and classified using the Nova system, was modeled as quintiles of energy-adjusted servings per day. Of the nurses enrolled, those who had completed the baseline 1991 food-frequency questionnaire, undergone at least 1 lower endoscopy before age 50 years after baseline, had no history of cancer (except for nonmelanoma skin cancer) before endoscopy, and no colorectal polyp or inflammatory bowel disease were included.

MAIN OUTCOMES AND MEASURES: Incidence of EOCRC precursors, including conventional adenomas and serrated lesions, confirmed via medical records and pathology reports. Multivariable logistic regression models with generalized estimating equations for clustered data were used to estimate adjusted odds ratios (AORs) and 95% CIs, accounting for known and putative risk factors.

RESULTS: Among 29 105 female participants (mean [SD] age, 45.2 [4.5] years) over 24 years of follow-up, 1189 cases were documented of early-onset conventional adenomas and 1598 serrated lesions. UPFs provided 34.8% of total daily calories (median, 5.7 [IQR, 4.5-7.4] servings per day). Participants with higher UPF intake had an increased risk of early-onset conventional adenomas (highest vs lowest intake: AOR, 1.45; 95% CI, 1.19-1.77; overall P < .001) but not serrated lesions (AOR, 1.04; 95% CI, 0.89-1.22; P = .48 for trend). Findings were consistent after further adjustment for body mass index, type 2 diabetes, dietary factors (fiber, folate, calcium, and vitamin D), and Alternative Healthy Eating Index-2010 score.

CONCLUSIONS AND RELEVANCE: In this study, higher UPF intake was associated with increased risk of early-onset colorectal conventional adenomas. These data highlight the important role of UPFs in early-onset colorectal tumorigenesis and support improving dietary quality as a strategy to mitigate the increasing burden of EOCRC.

**中文摘要译文：**
重要性：早发性结直肠癌（EOCRC）（诊断年龄<50岁）的发病率在全球范围内呈上升趋势，这与超加工食品（UPFs）消费的增加相平行。UPFs在早发性结直肠肿瘤形成中的作用尚待充分探究。

目的：评估UPFs摄入与EOCRC癌前病变风险之间的关联。

设计、地点与参与者：本前瞻性队列研究纳入了“护士健康研究II”的参与者，这是一项始于1989年的、正在进行的美国女性注册护士前瞻性队列研究。参与者的随访时间为1991年6月1日至2015年6月1日。数据分析时间为2024年10月至2025年7月。UPFs摄入量通过每4年进行一次的食物频率问卷获得，并使用Nova系统进行分类，建模为能量调整后每日摄入份数的五分位数。入组的护士中，纳入了那些在基线后、50岁前完成了1991年基线食物频率问卷、接受了至少1次下消化道内镜检查、在内镜检查前无癌症史（非黑色素瘤皮肤癌除外）、且无结直肠息肉或炎症性肠病的参与者。

主要结局与测量指标：通过医疗记录和病理报告确认的EOCRC癌前病变（包括常规腺瘤和锯齿状病变）的发生率。采用包含广义估计方程的多变量逻辑回归模型来处理聚集性数据，估算调整后的比值比（AORs）和95%置信区间（CIs），并对已知和假定的风险因素进行了校正。

结果：在24年的随访中，共29105名女性参与者（平均[标准差]年龄，45.2[4.5]岁）被纳入分析，记录了1189例早发性常规腺瘤和1598例锯齿状病变。UPFs提供了每日总热量的34.8%（中位数，每日5.7份[IQR, 4.5-7.4]）。与摄入量最低者相比，UPFs摄入量最高的参与者发生早发性常规腺瘤的风险增加（AOR, 1.45; 95% CI, 1.19-1.77; 总体P < .001），但与锯齿状病变的风险无显著关联（AOR, 1.04; 95% CI, 0.89-1.22; 趋势P = .48）。在进一步校正体重指数、2型糖尿病、膳食因素（纤维、叶酸、钙和维生素D）以及“替代健康饮食指数-2010”得分后，研究结果保持一致。

结论与相关性：在本研究中，较高的UPFs摄入与早发性结直肠常规腺瘤风险增加相关。这些数据凸显了UPFs在早发性结直肠肿瘤发生中的重要作用，并支持将改善膳食质量作为一种策略，以减轻日益沉重的EOCRC负担。

### 第二部分 AI 大师评价

本研究基于一项大规模前瞻性队列，精准地探讨了超加工食品（UPFs）摄入与女性早发性结直肠癌（EOCRC）癌前病变风险的关联。其核心发现是，高UPFs摄入显著增加了早发性常规腺瘤的风险，但与锯齿状病变无明显关系，这为EOCRC发病机制的探讨提供了新视角。该研究设计严谨，数据扎实，其结论不仅为解释EOCRC发病率上升的“饮食假说”提供了有力证据，也为制定针对年轻人群的结直肠癌一级预防策略（如倡导健康饮食）提供了重要的科学依据。

---

## 5. 免疫检查点抑制剂相关心血管毒性效应：国际心脏肿瘤学会立场声明

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231466](https://pubmed.ncbi.nlm.nih.gov/41231466)
**期刊：** JAMA oncology
**PMID：** 41231466
**DOI：** 10.1001/jamaoncol.2025.4543

### 第一部分 原文与翻译

**英文原标题：** Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement.

**英文摘要原文：**
IMPORTANCE: The introduction of immune checkpoint inhibitor (ICI) therapy has improved cancer outcomes but at the cost of adverse events, mainly related to the immune system. Cardiovascular (CV) toxic effects, and especially myocarditis, are of particular concern and are the subject of this position statement by the International Cardio-Oncology Society with representation of experts from oncology, hematology, and cardiology.

OBSERVATIONS: CV toxic effects of ICI therapies include inflammation-associated diseases, such as myocarditis, pericarditis, and vasculitis, as well as the aggravation of chronic inflammatory conditions, such as atherosclerosis with acute ischemic complications (myocardial infarction and stroke). Patients taking ICI therapies can also develop cardiac dysfunction, stress-induced cardiomyopathy (Takotsubo or apical ballooning syndrome), and heart failure without inflammatory cell infiltration of the myocardium. Atrial and ventricular arrhythmias can emerge in the setting of a systemic inflammatory milieu, myocarditis, or ischemia. Of all potential CV adverse effects, myocarditis remains of highest concern, although fatality rates have declined over time with a broadening spectrum of presentations ranging from troponin elevation of uncertain significance to smoldering, nonsevere, and severe or fulminant myocarditis.

CONCLUSIONS AND RELEVANCE: Concerns for myocarditis continue to dominate the spectrum of CV toxic effects in patients receiving ICI therapy. Recommendations for management vary according to severity. Multidisciplinary collaborations remain key for managing acute toxic effects and future cancer treatment decisions, including ICI rechallenge. Ischemic heart disease constitutes the main differential diagnosis in these patients, while pericarditis can be concomitantly present, and atrial and ventricular arrhythmias can also complicate the clinical picture. Several gaps in knowledge are identified and require further research.

**中文摘要译文：**
重要性：免疫检查点抑制剂（ICI）疗法的引入改善了癌症的治疗结局，但其代价是主要与免疫系统相关的不良事件。心血管（CV）毒性效应，特别是心肌炎，尤为引人关注，并且是本立场声明的主题，该声明由国际心脏肿瘤学会发布，汇集了来自肿瘤学、血液学和心脏病学领域的专家代表。

观察：ICI疗法的心血管毒性效应包括炎症相关疾病，如心肌炎、心包炎和血管炎，以及慢性炎症性疾病的加重，如伴有急性缺血性并发症（心肌梗死和中风）的动脉粥样硬化。接受ICI治疗的患者还可能出现心脏功能障碍、应激性心肌病（Takotsubo或心尖球囊综合征）以及无心肌炎性细胞浸润的心力衰竭。在全身性炎症环境、心肌炎或缺血的情况下，可能会出现房性或室性心律失常。在所有潜在的心血管不良反应中，心肌炎仍然是最受关注的问题，尽管其致死率已随时间推移而下降，临床表现谱也日益拓宽，从意义不明确的肌钙蛋白升高到隐匿性、非重症、重症或暴发性心肌炎。

结论与相关性：在接受ICI治疗的患者中，对心肌炎的担忧仍然是心血管毒性效应谱中的主要问题。管理建议因严重程度而异。多学科协作对于管理急性毒性效应和未来的癌症治疗决策（包括再次使用ICI）仍然至关重要。缺血性心脏病是这些患者的主要鉴别诊断，同时可能伴有心包炎，而房性和室性心律失常也可能使临床情况复杂化。本文指出了若干知识空白，有待进一步研究。

### 第二部分 AI 大师评价

该文献是国际心脏肿瘤学会发布的立场声明，旨在系统阐述免疫检查点抑制剂（ICI）相关心血管毒性的管理策略。文章全面梳理了包括心肌炎、心包炎、心律失常及动脉粥样硬化加重在内的多种毒性反应，并重点聚焦于心肌炎的诊断与分级管理。作为一份权威的专家共识，该声明为临床医生提供了关键的指导性建议，强调了多学科协作在处理急性毒性及决定后续治疗中的核心作用，对规范临床实践、提升患者安全性具有重要的指导价值。

---

## 6. 肿瘤微环境的守护者：中性粒细胞传奇

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231462](https://pubmed.ncbi.nlm.nih.gov/41231462)
**期刊：** Blood
**PMID：** 41231462
**DOI：** 10.1182/blood.2025030664

### 第一部分 原文与翻译

**英文原标题：** Guardians of the tumor microenvironment: the neutrophil saga.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

根据标题推断，本文可能是一篇深刻的综述，旨在系统阐述中性粒细胞在肿瘤微环境中的复杂角色。标题将中性粒细胞喻为“守护者”并以“传奇”为题，生动地暗示了文章将聚焦其在抗肿瘤与促肿瘤之间的动态平衡与关键作用。虽然缺乏摘要信息，但发表于顶尖期刊《Blood》预示了其高质量与权威性，可能为肿瘤免疫研究和靶向中性粒细胞的治疗策略提供了宝贵的见解与方向。

---

## 7. 重新定义慢性淋巴细胞白血病（CLL）的健康状态评估

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231458](https://pubmed.ncbi.nlm.nih.gov/41231458)
**期刊：** Blood
**PMID：** 41231458
**DOI：** 10.1182/blood.2025030837

### 第一部分 原文与翻译

**英文原标题：** Refitting fitness in CLL.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
本文献无摘要。

### 第二部分 AI 大师评价

该文献从标题推断，应为一篇评论或观点性文章，旨在探讨当前慢性淋巴细胞白血病（CLL）患者健康状态（fitness）评估方法的局限性。随着靶向治疗等新疗法的出现，作者可能主张传统的评估模型已无法完全适应现代临床决策的需求。本文的价值在于呼吁对现有评估标准进行“重新校准”，以实现更精准的患者分层和个体化治疗选择，这对于推动CLL领域的精准医疗具有重要的概念性指导意义。

---

## 8. 伴KMT2A基因重排的套细胞淋巴瘤

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231456](https://pubmed.ncbi.nlm.nih.gov/41231456)
**期刊：** Blood
**PMID：** 41231456
**DOI：** 10.1182/blood.2025030135

### 第一部分 原文与翻译

**英文原标题：** Mantle cell lymphoma with KMT2A rearrangement.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献报道了一种罕见的分子亚型——伴有KMT2A基因重排的套细胞淋巴瘤（MCL）。此发现拓展了我们对MCL遗传异质性的认知，并揭示了一个潜在的新分子特征。尽管无摘要内容可能意味着这仅是一篇简报或病例报道，但其重要科学价值在于，提示了KMT2A重排可能作为MCL中一个新的预后生物标志物或潜在治疗靶点，为未来的临床诊疗和靶向药物研发提供了新方向。

---

## 9. 倒退的进展——医疗补助计划削减与癌症治疗的未来

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231452](https://pubmed.ncbi.nlm.nih.gov/41231452)
**期刊：** JAMA oncology
**PMID：** 41231452
**DOI：** 10.1001/jamaoncol.2025.4730

### 第一部分 原文与翻译

**英文原标题：** Unwinding Progress-Medicaid Cuts and the Future of Cancer Care.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文似乎是一篇评论性文章，旨在探讨美国医疗补助计划（Medicaid）的资金削减可能如何逆转癌症治疗领域已取得的进展。文章可能重点分析了这些政策变化对癌症筛查、诊断、治疗可及性以及患者预后的潜在负面影响，特别是对于低收入和弱势群体。尽管没有提供摘要，但从标题推断，该文的核心价值在于从宏观政策层面警示医疗资金变动对肿瘤学实践和患者生存构成的威胁，为相关卫生政策的制定和讨论提供了重要的临床视角。

---

## 10. 室温水

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231448](https://pubmed.ncbi.nlm.nih.gov/41231448)
**期刊：** JAMA
**PMID：** 41231448
**DOI：** 10.1001/jama.2025.19634

### 第一部分 原文与翻译

**英文原标题：** Room-Temperature Water.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

由于该文献没有提供摘要，仅从标题《室温水》难以准确判断其具体内容和研究类型。这篇文章可能并非一篇原创性研究，而更可能是一篇评论、社论、读者来信或医学人文作品，旨在探讨某个与临床实践或医学体验相关的特定观点。因此，无法评估其研究方法、关键发现及具体的科学价值，需阅读全文方能获知其核心主旨与意义。

---

## 11. CanSig：对从单细胞转录组数据中发现可重复性癌细胞状态的方法进行基准评估

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231245](https://pubmed.ncbi.nlm.nih.gov/41231245)
**期刊：** Cancer research
**PMID：** 41231245
**DOI：** 10.1158/0008-5472.CAN-25-0940

### 第一部分 原文与翻译

**英文原标题：** CanSig Benchmarks Methods for Reproducible Cancer Cell State Discovery from Single-Cell Transcriptomic Data.

**英文摘要原文：**
Single-cell RNA-sequencing (scRNA-seq) facilitates the discovery of gene expression signatures that define cell states across patients, which could be used in patient stratification and precision oncology. However, the lack of standardization in computational methodologies that are used to analyze these data impedes the reproducibility of signature detection. To address this, we developed CanSig, a comprehensive benchmarking tool that evaluates methods for identifying transcriptional signatures in cancer. CanSig integrates metrics for batch correction and biological signal conservation with a transcriptional signature correlation metric to score methods according to signature rediscovery, cross-dataset reproducibility, and clinical relevance. CanSig was applied to thirteen methods on twelve scRNA-seq datasets from five human cancer types-glioblastoma, breast cancer, lung adenocarcinoma, rhabdomyosarcoma, and cutaneous squamous cell carcinoma-representing 185 patients and 174,000 malignant cells. The signatures identified with these methods correlated with clinically relevant outcomes, including patient survival and lymph node metastasis. These results identified Harmony, BBKNN, and fastMNN as the highest-scoring integration methods for discovering shared transcriptional states in cancer. Overall, CanSig provides a standardized, reproducible framework for uncovering clinically relevant cancer cell states in single-cell transcriptomics.

**中文摘要译文：**
单细胞RNA测序（scRNA-seq）促进了能够定义不同患者细胞状态的基因表达特征的发现，这些特征可用于患者分层和精准肿瘤学。然而，用于分析这些数据的计算方法学缺乏标准化，这阻碍了特征检测的可重复性。为了解决这个问题，我们开发了CanSig，这是一个全面的基准测试工具，用于评估癌症中转录特征的识别方法。CanSig整合了批次校正和生物信号保守性的评估指标，并结合转录特征相关性指标，根据特征的再发现能力、跨数据集的可重复性以及临床相关性对各种方法进行评分。CanSig被应用于13种方法，这些方法作用于来自五种人类癌症类型（胶质母细胞瘤、乳腺癌、肺腺癌、横纹肌肉瘤和皮肤鳞状细胞癌）的12个scRNA-seq数据集，共代表了185名患者和174,000个恶性细胞。通过这些方法识别出的特征与临床相关结局相关，包括患者生存期和淋巴结转移。研究结果表明，Harmony、BBKNN和fastMNN是在发现癌症共享转录状态方面得分最高的整合方法。总而言之，CanSig为在单细胞转录组学中揭示具有临床意义的癌细胞状态提供了一个标准化、可重复的框架。

### 第二部分 AI 大师评价

本研究旨在解决单细胞转录组学分析中因计算方法不统一而导致结果可重复性差的关键问题。研究者为此开发了一个名为CanSig的综合性基准测试框架，该框架通过整合批次校正、生物信号保守性和临床相关性等多维度指标，系统性地评估了13种主流的计算方法。研究的核心发现不仅确定了Harmony、BBKNN和fastMNN等在癌细胞状态发现方面表现最优的方法，还证实了所识别的基因特征与患者生存期等临床结局显著相关。此项工作极具价值，它为癌症单细胞研究领域提供了一个标准化的方法评估体系，有力地推动了从海量数据中发掘可靠且具临床转化潜力的生物标志物的进程。

---

## 12. 伊布替尼与PD-1阻断在胰腺癌临床前模型中增强靶向间皮素的CAR-T细胞疗法的疗效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231131](https://pubmed.ncbi.nlm.nih.gov/41231131)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41231131
**DOI：** 10.1158/1078-0432.CCR-25-2907

### 第一部分 原文与翻译

**英文原标题：** Ibrutinib and PD-1 blockade potentiate mesothelin-targeting CAR-T cell therapy in preclinical models of pancreatic cancer.

**英文摘要原文：**
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) remains refractory to chimeric antigen receptor (CAR) T cell therapies due to its immunosuppressive microenvironment and a dense extracellular matrix deposited by cancer-associated fibroblasts (CAFs), which impair CAR-T cell infiltration. To address these barriers, we previously developed a dual-targeting CAR-TEAM platform in which mesothelin-specific CAR-T cells secrete a FAP-targeting T cell engager antibody molecule (TEAM) to simultaneously kill tumor cells and CAFs. Here, we leveraged mesothelin-targeting CAR-T cells and tested rational drug combinations and optimal delivery strategies to enhance therapeutic efficacy and guide potential combinations that could be incorporated into a clinical study.

EXPERIMENTAL DESIGN: Tumor mesothelin shedding by proteases and CAR-T cell dysfunction remain key obstacles to CAR-T cell efficacy. Using pre-clinical PDAC models, we tested mesothelin-targeting CAR-T cells in combination with agents that increase tumor mesothelin expression, promote T cell polarization and persistence, and support T cell function. Furthermore, we compared intravenous versus intraperitoneal delivery routes to treat peritoneal metastases.

RESULTS: We demonstrated that ibrutinib enhanced CAR-T cell expansion, Th1 skewing, and anti-tumor activity in PDAC. PD-1 blockade synergistically improved CAR-T cell anti-tumor function in a patient-derived PDAC xenograft and intraperitoneal delivery proved superior against peritoneal disease. Conversely, while an ADAM10/17 inhibitor prevented mesothelin shedding and improved tumor killing in vitro, it did not enhance efficacy in vivo.

CONCLUSION: These findings identify clinically actionable strategies to optimize CAR-T cell therapy against PDAC. A phase-I clinical trial testing meso-FAP CAR-TEAM T cells, alone or in combination with ibrutinib or PD-1 blockade is in development.

**中文摘要译文：**
目的：由于其免疫抑制性微环境以及由癌症相关成纤维细胞（CAFs）沉积的致密细胞外基质（这会削弱CAR-T细胞的浸润），胰腺导管腺癌（PDAC）对嵌合抗原受体（CAR）T细胞疗法仍然表现出难治性。为解决这些障碍，我们先前开发了一种双靶向CAR-TEAM平台，在该平台中间皮素特异性CAR-T细胞可分泌一种靶向FAP的T细胞衔接抗体分子（TEAM），从而同时杀伤肿瘤细胞和CAFs。在此，我们利用靶向间皮素的CAR-T细胞，测试了合理的药物组合与最佳递送策略，以增强治疗效果，并为可能被纳入临床研究的潜在组合提供指导。

实验设计：由蛋白酶引起的肿瘤间皮素脱落以及CAR-T细胞功能障碍仍然是影响CAR-T细胞疗效的关键障碍。我们利用临床前PDAC模型，测试了靶向间皮素的CAR-T细胞与能够增加肿瘤间皮素表达、促进T细胞极化与持久性以及支持T细胞功能的药物的组合。此外，我们比较了静脉注射与腹腔注射两种递送途径在治疗腹膜转移中的效果。

结果：我们证明，在PDAC中，伊布替尼能增强CAR-T细胞的扩增、Th1偏向分化及其抗肿瘤活性。在患者来源的PDAC异种移植模型中，PD-1阻断能协同性地改善CAR-T细胞的抗肿瘤功能，而腹腔内递送在对抗腹膜疾病方面表现更优。相反，尽管一种ADAM10/17抑制剂在体外能阻止间皮素脱落并改善肿瘤杀伤效果，但它在体内未能增强疗效。

结论：这些发现为优化针对PDAC的CAR-T细胞疗法确定了具有临床可行性的策略。一项测试meso-FAP CAR-TEAM T细胞单独使用，或与伊布替尼或PD-1阻断联合使用的I期临床试验正在筹备中。

### 第二部分 AI 大师评价

本研究旨在探索并优化靶向间皮素（mesothelin）的CAR-T细胞疗法在治疗胰腺癌（PDAC）中的具体策略。研究者通过临床前模型，系统性地测试了伊布替尼、PD-1阻断剂等药物的联合应用以及不同的细胞递送途径。研究的关键发现明确指出，伊布替尼与PD-1阻断能显著增强CAR-T细胞的扩增、功能及抗肿瘤活性，且腹腔内给药对治疗腹膜转移更具优势。这项工作具有重要的临床转化价值，它为解决实体瘤CAR-T疗法所面临的免疫抑制和细胞持久性等核心挑战提供了具备临床可行性的方案，并为即将开展的相关I期临床试验奠定了坚实的科学基础。

---

## 13. 工程化迁移体提供了一个强大且热稳定的疫苗平台

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231123](https://pubmed.ncbi.nlm.nih.gov/41231123)
**期刊：** eLife
**PMID：** 41231123
**DOI：** 10.7554/eLife.97621

### 第一部分 原文与翻译

**英文原标题：** Engineered migrasomes provide a robust and thermally stable vaccination platform.

**英文摘要原文：**
The growing ability of pathogens and tumor cells to evade immune surveillance underscores the urgent need for new vaccine platforms that harness diverse biological mechanisms. Logistical constraints associated with cold-chain transport further limit vaccine accessibility, particularly in resource-limited settings. Migrasomes-specialized organelles produced during cell migration-are inherently stable and enriched with immune-modulating molecules. To overcome the low yield of natural migrasomes, we engineered migrasome-like vesicles (eMigrasomes) using hypotonic shock combined with cytoskeletal disruption to promote vesicle formation. eMigrasome biogenesis depends on core migrasome machinery and recapitulates the biophysical and molecular features of native migrasomes while achieving higher production efficiency. In murine models, eMigrasomes loaded with a model antigen elicited potent antibody responses and retained structural integrity and immunogenicity at room temperature. Moreover, eMigrasomes displaying the SARS-CoV-2 Spike protein induced strong humoral responses and conferred protection against viral challenge in mice. These results establish eMigrasomes as an innovative, thermally stable, and broadly applicable vaccine platform derived from migrasome biology.

**中文摘要译文：**
病原体和肿瘤细胞逃避免疫监视的能力日益增强，这凸显了开发利用不同生物学机制的新型疫苗平台的迫切需求。与冷链运输相关的物流限制进一步限制了疫苗的可及性，尤其是在资源有限的地区。迁移体是在细胞迁移过程中产生的特化细胞器，其本身具有稳定性，并富含免疫调节分子。为了克服天然迁移体产量低的问题，我们利用低渗休克结合细胞骨架破坏的方法来促进囊泡形成，从而工程化改造出迁移体样囊泡（eMigrasomes）。eMigrasome的生物发生依赖于迁移体的核心机制，并重现了天然迁移体的生物物理和分子特征，同时实现了更高的生产效率。在小鼠模型中，装载了模型抗原的eMigrasome可引发强有力的抗体反应，并在室温下保持其结构完整性和免疫原性。此外，展示SARS-CoV-2刺突蛋白的eMigrasome在小鼠体内诱导了强烈的体液免疫应答，并赋予了其抵抗病毒攻击的保护力。这些结果确立了eMigrasome作为一个源于迁移体生物学的创新性、热稳定且具有广泛应用前景的疫苗平台。

### 第二部分 AI 大师评价

本研究旨在开发一种基于迁移体生物学的新型疫苗平台，以应对病原体免疫逃逸及疫苗冷链运输的挑战。研究团队通过创新的工程化方法高效制备了迁移体样囊泡（eMigrasomes），并证实其在室温下仍能保持结构完整与免疫原性。关键发现表明，搭载了新冠病毒刺突蛋白的eMigrasomes能在小鼠模型中诱导强效的保护性免疫反应。这项工作不仅为疫苗研发提供了一个极具潜力的新策略，其卓越的热稳定性更预示了其在克服全球疫苗分发物流障碍方面的巨大价值。

---

## 14. 复发/难治性生殖细胞肿瘤的新型大剂量化疗方案：我们取得进展了吗？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231121](https://pubmed.ncbi.nlm.nih.gov/41231121)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41231121
**DOI：** 10.1158/1078-0432.CCR-25-3334

### 第一部分 原文与翻译

**英文原标题：** Novel High-dose Chemotherapy Regimens in Relapsed/Refractory Germ Cell Cancer: Have we made Progress?

**英文摘要原文：**
Sequential carboplatin/etoposide based high-dose chemotherapy with stem cell support is a standard therapy option for relapsed germ-cell tumors resulting in cure for approximately 50% of patients. In a recent single-center phase 2 study, results were reported for a novel combination including gemcitabine, melphalan, docetaxel and carboplatin.

**中文摘要译文：**
基于序贯使用卡铂/依托泊苷并联合干细胞支持的大剂量化疗是复发性生殖细胞肿瘤的一种标准治疗选择，可使约50%的患者获得治愈。在最近一项单中心II期研究中，报道了一种包含吉西他滨、马法兰、多西他赛和卡铂的新型组合方案的疗效结果。

### 第二部分 AI 大师评价

本文聚焦于复发/难治性生殖细胞肿瘤治疗领域的一个核心议题：新型大剂量化疗方案是否带来了实质性进展。文章以近期一项评估吉西他滨、马法兰、多西他赛和卡铂新组合方案的II期临床研究为切入点，与现有基于卡铂/依托泊苷的标准方案进行对比和探讨。该评价的价值在于审视了该领域的前沿探索，并对未来治疗策略的优化方向提出了深刻诘问。尽管所讨论的研究仅为单中心II期数据，但其为改善这一高危患者群体的预后提供了新的循证视角和思考。

---

## 15. 贝伐珠单抗联合厄洛替尼治疗伴克雷布斯循环基因突变的晚期实体癌：一项多中心II期研究 (BRISK; KCSG AL22-16)

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231120](https://pubmed.ncbi.nlm.nih.gov/41231120)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41231120
**DOI：** 10.1158/1078-0432.CCR-25-2117

### 第一部分 原文与翻译

**英文原标题：** Bevacizumab plus erlotinib in advanced solid cancers with Krebs cycle gene mutations: A multicenter phase II study (BRISK; KCSG AL22-16).

**英文摘要原文：**
PURPOSE: Targeting aberrant metabolism in tumors with alterations in genes encoding Krebs cycle enzymes, a central component of glucose metabolism, is a promising therapeutic strategy. These tumors rely on aerobic glycolysis and promote VEGF-dependent angiogenesis; furthermore, EGFR signaling enhances aerobic glycolysis. This phase 2 trial evaluated bevacizumab and erlotinib in patients with solid tumors harboring Krebs cycle gene mutations.

PATIENTS AND METHODS: Eligible patients had solid tumors bearing pathogenic mutations in FH, IDH1/2, SDHx, or MDH2, and measurable disease per RECIST v1.1 or RANO 2.0 criteria. Participants received bevacizumab(10 mg/kg IV on Day 1) and erlotinib(150 mg orally once daily) every 14 days until progression or unacceptable toxicity. Primary endpoint was objective response rate(ORR); secondary endpoints were progression-free survival(PFS), overall survival(OS), and safety.

RESULTS: From February to November 2023, 35 were enrolled: 19 with biliary tract cancer(BTC, 54.3%), 7 with brain tumors(20.0%), and 5 with FH-deficient renal cell carcinomas(FH-deficient RCC, 17.1%). ORR was 37.1%(1 complete, 12 partial responses). Disease control rate was 85.7%. Subgroup ORRs were 80.0% in FH-deficient RCC, 36.8% in BTC, and 28.6% in brain tumors. At a median follow-up of 11.7 months, median PFS was 8.3 months; median OS was not reached. No new safety signals were observed. Exploratory transcriptomic analyses revealed VEGF and immune pathway enrichment in patients with favorable PFS, whereas amino acid, fatty acid metabolism, and oxidative phosphorylation-related pathways were enriched with poor PFS.

CONCLUSIONS: Bevacizumab plus erlotinib demonstrated promising efficacy in tumors with Krebs cycle gene mutations, warranting further investigation beyond FH-deficient RCC.

**中文摘要译文：**
目的：靶向携带克雷布斯循环（葡萄糖代谢的核心组成部分）酶编码基因突变的肿瘤的异常代谢是一种有前景的治疗策略。这类肿瘤依赖有氧糖酵解并促进VEGF依赖性血管生成；此外，EGFR信号传导会增强有氧糖酵解。本II期试验旨在评估贝伐珠单抗和厄洛替尼在携带克雷布斯循环基因突变的实体瘤患者中的疗效。

患者与方法：符合入组条件的患者需患有携带FH、IDH1/2、SDHx或MDH2致病性突变的实体瘤，并根据RECIST v1.1或RANO 2.0标准具有可测量病灶。参与者每14天接受一次贝伐珠单抗（第1天静脉注射10 mg/kg）和厄洛替尼（每日一次口服150 mg），直至疾病进展或出现不可接受的毒性。主要终点为客观缓解率（ORR）；次要终点为无进展生存期（PFS）、总生存期（OS）和安全性。

结果：自2023年2月至11月，共纳入35名患者：其中19例为胆道癌（BTC, 54.3%），7例为脑肿瘤（20.0%），5例为FH缺陷型肾细胞癌（FH-deficient RCC, 17.1%）。总客观缓解率（ORR）为37.1%（1例完全缓解，12例部分缓解）。疾病控制率为85.7%。亚组分析显示，FH缺陷型肾细胞癌的ORR为80.0%，胆道癌为36.8%，脑肿瘤为28.6%。中位随访11.7个月时，中位PFS为8.3个月；中位OS尚未达到。未观察到新的安全性信号。探索性转录组分析显示，PFS较佳的患者中VEGF和免疫通路富集，而氨基酸、脂肪酸代谢和氧化磷酸化相关通路则在PFS较差的患者中富集。

结论：贝伐珠单抗联合厄洛替尼在携带克雷布斯循环基因突变的肿瘤中显示出有前景的疗效，值得在FH缺陷型肾细胞癌以外的肿瘤中进行进一步研究。

### 第二部分 AI 大师评价

本研究创新性地提出了一种靶向治疗策略，旨在针对携带克雷布斯循环基因突变的实体瘤所特有的代谢脆弱性。通过一项II期临床试验，研究者评估了抗血管生成药物贝伐珠单抗与EGFR抑制剂厄洛替尼的联合疗效，其理论基础坚实。研究的关键发现是该联合方案取得了37.1%的总体客观缓解率，尤其在FH缺陷型肾细胞癌中高达80%，显示出令人鼓舞的抗肿瘤活性和可控的安全性。尽管研究的样本量有限，但其结果为这一罕见突变类型的肿瘤患者提供了重要的循证医学证据，并为未来的精准治疗探索了新方向，具有显著的临床转化潜力。

---

## 16. 肠道菌群及丁酸盐在增强CAR-T细胞疗法治疗非霍奇金淋巴瘤中的潜力

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231114](https://pubmed.ncbi.nlm.nih.gov/41231114)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41231114
**DOI：** 10.1158/1078-0432.CCR-25-1676

### 第一部分 原文与翻译

**英文原标题：** The Potential of the Gut Microbiota and Butyrate to Enhance CAR-T Cell Therapy in Non-Hodgkin Lymphoma.

**英文摘要原文：**
PURPOSE: The microbiota is recognized as an important contributor to the efficacy of immunotherapies. The aim of this study is to analyse the role of gut microbiota, and related metabolites, in the response of CAR-T cells for non-Hodgkin lymphoma (NHL).

EXPERIMENTAL DESIGN: Stool, serum, and clinical data were collected from 84 NHL patients from four hospitals before CD19 CAR-T treatment. The microbiota was characterized through 16S rRNA gene sequencing and serum short-chain fatty acids (SCFAs) were measured using mass spectroscopy. CAR-T cells were exposed to butyrate; their in vitro cytotoxicity was determined, and molecular mechanisms were characterized by flow cytometry and RNA-seq, then assessed in an in vivo model.

RESULTS: Since we confirmed the negative impact of antibiotics on the response, we delved into the mechanisms involved. We showed that they reduce microbiota diversity, and that their composition correlates with the response. We identified SCFA-producing bacterial groups including Prevotella, Ruminococcus, or Butyricicoccus as having a relatively higher abundance in the microbiota of patients who responded to CAR-T. Analysis of butyrate levels revealed a positive correlation with survival, potentially representing a novel biomarker of response. Finally, we found that stimulation of CAR-T cells with butyrate induced phenotypic and transcriptomic changes associated with enhanced antitumor efficacy.

CONCLUSIONS: Our results support the relationship between microbiota and CAR-T therapy major outcomes. Analysis of microbiota led to the identification of SCFAs, especially butyrate as a prognostic factor, and also provides the basis for considering them as chemical modifiers of CAR-T cells to improve their efficacy.

**中文摘要译文：**
目的：肠道菌群被公认为是影响免疫疗法疗效的重要因素。本研究旨在分析肠道菌群及其相关代谢产物在非霍奇金淋巴瘤（NHL）CAR-T细胞疗法应答中的作用。

实验设计：在进行CD19 CAR-T治疗前，我们收集了来自四家医院的84名非霍奇金淋巴瘤患者的粪便、血清及临床数据。通过16S rRNA基因测序对菌群进行表征，并采用质谱法检测血清中的短链脂肪酸（SCFAs）。我们将CAR-T细胞暴露于丁酸盐环境中，测定了其体外细胞毒性，通过流式细胞术和RNA测序揭示其分子机制，并最终在体内模型中进行了评估。

结果：在证实抗生素对治疗应答存在负面影响后，我们深入探究了其内在机制。我们发现抗生素会降低菌群多样性，且菌群的构成与治疗应答相关。我们鉴定出，在对CAR-T治疗有应答的患者菌群中，包括普雷沃氏菌属、瘤胃球菌属或丁酸球菌属在内的产短链脂肪酸菌群丰度相对更高。对丁酸盐水平的分析显示，其与患者生存率呈正相关，可能成为一种新的治疗应答生物标志物。最终，我们发现用丁酸盐刺激CAR-T细胞可诱导其发生表型和转录组学变化，这些变化与抗肿瘤效果的增强有关。

结论：我们的研究结果支持肠道菌群与CAR-T疗法主要临床结局之间存在关联。对菌群的分析不仅鉴定出短链脂肪酸，特别是丁酸盐，可作为一个预后因素，也为考虑将其作为CAR-T细胞的化学修饰剂以提高疗效提供了依据。

### 第二部分 AI 大师评价

本研究旨在探索肠道菌群及其代谢产物丁酸盐对非霍奇金淋巴瘤CAR-T细胞疗法效果的影响。研究团队通过多中心临床样本分析结合体外及体内实验，发现产短链脂肪酸菌群的丰度及血清丁酸盐水平与更佳的治疗应答和生存率显著相关。更具创新性的是，研究证实丁酸盐能直接增强CAR-T细胞的抗肿瘤活性。此项工作不仅揭示了丁酸盐作为疗效预测生物标志物的潜力，更为重要的是，它提出了一个将丁酸盐作为CAR-T细胞增效剂的全新策略，为改善CAR-T疗法提供了极具临床转化价值的新思路。

---

## 17. 阿基仑赛注射液联合阿替利珠单抗治疗难治性弥漫性大B细胞淋巴瘤患者的1/2期ZUMA-6试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41231109](https://pubmed.ncbi.nlm.nih.gov/41231109)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41231109
**DOI：** 10.1158/1078-0432.CCR-25-0602

### 第一部分 原文与翻译

**英文原标题：** Axicabtagene Ciloleucel in Combination With Atezolizumab in Patients With Refractory Diffuse Large B-cell Lymphoma: The Phase 1/2 ZUMA-6 Trial.

**英文摘要原文：**
PURPOSE: Chimeric antigen receptor (CAR) T-cell therapies have improved outcomes in patients with relapsed/refractory large B-cell lymphoma (LBCL). However, up to two-thirds of these patients do not maintain long-term responses. The Phase 1/2 ZUMA-6 study investigated the feasibility of combining the CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel) with the PD-L1 inhibitor atezolizumab as a potential approach to increase treatment efficacy while maintaining acceptable safety.

METHODS: Patients with refractory diffuse LBCL received a single axi-cel infusion (2×106 cells/kg) followed by atezolizumab 1,200 mg intravenously every 21 days for 4 cycles. Primary endpoints were dose-limiting toxicities (DLTs; Phase 1) and complete response (CR) rate (Phase 2). Other efficacy and safety outcomes and pharmacokinetics/pharmacodynamics were assessed.

RESULTS: Overall, 34 patients received axi-cel plus atezolizumab in ZUMA-6. Median follow-up for the final analysis was 56.9 months. In Phase 1, 1 patient experienced DLTs (Grade 4 neutropenia and thrombocytopenia). Thirty patients (88%) experienced Grade ≥3 treatment-emergent adverse events. Three (9%) and 11 (32%) patients experienced Grade ≥3 cytokine release syndrome and neurologic events, respectively. In the final analysis, 15 patients (54%) had a CR. Median PFS and OS were 9.0 months and 32.2 months, respectively. Peak CAR T-cell and cytokine profiles were comparable to those previously reported for axi-cel monotherapy (ZUMA-1).

Conclusions: Axi-cel plus atezolizumab had a managable safety profile, with no new safety signals. Safety and efficacy of this combination were consistent with axi-cel monotherapy. Correlative analyses could inform as to which LBCL patients may benefit from axi-cel and immune checkpoint inhibitor combinations.

**中文摘要译文：**
目的：嵌合抗原受体（CAR）T细胞疗法改善了复发/难治性大B细胞淋巴瘤（LBCL）患者的预后。然而，高达三分之二的患者未能维持长期缓解。这项1/2期ZUMA-6研究旨在探讨将CD19导向的CAR T细胞疗法阿基仑赛注射液（axi-cel）与PD-L1抑制剂阿替利珠单抗相结合作为一种潜在方法的有效性，以期在维持可接受安全性的同时提高治疗效果。

方法：难治性弥漫性LBCL患者接受单次axi-cel输注（2×10^6 细胞/kg），随后每21天静脉注射1200毫克阿替利珠单抗，共4个周期。主要终点是剂量限制性毒性（DLTs；1期）和完全缓解（CR）率（2期）。此外，还评估了其他疗效和安全性结果以及药代动力学/药效动力学。

结果：总体而言，ZUMA-6研究中有34名患者接受了axi-cel联合阿替利珠单抗的治疗。最终分析的中位随访时间为56.9个月。在1期研究中，1名患者出现了剂量限制性毒性（4级中性粒细胞减少症和血小板减少症）。三十名患者（88%）经历了≥3级的治疗期间出现的不良事件。分别有3名（9%）和11名（32%）患者经历了≥3级的细胞因子释放综合征和神经系统事件。在最终分析中，15名患者（54%）达到了完全缓解。中位无进展生存期（PFS）和总生存期（OS）分别为9.0个月和32.2个月。CAR T细胞和细胞因子水平的峰值与先前报道的axi-cel单药治疗（ZUMA-1研究）相当。

结论：Axi-cel联合阿替利珠单抗具有可控的安全性，且未发现新的安全信号。该联合方案的安全性和有效性与axi-cel单药治疗一致。相关性分析或可为筛选可能从axi-cel与免疫检查点抑制剂联合治疗中获益的LBCL患者提供信息。

### 第二部分 AI 大师评价

本研究旨在探索CAR-T疗法（Axi-cel）联合PD-L1抑制剂（Atezolizumab）治疗难治性弥漫性大B细胞淋巴瘤的安全性和有效性，以期改善现有CAR-T疗法的长期缓解率。研究通过一项1/2期临床试验发现，该联合方案具有可控的安全性，且未出现新的安全警示。然而，其疗效与Axi-cel单药治疗的历史数据相当，并未显示出显著的协同增强效果。这项研究虽未证实联合用药的普适性优势，但为未来探索免疫联合疗法提供了重要的安全性和可行性数据，并强调了通过生物标志物筛选潜在获益人群的必要性。

---

## 18. 沙库巴曲缬沙坦用于预防化疗期间心脏肌钙蛋白I浓度升高的患者发生蒽环类药物心脏毒性：一项双盲随机安慰剂对照临床试验（SARAH试验）

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41230611](https://pubmed.ncbi.nlm.nih.gov/41230611)
**期刊：** Circulation
**PMID：** 41230611
**DOI：** 10.1161/CIRCULATIONAHA.125.073322

### 第一部分 原文与翻译

**英文原标题：** Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial.

**英文摘要原文：**
BACKGROUND: The clinical effects of sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, on anthracycline-induced cardiotoxicity remain unknown. Experimental evidence suggests cardioprotective properties. This study evaluated the efficacy of sacubitril-valsartan in reducing cardiotoxicity in patients with increased cardiac troponin I concentrations during anthracycline chemotherapy.

METHODS: This randomized, double-blind, placebo-controlled trial enrolled 114 patients with elevated cardiac troponin I levels during anthracycline treatment. Participants were randomized 1:1 to receive either sacubitril-valsartan or placebo for 6 months, with a target dose of 97/103 mg twice daily. The primary end point was the occurrence of a >15% reduction in the global longitudinal strain from baseline to 6 months. Secondary end points included changes in biomarkers, echocardiographic and cardiac magnetic resonance parameters, and adverse events. This trial was initially conceptualized as a pilot investigation because of its exploratory nature. Data were analyzed according to the intention-to-treat principle.

RESULTS: Among the randomized patients, 90% were women, and 80.7% had breast cancer. The primary end point occurred in 4 patients (7%) in the sacubitril-valsartan group and 14 patients (25%) in the placebo group (odds ratio, 0.23 [95% CI, 0.07-0.75]; 0.015). The sacubitril-valsartan group showed a 2.5% improvement in global longitudinal strain, whereas the placebo group experienced a 7.6% decline (<0.001). No significant differences in changes in cardiac troponin I or NT-proBNP (N-terminal pro-B-type natriuretic peptide) were observed. Hypotension (systolic blood pressure <100 mm Hg) occurred more frequently in the sacubitril-valsartan group than in the placebo group (8 cases versus 1 case; =0.032).

CONCLUSIONS: The SARAH trial (Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated hs-cTnI Concentrations During Chemotherapy) demonstrated the potential of sacubitril-valsartan therapy to reduce the incidence of left ventricular dysfunction, as assessed by global longitudinal strain, in patients with elevated high-sensitivity cardiac troponin I after anthracycline treatment.

REGISTRATION: URL: https://ensaiosclinicos.gov.br/rg/RBR-5q4gm5b; UTN code: U1111-1274-1961.

**中文摘要译文：**
背景：血管紧张素受体-脑啡肽酶抑制剂沙库巴曲缬沙坦对蒽环类药物所致心脏毒性的临床效果尚不明确。实验证据表明其具有心脏保护特性。本研究旨在评估沙库巴曲缬沙坦在降低蒽环类药物化疗期间心脏肌钙蛋白I浓度升高的患者的心脏毒性方面的功效。

方法：这项随机、双盲、安慰剂对照试验共纳入114名在蒽环类药物治疗期间出现心脏肌钙蛋白I水平升高的患者。受试者被以1:1的比例随机分配，接受沙库巴曲缬沙坦或安慰剂治疗，为期6个月，目标剂量为97/103毫克，每日两次。主要终点是从基线到6个月时，总体纵向应变下降超过15%的事件发生率。次要终点包括生物标志物、超声心动图和心脏磁共振参数的变化，以及不良事件。由于其探索性，该试验最初被构想为一项初步研究。数据分析遵循意向性治疗原则。

结果：在随机分组的患者中，90%为女性，80.7%患有乳腺癌。主要终点事件在沙库巴曲缬沙坦组中有4名患者（7%）发生，在安慰剂组中有14名患者（25%）发生（比值比为0.23 [95% CI, 0.07-0.75]；P=0.015）。沙库巴曲缬沙坦组的总体纵向应变改善了2.5%，而安慰剂组则下降了7.6%（P<0.001）。在心脏肌钙蛋白I或N末端B型利钠肽原（NT-proBNP）的变化方面，未观察到显著差异。低血压（收缩压<100毫米汞柱）在沙库巴曲缬沙坦组中比安慰剂组更常见（8例 vs 1例；P=0.032）。

结论：SARAH试验（沙库巴曲缬沙坦用于预防化疗期间高敏心肌肌钙蛋白I浓度升高的患者发生蒽环类药物心脏毒性）表明，对于接受蒽环类药物治疗后高敏心肌肌钙蛋白I升高的患者，沙库巴曲缬沙坦疗法有潜力通过总体纵向应变评估，降低左心室功能障碍的发生率。

注册信息：URL: https://ensaiosclinicos.gov.br/rg/RBR-5q4gm5b; UTN代码: U1111-1274-1961.

### 第二部分 AI 大师评价

本研究（SARAH试验）精准地探讨了沙库巴曲缬沙坦在预防蒽环类化疗所致心脏毒性中的作用，其创新之处在于将研究对象聚焦于化疗期间已出现心肌损伤标志物（肌钙蛋白I）升高的特定高危人群。该研究采用双盲随机对照试验设计，并以更敏感的总体纵向应变（GLS）作为主要终点，这增强了研究结果的可靠性与前沿性。研究发现沙库巴曲缬沙坦能有效减少左心室功能障碍的发生，为肿瘤心脏病学领域提供了强有力的循证医学证据，预示着该药物在化疗心脏保护方面具有重要的临床应用前景，尽管需要关注其引起的低血压风险。

---

## 19. 越来越多的证据表明醋酸甲羟孕酮与脑膜瘤风险相关，但其作用机制有待进一步研究。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41230569](https://pubmed.ncbi.nlm.nih.gov/41230569)
**期刊：** Neuro-oncology
**PMID：** 41230569
**DOI：** 10.1093/neuonc/noaf267

### 第一部分 原文与翻译

**英文原标题：** Mounting evidence implicates medroxyprogesterone acetate in meningioma risk, but mechanisms require further investigation.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题明确指出了醋酸甲羟孕酮与脑膜瘤风险之间日益增多的证据关联，并点明了当前研究的空白——其潜在的生物学机制尚不明确。此文很可能是一篇综述或评论性文章，旨在整合现有研究发现，以警示临床医生关注此药物的潜在风险。其核心价值在于强调了进一步开展机制研究的必要性，这对于理解激素依赖性肿瘤的病理生理过程以及指导临床用药安全具有重要的指导意义。

---

## 20. 整合多组学分析揭示了可预测胃癌联合免疫治疗疗效的免疫学表型

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41229377](https://pubmed.ncbi.nlm.nih.gov/41229377)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41229377
**DOI：** 10.1002/advs.202514482

### 第一部分 原文与翻译

**英文原标题：** Integrative Multi-Omics Analysis Uncovers Immunological Phenotypes Predictive of Combinatorial Immunotherapy Response in Gastric Cancer.

**英文摘要原文：**
Current understanding of immune characteristics in gastric cancer remains limited for guiding clinical practice, particularly immunotherapy. This study aims to elucidate the multidimensional landscape of tumor microenvironment in gastric cancer, identify predictive biomarkers potentially associated with favorable immunotherapy response, and propose a precision stratification framework to inform therapeutic strategies. This study introduces a novel immune classification system tumor immune microenvironment (TIME)-inflamed, TIME-desert, and TIME-excluded), and characterize the cellular and molecular characteristics of each subtype. TIME-inflamed tumors exhibit significantly higher infiltration of immune cells in tumor regions, as well as increased expression of inflamed-genes. TIME-desert tumors display minimal immune cell infiltration and feature abnormal microvasculature. TIME-excluded subtype is defined by immune cell accumulation outside the tumor with ineffective intratumoral infiltration, prominent fibroblast activity, and collagen deposition. Application of this immune classification system to stratify gastric cancer within the SPACE cohort successfully demonstrates potential for predicting favorable outcomes of a subset of "cold tumor" patients upon receiving combined immunotherapy and chemotherapy. The findings contribute to advancing the classification of gastric cancer from traditional histopathological subtyping to functional immunological subtyping, providing a valuable scientific foundation for precise patient stratification and the development of individualized immunotherapy strategies in clinical practice.

**中文摘要译文：**
目前对胃癌免疫特征的理解在指导临床实践，特别是免疫治疗方面仍然有限。本研究旨在阐明胃癌肿瘤微环境的多维景观，识别可能与良好免疫治疗反应相关的预测性生物标志物，并提出一个为治疗策略提供信息的精准分层框架。本研究引入了一种新的免疫分类系统（肿瘤免疫微环境(TIME)-炎症型、TIME-沙漠型和TIME-排斥型），并描述了每种亚型的细胞和分子特征。TIME-炎症型肿瘤在肿瘤区域表现出显著更高的免疫细胞浸润，以及炎症基因的表达增加。TIME-沙漠型肿瘤显示出极少的免疫细胞浸润，并以异常的微血管系统为特征。TIME-排斥型亚型的定义是免疫细胞在肿瘤外积聚，但无法有效进行瘤内浸润，并伴有显著的成纤维细胞活性和胶原蛋白沉积。在SPACE队列中应用此免疫分类系统对胃癌进行分层，成功地证明了其在预测一部分“冷肿瘤”患者接受联合免疫治疗和化疗后获得良好预后方面的潜力。这些发现有助于将胃癌的分类从传统的组织病理学分型推进到功能性免疫学分型，为临床实践中精准的患者分层和个体化免疫治疗策略的制定提供了宝贵的科学基础。

### 第二部分 AI 大师评价

本研究利用整合多组学分析方法，创新性地提出了一个基于肿瘤免疫微环境（TIME）的胃癌新分型系统，即炎症型、沙漠型和排斥型。该分型的核心价值在于揭示了不同免疫表型的分子与细胞特征，并成功验证了其预测潜力，特别是能识别出部分传统意义上的“冷肿瘤”患者可能从联合免疫与化疗中获益。此研究将胃癌分型从传统病理学推向了功能免疫学层面，为实现胃癌的精准免疫治疗和患者个体化分层策略提供了重要的科学依据与临床转化前景。

---

## 21. 肝脏低温灌注下肝切除术：单中心110例病例分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225706](https://pubmed.ncbi.nlm.nih.gov/41225706)
**期刊：** Annals of surgery
**PMID：** 41225706
**DOI：** 10.1097/SLA.0000000000006982

### 第一部分 原文与翻译

**英文原标题：** Hepatectomies under Hypothermic Perfusion of the Liver: Analysis of 110 Cases from a Single Center.

**英文摘要原文：**
OBJECTIVE: To propose a surgical strategy guiding the total vascular exclusion (TVE) subtype during liver resection under hypothermic perfusion (LR-HypoT); to analyze the latter's outcome futility, the risk of severe postoperative liver failure (POLF); and whether LT could have been an alternative treatment.

BACKGROUND: Series on LR-HypoT lack granularity, and none analyzed outcome futility or liver transplantation (LT) as an alternative treatment.

METHODS: Single-center retrospective analysis of 110 consecutive LR-HypoT performed between 1997 and 2024 for malignant (n=100) or benign tumors (n=10). The subtypes of TVE used, 90-D mortality, and outcome futility (90-D death or tumor recurrence within six months of surgery) were analyzed. Risk of POLF was analyzed by recursive partitioning analysis.

RESULTS: LR-HypoT was performed in situ in 108 (98.2%) patients and ex situ in 2 (1.8%). 90-D mortality was 15.5% (n=17). POLF, the leading cause of 90-D mortality (14/17, 82.3%), occurred in 32 (29%) patients. Biliary reconstruction (P=0.023) and the need for extended hepatectomy (P=0.033) were the two risk factors for POLF. In patients with cancer, early tumor recurrence and outcome futility rate was 17.2% and 30.0%, respectively. With a median follow-up of 100 (3-183) months, 5-years survival was 36.8%, 30.0%, and 100% for the study population, patients with malignant or benign tumors, respectively. LT criteria were not met by 92% (92/100) of patients with cancer.

CONCLUSIONS: LR-HypoT can be performed in situ in most cases. In patients presenting otherwise unresectable or untransplantable malignant tumors, encouraging long-term results can be obtained in one third of patients.

**中文摘要译文：**
目的：旨在提出一种手术策略，以指导低温灌注下肝切除术（LR-HypoT）中全肝血流阻断（TVE）的亚型选择；分析该术式的无效终点、术后严重肝功能衰竭（POLF）的风险，并探讨肝移植（LT）是否可作为替代治疗方案。

背景：关于低温灌注下肝切除术（LR-HypoT）的系列研究缺乏精细化的数据，且尚无研究分析其无效终点或将肝移植（LT）作为替代治疗方案。

方法：本研究对1997年至2024年间因恶性（n=100）或良性肿瘤（n=10）而接受低温灌注下肝切除术（LR-HypoT）的110例连续病例进行单中心回顾性分析。研究分析了所采用的全肝血流阻断（TVE）亚型、90天死亡率以及无效终点（定义为90天内死亡或术后六个月内肿瘤复发）。通过递归分割分析法评估术后严重肝功能衰竭（POLF）的风险。

结果：108例（98.2%）患者接受了原位低温灌注下肝切除术，2例（1.8%）接受了离体手术。90天死亡率为15.5%（n=17）。术后严重肝功能衰竭（POLF）是90天死亡的主要原因（14/17, 82.3%），共发生于32例（29%）患者。胆道重建（P=0.023）和需要进行扩大的肝切除术（P=0.033）是POLF的两个风险因素。在癌症患者中，早期肿瘤复发率和无效终点率分别为17.2%和30.0%。中位随访时间为100（3-183）个月，整个研究人群、恶性肿瘤患者和良性肿瘤患者的5年生存率分别为36.8%、30.0%和100%。92%（92/100）的癌症患者不符合肝移植标准。

结论：低温灌注下肝切除术（LR-HypoT）在大多数情况下可于原位完成。对于那些原本无法切除或无法移植的恶性肿瘤患者，该技术可为三分之一的患者带来令人鼓舞的长期生存结果。

### 第二部分 AI 大师评价

本研究通过对长达27年的110例单中心数据进行回顾性分析，系统评估了肝脏低温灌注下肝切除术这一高难度技术的临床结局。其核心价值在于不仅明确了术后严重肝功能衰竭的关键风险因素（如胆道重建和扩大切除），还创新性地引入“无效终点”概念，并论证了该技术对于不符合肝移植标准、肿瘤无法切除的患者的独特价值。研究结果表明，尽管该手术风险较高，但仍能为约三分之一的特定恶性肿瘤患者提供长期生存的机会，为复杂肝脏手术的决策提供了重要依据。

---

## 22. 神经源性诱导剂通过促进肿瘤细胞转分化抑制胰腺癌的增殖

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225636](https://pubmed.ncbi.nlm.nih.gov/41225636)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41225636
**DOI：** 10.1186/s13046-025-03563-9

### 第一部分 原文与翻译

**英文原标题：** Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation.

**英文摘要原文：**
BACKGROUND: Tumor cell differentiation is a critical determinant of malignancy and clinical treatment selection. Pancreatic ductal adenocarcinoma (PDAC), a poorly differentiated and highly aggressive tumor, has a poor prognosis, whereas well-differentiated tumors often correlate with better outcomes. The mechanisms underlying differentiation and its therapeutic potential remain unclear.

OBJECTIVES: This study aims to investigate whether inducing transdifferentiation in pancreatic cancer cells can reduce malignancy, focusing on the role of the transcription factor NeuroD1 and its regulatory pathways.

METHODS: We analyzed single-cell RNA-seq data from the GEO database to identify differentiation-associated genes. NeuroD1 was overexpressed in PDAC cells to assess its effects on transdifferentiation and proliferation. Drug screening and molecular docking were performed to identify differentiation-inducing compounds. RNA sequencing, coimmunoprecipitation, and mass spectrometry were used to identify NeuroD1-interacting proteins. Cell/patient-derived xenograft mouse models are utilized for in vivo experiments and compound efficacy testing.

RESULTS: Highly differentiated tumor cells exhibited elevated NeuroD1 expression. NeuroD1 overexpression promoted neuronal transdifferentiation and suppressed proliferation. Neuropathiazol, a neurogenic inducer, was found to bind MET and upregulate NeuroD1 via the PI3K/Akt pathway, enhancing transdifferentiation and inhibiting tumor growth. Neurog3 was identified as a functional partner of NeuroD1.

CONCLUSION: Our findings demonstrate that pancreatic cancer cells can be induced to transdifferentiate through NeuroD1 activation or pharmacological induction, suggesting a potential therapeutic strategy to mitigate malignancy by reprogramming tumor cells into less aggressive states.

**中文摘要译文：**
背景：肿瘤细胞分化是决定恶性程度和临床治疗选择的关键因素。胰腺导管腺癌（PDAC）是一种低分化、高侵袭性的肿瘤，预后较差，而分化良好的肿瘤通常与更好的结局相关。分化的潜在机制及其治疗潜力尚不清楚。

目的：本研究旨在探讨诱导胰腺癌细胞转分化是否能降低其恶性程度，重点关注转录因子NeuroD1的作用及其调控通路。

方法：我们分析了GEO数据库的单细胞RNA测序数据，以鉴定与分化相关的基因。在PDAC细胞中过表达NeuroD1，以评估其对转分化和增殖的影响。通过药物筛选和分子对接来鉴定诱导分化的化合物。利用RNA测序、免疫共沉淀和质谱法鉴定与NeuroD1相互作用的蛋白。利用细胞/患者来源的异种移植小鼠模型进行体内实验和化合物药效测试。

结果：高度分化的肿瘤细胞表现出NeuroD1表达升高。过表达NeuroD1可促进神经元转分化并抑制增殖。研究发现，神经源性诱导剂Neuropathiazol能与MET结合，并通过PI3K/Akt通路上调NeuroD1，从而增强转分化并抑制肿瘤生长。Neurog3被鉴定为NeuroD1的一个功能伙伴。

结论：我们的研究结果表明，通过激活NeuroD1或药物诱导，可以促使胰腺癌细胞发生转分化，这提示了一种通过将肿瘤细胞重编程为低侵袭性状态来降低其恶性程度的潜在治疗策略。

### 第二部分 AI 大师评价

本研究聚焦于恶性程度极高的胰腺癌，创新性地探索了通过诱导肿瘤细胞“转分化”为神经元样细胞来抑制其增殖的治疗新策略。研究团队综合运用了单细胞测序、药物筛选和体内外模型，不仅明确了关键转录因子NeuroD1的核心作用，还筛选出小分子药物Neuropathiazol，并阐明了其通过MET-PI3K/Akt通路激活NeuroD1的分子机制。这项工作为胰腺癌治疗提供了“改邪归正”的新思路，揭示了分化疗法的巨大潜力，为后续药物开发和临床转化奠定了坚实基础。

---

## 23. 选择性BCL-xL降解剂DT2216在复发/难治性实体恶性肿瘤患者中的首次人体I期研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225624](https://pubmed.ncbi.nlm.nih.gov/41225624)
**期刊：** Journal of hematology & oncology
**PMID：** 41225624
**DOI：** 10.1186/s13045-025-01753-8

### 第一部分 原文与翻译

**英文原标题：** First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.

**英文摘要原文：**
BACKGROUND: Small molecule inhibition of BCL-XL with navitoclax resulted in on-target dose-limiting thrombocytopenia. DT2216 was more effective than navitoclax and reduced platelet toxicity in preclinical models by selectively degrading BCL-XL via the VHL E3 ligase, which is minimally expressed in platelets.

METHODS: A dose escalation study using a 3 + 3 design with doses ranging from 0.04 to 0.4 mg/kg IV twice weekly (BIW) was performed. Eligible subjects had solid tumors of any histology that had progressed on standard treatment and had measurable tumor by RECIST v1.1. Tumor assessment was performed at 8-week intervals. BCL-XL levels were measured in peripheral leukocytes by western blotting.

RESULTS: Twenty patients were enrolled, with a median age of 60.5 year; 60% were female. Only one dose-limiting toxicity was observed, grade 4 thrombocytopenia that resolved within 48 h. Stable disease, observed in 20% of the patients. The lowest platelet count in the first cycle ranged from 24,000 to 297,000. In all cases, the platelet count recovered to > 50,000 within 4 days and > 75,000 within 1 week. There were no episodes of bleeding or treatment emergent adverse events leading to death. The median overall survival was 7.9 months. The plasma AUC of DT2216 was dose proportional with no dose accumulation. Patients receiving 0.4 mg/kg DT2216 demonstrated rapid and sustained degradation of BCL-XL.

CONCLUSIONS: Based on the rapid recovery of transient thrombocytopenia that occurred only in the first cycle and the degradation of BCL-XL in peripheral leukocytes, the RP2D of DT2216 is 0.4 mg/kg IV BIW. (NCT04886622).

**中文摘要译文：**
背景：使用navitoclax对BCL-XL进行小分子抑制导致了靶向性的剂量限制性血小板减少症。在临床前模型中，DT2216通过VHL E3连接酶选择性降解BCL-XL，其效果优于navitoclax并降低了血小板毒性，因为该连接酶在血小板中表达极少。

方法：本研究采用3+3设计进行剂量爬坡研究，静脉注射（IV）剂量范围为0.04至0.4 mg/kg，每周两次（BIW）。符合条件的受试者为经标准治疗后病情进展、且根据RECIST v1.1标准具有可测量肿瘤的任何组织学类型的实体瘤患者。肿瘤评估每8周进行一次。通过蛋白质印迹法（western blotting）检测外周血白细胞中的BCL-XL水平。

结果：共招募了20名患者，中位年龄为60.5岁，其中60%为女性。仅观察到一例剂量限制性毒性，即4级血小板减少症，该症状在48小时内缓解。20%的患者观察到疾病稳定。在第一个周期中，最低血小板计数范围为24,000至297,000。所有病例的血小板计数均在4天内恢复至>50,000，并在1周内恢复至>75,000。未发生出血事件或导致死亡的治疗相关不良事件。中位总生存期为7.9个月。DT2216的血浆药时曲线下面积（AUC）呈剂量正相关，无剂量蓄积。接受0.4 mg/kg DT2216治疗的患者表现出快速且持续的BCL-XL降解。

结论：基于仅在第一周期发生的短暂性血小板减少症的快速恢复以及外周血白细胞中BCL-XL的降解情况，DT2216的2期推荐剂量（RP2D）为0.4 mg/kg，每周两次静脉注射。（NCT04886622）。

### 第二部分 AI 大师评价

该项I期临床研究旨在评估新型选择性BCL-xL降解剂DT2216在复发/难治性实体瘤患者中的安全性与初步活性。其核心创新在于利用PROTAC技术，巧妙地通过在血小板中低表达的VHL E3连接酶来降解BCL-xL，旨在解决既往同靶点抑制剂因严重血小板毒性而受限的临床难题。研究结果成功验证了此策略的安全性优势，即血小板减少症短暂且可快速恢复，并确定了II期推荐剂量，为后续开发提供关键依据。尽管作为早期研究，其疗效数据尚待进一步证实，但该研究为解锁BCL-xL这一重要抗凋亡靶点的治疗潜力提供了极具价值的临床证据。

---

## 24. 解码癌症休眠：整合基因组、表型和活细胞成像分析以揭示隐藏的癌细胞储存库

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225537](https://pubmed.ncbi.nlm.nih.gov/41225537)
**期刊：** Molecular cancer
**PMID：** 41225537
**DOI：** 10.1186/s12943-025-02499-0

### 第一部分 原文与翻译

**英文原标题：** Decoding cancer dormancy: integrative genomic, phenotypic and live-cell imaging analysis to reveal the hidden cancer cell reservoir.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

本研究旨在通过整合性的分析方法，深入解码癌症休眠的复杂机制。研究计划采用基因组学、表型分析与活细胞成像技术相结合的多维策略，以期揭示作为癌症复发根源的隐藏癌细胞储存库。该研究的创新性在于其系统性的研究设计，有望为理解肿瘤休眠提供新的见解，并为开发根除残留病灶、防止复发的治疗新策略提供关键的理论依据。然而，由于摘要缺失，无法评估其实际发现和具体结论。

---

## 25. FGD3介导溶解性细胞死亡，增强乳腺癌化疗药物的疗效和免疫原性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225536](https://pubmed.ncbi.nlm.nih.gov/41225536)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41225536
**DOI：** 10.1186/s13046-025-03559-5

### 第一部分 原文与翻译

**英文原标题：** FGD3 mediates lytic cell death, enhancing efficacy and immunogenicity of chemotherapy agents in breast cancer.

**英文摘要原文：**
BACKGROUND: Although anticancer therapies inducing necrosis, necroptosis and pyroptosis trigger cell swelling, plasma membrane rupture (PMR) and release of damage-associated molecular patterns (DAMPs), potentially facilitating antitumor immunity, little was known of proteins and mechanisms controlling the life-death decision of whether swollen and stressed cancer cells enter PMR and undergo lytic cell death.

METHODS: We conducted a genome-wide CRISPR screen with selection against a lytic cell death inducer, complemented by studies using breast cancer cells in 2D culture, patient-derived organoids and orthotopic mouse xenografts. The effect of FGD3 on immunogenicity was explored by immunoblotting, immunofluorescence staining and NK-cell mediated cytotoxicity assays. The correlation between the level of FGD3 expression and patient prognosis and response to chemotherapy was assessed by analysis of patient databases.

RESULTS: We identified FGD3 as a key mediator, coupling cell swelling to PMR and lytic cell death induced by emerging and current breast cancer therapies, including ErSO, aprepitant, doxorubicin and epirubicin. FGD3 coupled cell swelling to PMR across the spectrum of immunogenic lytic cell death pathways, including necrosis, necroptosis and pyroptosis. Mechanistically, FGD3 facilitated PMR by controlling actin reorganization via the Cdc42-ARP2/3 axis. Notably, elevated FGD3 increased release of DAMPs, strongly enhanced exposure of immunogenic cell surface calreticulin and increased sensitivity of cancer cells to NK cell-mediated lysis. Supporting clinical relevance, high FGD3 expression strongly correlated with improved relapse-free survival in breast cancer patients after chemotherapy and this correlation was stronger than was seen for NINJ1 and other proteins associated with lytic cell death.

CONCLUSION: FGD3 is a key mediator of chemotherapy-induced plasma membrane rupture and lytic cell death. It is also a useful biomarker for identifying breast cancer patients most likely to benefit from lytic cell death-inducing immunogenic anticancer therapies.

**中文摘要译文：**
背景：尽管诱导坏死、坏死性凋亡和焦亡的抗癌疗法会引发细胞肿胀、质膜破裂（PMR）以及损伤相关分子模式（DAMPs）的释放，从而可能促进抗肿瘤免疫，但对于控制肿胀和应激状态下的癌细胞是否进入PMR并发生溶解性细胞死亡这一生死抉择的蛋白质及机制，我们知之甚少。

方法：我们进行了一项全基因组CRISPR筛选，以抵抗一种溶解性细胞死亡诱导剂为筛选条件，并辅以使用二维培养的乳腺癌细胞、患者来源的类器官以及原位小鼠异种移植模型进行的研究。通过免疫印迹、免疫荧光染色和NK细胞介导的细胞毒性试验，我们探究了FGD3对免疫原性的影响。通过分析患者数据库，我们评估了FGD3表达水平与患者预后及化疗反应之间的相关性。

结果：我们鉴定出FGD3是一个关键介导因子，它能将细胞肿胀与由新兴及现有乳腺癌疗法（包括ErSO、阿瑞匹坦、多柔比星和表柔比星）诱导的PMR及溶解性细胞死亡联系起来。在包括坏死、坏死性凋亡和焦亡在内的多种免疫原性溶解性细胞死亡途径中，FGD3均能将细胞肿胀与PMR联系起来。在机制上，FGD3通过Cdc42-ARP2/3轴控制肌动蛋白重组来促进PMR。值得注意的是，FGD3水平升高会增加DAMPs的释放，显著增强免疫原性细胞表面钙网蛋白的暴露，并提高癌细胞对NK细胞介导的裂解的敏感性。支持其临床相关性的是，在接受化疗的乳腺癌患者中，FGD3的高表达与改善的无复发生存率密切相关，且这种相关性强于NINJ1及其他与溶解性细胞死亡相关的蛋白。

结论：FGD3是化疗诱导的质膜破裂和溶解性细胞死亡的关键介导因子。它也是一个有用的生物标志物，可用于识别最有可能从诱导溶解性细胞死亡的免疫原性抗癌疗法中获益的乳腺癌患者。

### 第二部分 AI 大师评价

本研究旨在揭示调控癌细胞在治疗压力下发生溶解性死亡的关键蛋白与机制。研究团队综合运用全基因组CRISPR筛选、细胞与类器官模型及临床数据分析等前沿技术，发现并验证了FGD3是介导多种免疫原性溶解性细胞死亡（如坏死、焦亡）的核心分子。其关键发现是，FGD3通过Cdc42-ARP2/3轴调控肌动蛋白重组来促进质膜破裂，从而增强化疗药物的免疫原性，并且其高表达与乳腺癌患者化疗后的更佳预后显著相关。这项工作不仅创新性地填补了对溶解性细胞死亡调控机制认识的空白，更揭示了FGD3作为预测化疗疗效的潜在生物标志物，具有重要的临床转化价值。

---

## 26. SHOX2、RASSF1A、Septin9和HOXA9基因甲基化在胸腔积液淋巴瘤中的诊断效能及亚组异质性研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225534](https://pubmed.ncbi.nlm.nih.gov/41225534)
**期刊：** Clinical epigenetics
**PMID：** 41225534
**DOI：** 10.1186/s13148-025-01996-9

### 第一部分 原文与翻译

**英文原标题：** Diagnostic efficacy and subgroup heterogeneity of SHOX2, RASSF1A, Septin9, and HOXA9 methylation in pleural effusion lymphoma.

**英文摘要原文：**
BACKGROUND: DNA methylation profiling has emerged as a promising tool for improving pathological diagnosis. This study investigates the diagnostic efficacy and subgroup heterogeneity of SHOX2, RASSF1A, Septin9, and HOXA9 methylation in pleural effusion lymphoma, aiming to enhance diagnostic accuracy and identify high-risk molecular subgroups.

METHODS: A cohort of 109 patients (73 lymphoma, 36 benign pleural effusions) was analyzed using quantitative methylation-specific PCR for the four biomarkers. Receiver operating characteristic (ROC) curves were constructed to determine optimal cutoff values for each marker, and their diagnostic performance was evaluated in different lymphoma subgroups.

RESULTS: The cycle threshold values for the internal control β-actin predominantly ranged from 18 to 23, suggesting consistent DNA input for methylation analysis. ROC curve revealed that the area under the curve (AUC) values were 0.871 (SHOX2), 0.779 (HOXA9), 0.611 (Septin9), and 0.548 (RASSF1A). When combined, the four markers achieved an AUC of 0.896, with an overall diagnostic sensitivity of 83.6% and a specificity of 94.4%. SHOX2 and HOXA9 demonstrated higher sensitivity within diffuse large B-cell lymphoma (DLBCL) subgroups, with SHOX2 achieving 100% sensitivity in the non-GCB subgroup and HOXA9 achieving 90.9% sensitivity in the GCB subgroup. Septin9 methylation was significantly associated with the presence of B symptoms (P = 0.041). Importantly, RASSF1A methylation was more strongly associated with TP53 deletion rather than with Bcl-2/IGH, Bcl-6, or c-MYC rearrangements.

CONCLUSION: Integrating methylation markers SHOX2, HOXA9, Septin9, and RASSF1A exhibits significant diagnostic potential in pleural effusion lymphoma, especially within DLBCL subgroups. These markers could prove valuable in identifying high-risk subgroups and guiding clinical decision-making.

**中文摘要译文：**
背景：DNA甲基化分析已成为改善病理诊断的一种有前景的工具。本研究旨在探讨SHOX2、RASSF1A、Septin9和HOXA9基因甲基化在胸腔积液淋巴瘤中的诊断效能及亚组异质性，以期提高诊断准确性并识别高风险分子亚组。

方法：采用定量甲基化特异性PCR技术，对一个包含109名患者（73例淋巴瘤，36例良性胸腔积液）的队列进行了四个生物标志物的分析。构建受试者工作特征（ROC）曲线以确定每个标志物的最佳截断值，并评估其在不同淋巴瘤亚组中的诊断性能。

结果：内参基因β-actin的循环阈值主要分布在18至23之间，表明用于甲基化分析的DNA起始量一致。ROC曲线分析显示，曲线下面积（AUC）值分别为0.871（SHOX2）、0.779（HOXA9）、0.611（Septin9）和0.548（RASSF1A）。当联合使用时，这四个标志物的AUC达到0.896，总体诊断灵敏度为83.6%，特异性为94.4%。在弥漫性大B细胞淋巴瘤（DLBCL）亚组中，SHOX2和HOXA9表现出更高的灵敏度，其中SHOX2在非生发中心B细胞样（non-GCB）亚组中灵敏度达到100%，而HOXA9在生发中心B细胞样（GCB）亚组中灵敏度达到90.9%。Septin9甲基化与B症状的出现显著相关（P = 0.041）。重要的是，RASSF1A甲基化与TP53缺失的关联性强于其与Bcl-2/IGH、Bcl-6或c-MYC重排的关联。

结论：联合应用SHOX2、HOXA9、Septin9和RASSF1A甲基化标志物在胸腔积液淋巴瘤，尤其是在DLBCL亚组中，展现出显著的诊断潜力。这些标志物可能在识别高风险亚组和指导临床决策方面具有重要价值。

### 第二部分 AI 大师评价

本研究通过检测胸腔积液样本中四个特定基因（SHOX2, HOXA9, Septin9, RASSF1A）的甲基化水平，旨在评估其对淋巴瘤的诊断效能。研究发现，这四种标志物的联合检测展现出优异的诊断准确性，特别是SHOX2和HOXA9在区分弥漫性大B细胞淋巴瘤的不同亚型方面表现突出。该研究的价值在于提出了一种基于液体活检的微创诊断新策略，不仅有助于淋巴瘤的早期识别，还能通过分子标志物对患者进行风险分层，为实现精准治疗提供了重要依据。

---

## 27. MicroRNA-142可增强IL1RAP CAR-T细胞在急性髓系白血病中的活性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225489](https://pubmed.ncbi.nlm.nih.gov/41225489)
**期刊：** Journal of hematology & oncology
**PMID：** 41225489
**DOI：** 10.1186/s13045-025-01755-6

### 第一部分 原文与翻译

**英文原标题：** MicroRNA-142 improves IL1RAP CAR-T cell activity in acute myeloid leukemia.

**英文摘要原文：**
BACKGROUND: Interleukin-1 receptor accessory protein (IL1RAP) is selectively expressed on both bulk blasts and leukemic stem cells (LSCs) in acute myeloid leukemia (AML), while its expression is virtually absent on normal hematopoietic stem cells (HSCs), making it an appealing target for chimeric antigen receptor (CAR) T cell therapy.

METHODS: We developed a novel IL1RAP-targeting CAR-T cells using a single-chain Fab (24scFab) fused to CD28 and CD3ζ costimulatory domains. CAR-T cells with a mutated IL1RAP-binding paratope were also generated as a control by introducing two point-mutations in the complementarity determining region (CDR) loops of the 24scFab domain. We tested the CAR-T cells in cell line-derived (CD) and patient-derived (PD) xenografts (X). To address persistence and activity of IL1RAP CAR-T cells, we then tested two approaches. First, we mutated two of the three immunoreceptor tyrosine-based activation motifs (ITAMs) within the CD3ζ domain (i.e., IL1RAP-1XX CAR-T). Second, we co-administered a synthetic miR-142 mimic (M-miR-142), previously shown to enhance T cell antileukemic activity, with IL1RAP CAR-T cells to AML xenografted mice.

RESULTS: IL1RAP CAR-T cells demonstrated a potent antileukemic activity in both AML CDX and PDX models. Target specificity was confirmed by the complete loss of function of IL1RAP-mutated CAR-T cells. IL1RAP-1XX CAR-T cells improved T cell persistence in vitro but failed to demonstrate therapeutic benefit compared with IL1RAP CAR-T cells in vivo. We previously reported that leukemic cell growth suppresses miR-142 biogenesis, thereby hindering the metabolic switch and impairing host T cell antileukemic activity; this was rescued by administration of M-miR-142. Thus, we hypothesized a similar impact of leukemic cells on CAR-T and that M-miR-142 treatment could rescue it and enhance the IL1RAP CAR-T cell antileukemic activity. We showed that both CDXs and PDXs receiving M-miR-142 and IL1RAP CAR-T lived significantly longer than those receiving scrambled oligonucleotide and IL1RAP CAR-T or mutated CAR-T controls (median survival of PDX: 78 vs 51 vs 24 days).

CONCLUSIONS: We have identified a potentially novel strategy to enhance CAR-T cell persistence and efficacy in AML by counteracting a leukemia-induced, microRNA-deficiency mediated mechanism of immune suppression.

**中文摘要译文：**
背景：白介素-1受体辅助蛋白（IL1RAP）在急性髓系白血病（AML）的肿瘤细胞和白血病干细胞（LSCs）上选择性表达，而在正常造血干细胞（HSCs）上几乎不表达，这使其成为嵌合抗原受体（CAR）T细胞治疗的一个有吸引力的靶点。

方法：我们利用与CD28和CD3ζ共刺激域融合的单链Fab（24scFab），开发了一种新型靶向IL1RAP的CAR-T细胞。通过在24scFab结构域的互补决定区（CDR）环中引入两个点突变，我们还生成了IL1RAP结合互补位突变的CAR-T细胞作为对照。我们在细胞系来源（CD）和患者来源（PD）的异种移植（X）模型中测试了这些CAR-T细胞。为解决IL1RAP CAR-T细胞的持久性和活性问题，我们接着测试了两种方法。首先，我们突变了CD3ζ结构域内三个免疫受体酪氨酸活化基序（ITAMs）中的两个（即IL1RAP-1XX CAR-T）。其次，我们将一种先前已证明能增强T细胞抗白血病活性的合成miR-142模拟物（M-miR-142），与IL1RAP CAR-T细胞共同施用于AML异种移植小鼠。

结果：IL1RAP CAR-T细胞在AML CDX和PDX模型中均表现出强大的抗白血病活性。IL1RAP突变CAR-T细胞的功能完全丧失，证实了靶点特异性。IL1RAP-1XX CAR-T细胞在体外改善了T细胞的持久性，但与IL1RAP CAR-T细胞相比，在体内未能显示出治疗优势。我们先前报道，白血病细胞的增殖会抑制miR-142的生物合成，从而阻碍代谢转换并削弱宿主T细胞的抗白血病活性；而施用M-miR-142可挽救此现象。因此，我们假设白血病细胞对CAR-T细胞有类似影响，且M-miR-142治疗可以挽救并增强IL1RAP CAR-T细胞的抗白血病活性。我们发现，同时接受M-miR-142和IL1RAP CAR-T治疗的CDX和PDX模型小鼠，其存活期显著长于接受乱序寡核苷酸和IL1RAP CAR-T或突变CAR-T对照组的小鼠（PDX模型中位生存期：78天 vs 51天 vs 24天）。

结论：我们鉴定出一种潜在的新策略，通过抵消白血病诱导的、由microRNA缺陷介导的免疫抑制机制，来增强CAR-T细胞在AML中的持久性和疗效。

### 第二部分 AI 大师评价

该研究开发了一种靶向IL1RAP的新型CAR-T细胞疗法用于治疗急性髓系白血病（AML）。核心创新点在于，研究者发现通过联合使用一种合成的miR-142模拟物（M-miR-142），能够显著增强IL1RAP CAR-T细胞的抗白血病活性并延长异种移植模型的生存期。这项工作不仅验证了IL1RAP作为AML治疗靶点的有效性，更揭示了一种通过克服白血病诱导的免疫抑制来提升CAR-T疗法持久性和疗效的新策略，为AML的免疫治疗提供了富有前景的新思路。

---

## 28. PredIG：一种可解释的T细胞表位免疫原性预测工具

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225487](https://pubmed.ncbi.nlm.nih.gov/41225487)
**期刊：** Genome medicine
**PMID：** 41225487
**DOI：** 10.1186/s13073-025-01569-8

### 第一部分 原文与翻译

**英文原标题：** PredIG: an interpretable predictor of T-cell epitope immunogenicity.

**英文摘要原文：**
BACKGROUND: Cytotoxic T cells are key effectors in the immune response against pathogens and tumors. Thus, identifying those immunogenic epitopes driving T-cell activation conforms a fundamental goal for antigen-based immunotherapies. T-cell antigen discovery is challenged by immense epitope landscapes, unfeasible to screen ad hoc experimentally due to the high cost and low throughput of immunogenicity validations. Precedingly, immunoinformatic models, with orders of magnitude higher throughput such as HLA-I binding affinity tools, are used to predict the antigenic potential of T-cell epitopes. However, the resulting immunogenicity screening success rates (ISSR)-the capacity to rank truly immunogenic epitopes among top-scored candidates prioritized for experimental validation-have remained incremental and the immunological explainability underlying model predictions limited.

RESULTS: PredIG is an interpretable predictor of T-cell epitope immunogenicity trained upon 17,448 peptide-HLA-I allele pairs (pHLAs) with reported immunogenicity in T-cell reactivity and binding assays. Upon pHLAs, PredIG integrates an in silico feature space of antigenic properties (proteasomal cleavage, TAP translocation, HLA-I binding affinity, and presentation), and physicochemical epitope descriptors, particularly focused on TCR-facing central residues. Leveraging this information, we built three antigen-specific XGBoost models to compute PredIG immunogenicity scores (PredIG-NeoAntigen, PredIG-NonCanonical, and PredIG-Pathogen). We then used Shapley Additive models (SHAP) to analyze their immunological interpretability pinpointing a balanced feature importance between antigenic and physicochemical properties. This highlighted the strong contribution of antigen processing likelihood and physicochemical characteristics, often overlooked in T-cell epitope predictions. Comparably, PredIG obtained cutting-edge ISSR performance in our pathogen and non-canonical cancer antigen held-outs versus immunogenicity, HLA-I binding, and pHLA stability predictors. In cancer neoantigens, we used PredIG to refine the success rates of HLA-I binding affinity predictions and to prioritize an additional set of immunogenic (neo)epitopes differing from top-binding candidates across the three antigen types tested.

CONCLUSIONS: Overall, we demonstrate how PredIG immunogenicity scores are instrumental to refine and expand the prioritization of actionable T-cell (neo)epitopes in infection and cancer, including non-canonical antigens not seen during training. Furthermore, PredIG displays an unprecedented immunological interpretability determining important immunogenicity drivers beyond HLA-I binding affinity. Ultimately, PredIG enables large throughput antigen discovery in open-source containerized environments ( https://github.com/BSC-CNS-EAPM/PredIG ) and facilitates accessibility via a streamlined webserver ( https://horus.bsc.es/predig ).

**中文摘要译文：**
背景：细胞毒性T细胞是抵抗病原体和肿瘤的免疫应答中的关键效应细胞。因此，识别那些驱动T细胞活化的免疫原性表位，构成了基于抗原的免疫疗法的一个基本目标。由于免疫原性验证的高成本和低通量，对巨大的表位图谱进行即时实验筛选是不可行的，这给T细胞抗原的发现带来了挑战。在此之前，人们使用通量高出几个数量级的免疫信息学模型，例如HLA-I结合亲和力工具，来预测T细胞表位的抗原潜能。然而，由此产生的免疫原性筛选成功率（ISSR）——即在优先进行实验验证的高分候选表位中对真正具有免疫原性的表位进行排序的能力——其提升一直很有限，且模型预测背后的免疫学可解释性也受到限制。

结果：PredIG是一种可解释的T细胞表位免疫原性预测工具，它基于17,448个在T细胞反应性和结合分析中已报道具有免疫原性的肽-HLA-I等位基因对（pHLAs）进行训练。PredIG在pHLAs的基础上，整合了一个包含抗原特性（蛋白酶体切割、TAP转运、HLA-I结合亲和力及呈递）和表位理化描述符的计算机模拟特征空间，并特别关注面向TCR的中心残基。利用这些信息，我们构建了三个抗原特异性的XGBoost模型来计算PredIG免疫原性评分（PredIG-NeoAntigen、PredIG-NonCanonical和PredIG-Pathogen）。随后，我们使用沙普利加性模型（SHAP）分析了它们的免疫学可解释性，指出了抗原特性和理化特性之间均衡的特征重要性。这突显了抗原处理可能性和理化特征的强大贡献，而这些在T细胞表位预测中常常被忽视。相比之下，在我们的病原体和非经典癌症抗原的保留测试集中，与免疫原性、HLA-I结合和pHLA稳定性预测工具相比，PredIG获得了前沿的ISSR性能。在癌症新抗原方面，我们使用PredIG来提高HLA-I结合亲和力预测的成功率，并在所测试的三种抗原类型中，优先筛选出不同于顶级结合候选物的额外一组免疫原性（新）表位。

结论：总的来说，我们证明了PredIG免疫原性评分有助于在感染和癌症中优化和扩展可操作的T细胞（新）表位的优先排序，包括那些在训练中未曾见过的非经典抗原。此外，PredIG展示了前所未有的免疫学可解释性，确定了超越HLA-I结合亲和力的重要免疫原性驱动因素。最终，PredIG在开源的容器化环境（https://github.com/BSC-CNS-EAPM/PredIG）中实现了高通量抗原发现，并通过一个简化的网络服务器（https://horus.bsc.es/predig）方便了用户访问。

### 第二部分 AI 大师评价

本研究旨在开发一种名为PredIG的可解释性计算模型，用以更准确地预测T细胞表位的免疫原性，从而提高肿瘤和病原体免疫治疗中抗原发现的效率。该模型基于大规模肽-HLA复合体数据，创新性地整合了抗原处理、呈递过程及表位理化性质等多维度特征，并利用XGBoost和SHAP技术构建了高精度且可解释的预测框架。研究关键发现，PredIG在多种抗原类型上均表现出顶尖的预测性能，超越了传统的仅依赖HLA结合亲和力的工具，并揭示了抗原加工和理化特性对免疫原性的同等重要性。这项工作不仅提供了一个强大的开源工具，极大地促进了T细胞（新）表位的筛选，其模型的可解释性也为深入理解免疫识别机制提供了新的见解，具有重要的科研和临床转化价值。

---

## 29. HER2阳性乳腺癌新辅助化疗联合曲妥珠单抗治疗的动态肿瘤免疫分型图谱

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225463](https://pubmed.ncbi.nlm.nih.gov/41225463)
**期刊：** Molecular cancer
**PMID：** 41225463
**DOI：** 10.1186/s12943-025-02483-8

### 第一部分 原文与翻译

**英文原标题：** The landscape of dynamic tumor immunophenotyping on neoadjuvant chemotherapy combined with trastuzumab for the treatment of HER2-positive breast cancer.

**英文摘要原文：**
BACKGROUND: For HER2-positive breast cancer (BC), patients who achieve pathologic complete response (pCR) are predicted to have better clinical outcomes. With the advent of the era of neoadjuvant chemotherapy (NAC) combined with targeted therapy, the pCR rate of HER2-positive BC has increased significantly, but about 50% of these patients still do not respond to targeted therapy. The dynamic changes in the tumor microenvironment (TME) may crucially influence pCR outcomes in HER2-positive BC. However, there is no specific immunophenotyping study that correlates with the efficacy during treatment.

METHODS: We conducted a comprehensive spatial expression profiling analysis on 94 ROIs procured from 28 HER2-positive BC patients, encompassing both their initial diagnostic stage and postoperative status. Leveraging DSP techniques, we precisely mapped and quantified the TME at these critical time points for patients.

RESULTS: Notably, we classified specimens into four groups: IM1, IM2, TM1, and TM2. IM1 and TM1, characterized by CD4⁺ naïve T cells and naïve B cells, showed higher pCR rates, whereas IM2 and TM2 exhibited lower rates. In addition, baseline IM1 patients who were classified as TM1 postoperatively achieved a 100% pCR rate, while baseline IM2 patients who were classified as TM2 postoperatively had a poor pCR rate of only 10%. The immunophenotypes defined by spatial transcriptomics were reproducible in both TCGA and single-cell datasets, and spatial analysis further revealed structured cellular transitions and functional heterogeneity at the tumor-immune interface.

CONCLUSION: Our dynamic immunophenotyping can provide prediction of the efficacy for NAC with trastuzumab in HER2-positive BC patients, and provide a basis for the selection of subsequent treatment regimens.

**中文摘要译文：**
背景：对于HER2阳性乳腺癌（BC），达到病理学完全缓解（pCR）的患者预计将获得更好的临床结局。随着新辅助化疗（NAC）联合靶向治疗时代的到来，HER2阳性乳腺癌的pCR率显著提高，但仍有约50%的患者对靶向治疗无应答。肿瘤微环境（TME）的动态变化可能对HER2阳性乳腺癌的pCR结局产生关键影响。然而，目前尚无与治疗期间疗效相关的特异性免疫分型研究。

方法：我们对28名HER2阳性乳腺癌患者的94个感兴趣区域（ROIs）进行了全面的空间表达谱分析，这些样本涵盖了患者的初诊阶段和术后状态。利用数字空间蛋白质组学（DSP）技术，我们精确地绘制并量化了患者在这些关键时间点的TME。

结果：值得注意的是，我们将样本分为四组：IM1、IM2、TM1和TM2。以CD4⁺初始T细胞和初始B细胞为特征的IM1和TM1组显示出较高的pCR率，而IM2和TM2组的pCR率较低。此外，基线时为IM1型并在术后归类为TM1型的患者实现了100%的pCR率，而基线时为IM2型并在术后归类为TM2型的患者的pCR率仅为10%。通过空间转录组学定义的免疫分型在TCGA和单细胞数据集中均可复现，并且空间分析进一步揭示了肿瘤-免疫界面上结构化的细胞转变和功能异质性。

结论：我们的动态免疫分型可为HER2阳性乳腺癌患者接受新辅助化疗联合曲妥珠单抗的疗效提供预测，并为后续治疗方案的选择提供依据。

### 第二部分 AI 大师评价

本研究创新性地运用数字空间蛋白质组学（DSP）技术，动态追踪了HER2阳性乳腺癌患者在新辅助化疗联合靶向治疗过程中的肿瘤免疫微环境演变。研究通过定义四种免疫分型，关键性地发现以初始T细胞和B细胞为特征的免疫表型与更高的病理学完全缓解率（pCR）显著相关。其核心价值在于揭示了从基线到术后的免疫分型转变对pCR具有强大的预测能力，为精准预测疗效和指导后续治疗策略提供了新的生物标志物，为理解治疗抵抗机制和开发个体化免疫治疗方案开辟了新思路。

---

## 30. 更正：鉴定胶质母细胞瘤细胞中细胞粘附介导的耐药性主导形式的一种新型转换机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225188](https://pubmed.ncbi.nlm.nih.gov/41225188)
**期刊：** Oncogene
**PMID：** 41225188
**DOI：** 10.1038/s41388-025-03628-1

### 第一部分 原文与翻译

**英文原标题：** Correction: Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
摘要不可用。

### 第二部分 AI 大师评价

该条目为一篇已发表研究的更正声明，并非原创性研究论文，因此不包含摘要信息。根据标题推断，原始研究可能揭示了胶质母细胞瘤中一种与细胞粘附相关的耐药性转换新机制，这对于理解和克服肿瘤耐药具有重要意义。然而，由于缺乏具体实验数据和摘要内容，无法对该研究的方法、关键发现及科学价值进行深入评估。读者需查阅原始文献及本更正的具体内容，以获得完整准确的研究信息。

---

## 31. 分子伴侣介导的自噬调控VEGFR1降解促进乳腺癌细胞与内皮细胞间的串扰，并通过VEGF-VEGFR2轴触发肿瘤发生

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225187](https://pubmed.ncbi.nlm.nih.gov/41225187)
**期刊：** Oncogene
**PMID：** 41225187
**DOI：** 10.1038/s41388-025-03619-2

### 第一部分 原文与翻译

**英文原标题：** Chaperone-mediated autophagy controlling VEGFR1 degradation contributes cross talk between breast cancer cells and endothelial cells triggering tumorigenesis via the VEGF-VEGFR2 axis.

**英文摘要原文：**
The reciprocal cross talk between breast cancer cells and the endothelial cells, through the secretion of growth factors, plays a vital role in angiogenesis and tumorigenesis. We previously demonstrated that chaperone-mediated autophagy (CMA) promotes breast cancer tumorigenesis. However, whether the cross talk between cancer cells with endothelial cells plays a role in CMA-mediated breast tumor tumorigenesis is unknown. We discovered that the conditioned medium (CM) from breast cancer cells with high CMA activity promoted tube formation of endothelial cells (ECs) via the VEGF-VEGFR2 axis. High CMA activity directly promoted angiogenesis of endothelial cells via the VEGF-VEGFR2 axis. The CM from ECs with high level CMA activity accelerated survival and migration of breast cancer cells in vitro via the VEGF-VEGFR2 axis. Co-injection of breast cancer cells mixed with ECs with high level CMA activity trigged angiogenesis and accelerated tumorigenesis in vivo. CMA activity and microvessel numbers were positively correlated with VEGF-VEGFR2 axis between paired breast tumor and normal adjacent tissue. CMA, a highly selective lysosome-dependent degradation process directly degrades VEGFR1 which can serve as a competitively regulatory factor for VEGFR2 regulating its signaling. Our study showed that the cross talk between breast cancer cells and endothelial cells induced by CMA -mediated degradation of VEGFR1 triggers angiogenesis and tumorigenesis via the VEGF-VEGFR2 axis.

**中文摘要译文：**
乳腺癌细胞与内皮细胞之间通过生长因子的分泌而产生的相互串扰，在血管生成和肿瘤发生中扮演着至关重要的角色。我们先前已证明，分子伴侣介导的自噬（CMA）能促进乳腺癌的肿瘤发生。然而，癌细胞与内皮细胞之间的串扰是否在CMA介导的乳腺肿瘤发生中发挥作用尚不明确。我们发现，来自高CMA活性乳腺癌细胞的条件培养基（CM）能通过VEGF-VEGFR2轴促进内皮细胞（ECs）的管腔形成。高CMA活性通过VEGF-VEGFR2轴直接促进了内皮细胞的血管生成。来自高水平CMA活性的ECs的条件培养基，在体外通过VEGF-VEGFR2轴加速了乳腺癌细胞的存活和迁移。在体内，将乳腺癌细胞与高水平CMA活性的ECs混合共注射，触发了血管生成并加速了肿瘤发生。在配对的乳腺肿瘤与癌旁正常组织中，CMA活性和微血管数量与VEGF-VEGFR2轴呈正相关。CMA作为一种高度选择性的溶酶体依赖性降解过程，能直接降解VEGFR1，而VEGFR1可作为VEGFR2的竞争性调节因子来调控其信号传导。我们的研究表明，由CMA介导的VEGFR1降解所诱导的乳腺癌细胞与内皮细胞间的串扰，通过VEGF-VEGFR2轴触发了血管生成和肿瘤发生。

### 第二部分 AI 大师评价

本研究旨在阐明分子伴侣介导的自噬（CMA）在乳腺癌细胞与内皮细胞相互作用中的具体机制及其对肿瘤发生的影响。研究通过体外细胞共培养、体内动物模型及临床样本分析，关键性地发现CMA通过降解VEGFR1，解除了其对VEGFR2信号的竞争性抑制，从而激活VEGF-VEGFR2轴，促进了肿瘤血管生成和进展。该研究的创新之处在于揭示了CMA调控肿瘤微环境串扰的新途径，为乳腺癌治疗提供了靶向CMA-VEGFR1轴的新策略，具有重要的科研价值和潜在的临床应用前景。

---

## 32. IL-1R和NFKBIZ通路介导间变性大细胞淋巴瘤的免疫调节反应及免疫治疗疗效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225182](https://pubmed.ncbi.nlm.nih.gov/41225182)
**期刊：** Leukemia
**PMID：** 41225182
**DOI：** 10.1038/s41375-025-02809-x

### 第一部分 原文与翻译

**英文原标题：** The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.

**英文摘要原文：**
Anaplastic large cell lymphoma (ALCL), an aggressive T-cell malignancy, is marked by elevated expression of CD30 and the immune checkpoint molecule PD-L1. While CD30-directed chimeric antigen receptor (CAR) therapies have demonstrated clinical promise, therapeutic resistance remains a major hurdle. Here, we conducted integrated genome-wide CRISPR-Cas9 loss-of-function screens using CD30-specific CAR-engineered natural killer (CAR-NK) cells, alongside a complementary PD-L1 regulator screen, and uncovered a critical role for interleukin-1 receptor (IL-1R) signaling in modulating CAR therapy efficacy in both ALK⁺ and ALK⁻ ALCL. Mechanistically, IL-1R signaling drives an NFKBIZ - IL-17F - MAPK axis that sustains PD-L1 expression via an autocrine loop, while simultaneously inducing proinflammatory cytokines and chemokines that reinforce immune evasion and shape an immunosuppressive tumor microenvironment. Notably, NFKBIZ (IκBζ) emerges as a central transcriptional regulator orchestrating this immune suppression program upstream of IL-17F. Importantly, pharmacologic inhibition of IL-1R signaling significantly enhances the antitumor activity of CD30-specific CAR therapies both in vitro and in ALCL xenograft models. Collectively, our findings uncover a novel mechanism of immune resistance and nominate IL-1R blockade as a promising combinatorial strategy to improve CAR-based immunotherapy in ALCL.

**中文摘要译文：**
间变性大细胞淋巴瘤（ALCL）是一种侵袭性T细胞恶性肿瘤，其特征是CD30和免疫检查点分子PD-L1的表达升高。尽管靶向CD30的嵌合抗原受体（CAR）疗法已显示出临床应用前景，但治疗抵抗仍是主要障碍。本研究中，我们使用靶向CD30的CAR工程化自然杀伤（CAR-NK）细胞，进行了全基因组范围的CRISPR-Cas9功能缺失筛选，并辅以一项PD-L1调控因子的补充筛选，揭示了白细胞介素-1受体（IL-1R）信号通路在调节CAR疗法对ALK⁺和ALK⁻ ALCL的疗效中发挥着关键作用。从机制上看，IL-1R信号通路驱动了一个NFKBIZ - IL-17F - MAPK轴，该轴通过自分泌环路维持PD-L1的表达，同时诱导促炎性细胞因子和趋化因子，从而加强免疫逃逸并塑造了一个免疫抑制性的肿瘤微环境。值得注意的是，NFKBIZ（IκBζ）作为核心转录调节因子，在IL-17F的上游调控了这一免疫抑制程序。重要的是，在体外和ALCL异种移植模型中，药物抑制IL-1R信号通路均能显著增强靶向CD30的CAR疗法的抗肿瘤活性。总而言之，我们的研究结果揭示了一种新的免疫抵抗机制，并提出IL-1R阻断剂可作为一种有前景的联合策略，用以改善针对ALCL的CAR免疫疗法。

### 第二部分 AI 大师评价

本研究利用前沿的CRISPR-Cas9筛选技术，旨在揭示间变性大细胞淋巴瘤（ALCL）对CD30靶向CAR疗法产生抵抗的关键机制。研究团队创新性地发现IL-1R及其下游的NFKBIZ信号通路是介导免疫逃逸的核心驱动力，它通过维持PD-L1表达及塑造免疫抑制微环境，削弱了免疫治疗效果。这项发现不仅深刻阐明了ALCL的免疫抵抗新机制，更重要的是，提出了将IL-1R阻断剂与CAR疗法联用的精准治疗新策略，为提高该类肿瘤患者的治疗响应率带来了明确的临床转化前景。

---

## 33. 靶向降解VISTA可增强抗肿瘤免疫治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225154](https://pubmed.ncbi.nlm.nih.gov/41225154)
**期刊：** Cell research
**PMID：** 41225154
**DOI：** 10.1038/s41422-025-01194-5

### 第一部分 原文与翻译

**英文原标题：** Targeted destruction of VISTA boosts anti-tumor immunotherapy.

**英文摘要原文：**
Immune checkpoints serve as regulatory pathways that are essential for regulating immune response and homeostasis. As such, many components along the pathway have emerged as pivotal targets in cancer therapy. To overcome the treatment resistance and limited efficacy encountered by current immune checkpoint therapies, there is an urgent need for new immunotherapeutic targets and strategies. V-domain Ig suppressor of T cell activation (VISTA) is an immune checkpoint protein with a unique expression pattern and has emerged as a novel therapeutic target in anti-tumor immunotherapy; however, the precise role of VISTA and its regulatory mechanisms in tumor cells remain incompletely understood. Here, we identify a novel strategy targeting VISTA for cancer immunotherapy, enhancing therapeutic outcomes. Mechanistically, we show that VISTA undergoes anaphase-promoting complex/cyclosome (APC/C)/CDH1-mediated ubiquitination and subsequent proteasomal degradation, a process that can be reversed by the deubiquitinase USP2. Therapeutically, the USP2 inhibitor MS102 significantly reduces VISTA protein abundance in vitro and in vivo, enhances T cell responses, and synergizes with anti-PD-1 immunotherapy to improve survival in syngeneic mouse tumor models. Our findings reveal a regulatory network for VISTA stability control and support the combination of USP2 inhibitors with anti-PD-1 immunotherapy to enhance anti-tumor immune responses.

**中文摘要译文：**
免疫检查点是调节免疫反应和维持体内平衡所必需的关键调控通路。因此，该通路中的许多组分已成为癌症治疗的关键靶点。为克服当前免疫检查点疗法遇到的治疗耐药性和疗效有限等问题，迫切需要寻找新的免疫治疗靶点和策略。VISTA（T细胞活化的V结构域Ig抑制因子）是一种具有独特性表达模式的免疫检查点蛋白，并已成为抗肿瘤免疫治疗中的一个新靶点；然而，VISTA在肿瘤细胞中的确切作用及其调控机制尚不完全清楚。本研究发现了一种针对VISTA的癌症免疫治疗新策略，可提升治疗效果。从机制上讲，我们发现VISTA会经历由后期促进复合物/细胞周期蛋白体（APC/C）/CDH1介导的泛素化及随后的蛋白酶体降解，而这一过程可被去泛素化酶USP2所逆转。在治疗层面，USP2抑制剂MS102在体内外均能显著降低VISTA蛋白的丰度，增强T细胞反应，并与抗PD-1免疫疗法协同作用，从而提高同系小鼠肿瘤模型的存活率。我们的研究结果揭示了调控VISTA稳定性的网络，并为联合使用USP2抑制剂与抗PD-1免疫疗法以增强抗肿瘤免疫反应提供了支持。

### 第二部分 AI 大师评价

本研究旨在探索靶向新型免疫检查点蛋白VISTA的抗肿瘤免疫治疗新策略。研究团队通过机制探究，首次揭示了VISTA蛋白的稳定性受到APC/C-CDH1介导的泛素化降解途径调控，且该过程可被去泛素化酶USP2逆转。其关键发现是，使用USP2抑制剂能有效降低VISTA蛋白水平，从而增强T细胞活性，并在动物模型中与抗PD-1疗法产生显著的协同抗肿瘤效应。这项工作创新性地提出了通过靶向降解免疫检查点蛋白来增效现有疗法的联合治疗方案，为克服免疫治疗耐药性提供了新思路，具有重要的临床转化潜力。

---

## 34. ZBP1将感染与癌症免疫治疗联系起来

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225153](https://pubmed.ncbi.nlm.nih.gov/41225153)
**期刊：** Cell research
**PMID：** 41225153
**DOI：** 10.1038/s41422-025-01196-3

### 第一部分 原文与翻译

**英文原标题：** ZBP1 links infections to cancer immunotherapy.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究标题揭示了其核心科学问题：ZBP1蛋白如何在感染与癌症免疫治疗之间建立联系。研究可能深入探讨了ZBP1介导的信号通路，阐明了感染如何通过此分子机制影响免疫治疗的效果。这项发现具有显著的创新性，为理解宿主-肿瘤-免疫互作提供了新视角，并可能为开发新型免疫增敏策略（如模拟感染或靶向ZBP1）提供了理论基础，具有重要的临床转化潜力。由于没有摘要，研究的具体方法和数据细节尚不明确。

---

## 35. T细胞中消融TRIM25可通过破坏VISTA增强癌症免疫疗法

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225152](https://pubmed.ncbi.nlm.nih.gov/41225152)
**期刊：** Cell research
**PMID：** 41225152
**DOI：** 10.1038/s41422-025-01186-5

### 第一部分 原文与翻译

**英文原标题：** Destruction of VISTA by TRIM25 ablation in T cells potentiates cancer immunotherapy.

**英文摘要原文：**
The limited success of current immunotherapies emphasizes the need for new targets and combination treatments. V-domain Ig suppressor of T cell activation (VISTA) is a promising immune checkpoint target in cancer immunotherapy, but its regulatory mechanism is poorly understood. Through CRISPR knockout screening and proteomic analysis, we identify tripartite motif containing 25 (TRIM25) as a positive regulator for VISTA largely through antagonizing its degradation signaling. Moreover, ERK-mediated phosphorylation of VISTA at Thr284 enhances its interaction with TRIM25, leading to VISTA stabilization. A VISTA-derived phospho-peptide competitively disrupts TRIM25-VISTA interaction, thereby reducing VISTA expression and potentiating the anti-tumor efficacy of PD-1/PD-L1 blockade. Moreover, single-cell RNA sequencing analysis shows that tumor-infiltrating cytotoxic CD8 T cells are increased in mice with T cell-specific knockout of Trim25. Of note, genetic ablation of Trim25 in T cells not only improves anti-PD-L1 immunotherapy, but also significantly ameliorates CAR T anti-tumor activity in various mouse tumor models. Collectively, this study unveils a mechanism for VISTA regulation in T cells and highlights targeting TRIM25-VISTA as a potential strategy to enhance tumor immunotherapy.

**中文摘要译文：**
当前免疫疗法的成功率有限，凸显了寻找新靶点和联合治疗方案的必要性。V-结构域Ig T细胞活化抑制因子（VISTA）是癌症免疫治疗中一个有前景的免疫检查点靶点，但其调控机制尚不明确。通过CRISPR基因敲除筛选和蛋白质组学分析，我们发现三联基序蛋白25（TRIM25）是VISTA的一个正向调节因子，其作用主要通过拮抗VISTA的降解信号来实现。此外，ERK介导的VISTA Thr284位点磷酸化增强了其与TRIM25的相互作用，从而导致VISTA的稳定。一种源自VISTA的磷酸化多肽能竞争性地破坏TRIM25与VISTA的相互作用，从而降低VISTA的表达，并增强PD-1/PD-L1阻断疗法的抗肿瘤效果。此外，单细胞RNA测序分析显示，在T细胞特异性敲除Trim25的小鼠中，肿瘤浸润的细胞毒性CD8 T细胞数量增加。值得注意的是，在T细胞中遗传性消融Trim25不仅能改善抗PD-L1免疫疗法的效果，还能在多种小鼠肿瘤模型中显著增强CAR-T细胞的抗肿瘤活性。总而言之，本研究揭示了T细胞中VISTA的一种调控机制，并强调靶向TRIM25-VISTA轴是增强肿瘤免疫治疗的一种潜在策略。

### 第二部分 AI 大师评价

本研究旨在揭示免疫检查点分子VISTA在T细胞中的翻译后调控新机制。研究综合运用CRISPR筛选、蛋白质组学和单细胞测序等前沿技术，发现E3泛素连接酶TRIM25能拮抗VISTA的降解，从而稳定其在T细胞中的表达。更重要的是，研究证实了在T细胞中消融TRIM25能够有效增强PD-L1抑制剂及CAR-T疗法的抗肿瘤活性。这项工作不仅阐明了VISTA蛋白稳定性的关键调控通路，也为开发靶向TRIM25-VISTA轴的协同增效型肿瘤免疫联合疗法提供了坚实的理论基础与极具潜力的治疗新策略。

---

## 36. 作者更正：利用生成式Transformer学习人类疾病的自然史

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225015](https://pubmed.ncbi.nlm.nih.gov/41225015)
**期刊：** Nature
**PMID：** 41225015
**DOI：** 10.1038/s41586-025-09879-y

### 第一部分 原文与翻译

**英文原标题：** Author Correction: Learning the natural history of human disease with generative transformers.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇作者更正，其指向的原创研究核心在于利用生成式Transformer模型学习人类疾病的自然史。这项工作通过分析大规模电子健康记录，旨在构建能够预测患者未来健康轨迹的深度学习模型。其创新性体现在将前沿的生成式AI技术应用于复杂的纵向医疗数据，为理解疾病进展动态提供了新范式，为实现精准医疗和早期风险预警开辟了新路径。

---

## 37. SIGLEC12在坏死性凋亡过程中介导细胞膜破裂

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225007](https://pubmed.ncbi.nlm.nih.gov/41225007)
**期刊：** Nature
**PMID：** 41225007
**DOI：** 10.1038/s41586-025-09741-1

### 第一部分 原文与翻译

**英文原标题：** SIGLEC12 mediates plasma membrane rupture during necroptotic cell death.

**英文摘要原文：**
Necroptosis is a form of lytic cell death that is overactivated during infections and in inflammatory pathologies. NINJ1 was recently found to be a mediator of plasma membrane rupture (PMR) during pyroptosis, toxin-induced necrosis, apoptosis, and ferroptosis, but the mediator of PMR during necroptotic cell death remained unknown. Here, using a CRISPR-Cas9-based genome-wide knockout approach, we identify SIGLEC12 as a key mediator of necroptosis downstream of MLKL at the PMR step. Cells with knockdown or knockout of SIGLEC12 are defective in necroptosis-induced PMR and demonstrate ballooning morphology. During necroptosis, SIGLEC12 undergoes dephosphorylation, interacts with MLKL, forms cytosolic puncta and assembles into fibrils. Notably, SIGLEC12 is cleaved by TMPRSS4 during necroptosis to produce a 20-kDa fragment highly homologous to NINJ1, and this cleavage event is required and sufficient to induce PMR during necroptosis. A SIGLEC12 variant associated with cancer (Ser458Phe) and a variant found in the general human population (Arg528Trp) attenuate SIGLEC12 cleavage by TMPRSS4. Knockout of Siglec12 in mouse cells does not affect PMR, suggesting a species-specific role. Our identification of SIGLEC12 as a mediator of PMR expands our understanding of how programmed necrosis is executed and offers new approaches for targeting this proinflammatory form of cell death in human diseases.

**中文摘要译文：**
坏死性凋亡是一种溶解性细胞死亡形式，在感染和炎症性病理中被过度激活。最近发现NINJ1是焦亡、毒素诱导的坏死、凋亡和铁死亡过程中细胞膜破裂（PMR）的介导者，但坏死性凋亡过程中的PMR介导者仍然未知。在此，我们利用基于CRISPR-Cas9的全基因组敲除方法，鉴定出SIGLEC12是MLKL下游在PMR步骤中介导坏死性凋亡的关键分子。敲低或敲除SIGLEC12的细胞在坏死性凋亡诱导的PMR方面存在缺陷，并表现出气球样形态。在坏死性凋亡过程中，SIGLEC12发生去磷酸化，与MLKL相互作用，形成胞质点状聚集体并组装成纤维。值得注意的是，在坏死性凋亡期间，SIGLEC12被TMPRSS4切割，产生一个与NINJ1高度同源的20-kDa片段，并且这一切割事件是诱导坏死性凋亡中PMR的必要且充分条件。一种与癌症相关的SIGLEC12变体（Ser458Phe）和在普通人群中发现的一种变体（Arg528Trp）会减弱TMPRSS4对SIGLEC12的切割作用。在小鼠细胞中敲除Siglec12不影响PMR，这表明其作用具有物种特异性。我们鉴定出SIGLEC12是PMR的介导者，这扩展了我们对程序性坏死执行机制的理解，并为靶向治疗人类疾病中这种促炎性细胞死亡形式提供了新方法。

### 第二部分 AI 大师评价

本研究旨在揭示在程序性坏死（necroptosis）过程中介导细胞膜破裂（PMR）的关键分子。研究者采用CRISPR-Cas9全基因组筛选技术，成功鉴定出SIGLEC12是MLKL下游执行PMR的核心蛋白。关键发现是，SIGLEC12被TMPRSS4切割后产生活性片段，从而诱导细胞膜破裂，且此机制表现出人类特异性。这项工作不仅填补了程序性坏死信号通路下游执行机制的认知空白，也为开发针对相关炎症性疾病的治疗策略提供了全新的靶点。

---

## 38. 胞质乙酰辅酶A是调控线粒体自噬的信号代谢物

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41225001](https://pubmed.ncbi.nlm.nih.gov/41225001)
**期刊：** Nature
**PMID：** 41225001
**DOI：** 10.1038/s41586-025-09745-x

### 第一部分 原文与翻译

**英文原标题：** Cytosolic acetyl-coenzyme A is a signalling metabolite to control mitophagy.

**英文摘要原文：**
Acetyl-coenzyme A (AcCoA) sits at the nexus of nutrient metabolism and shuttles between the canonical and non-canonical tricarboxylic acid cycle, which is dynamically regulated by nutritional status, such as fasting. Here we find that mitophagy is triggered after a reduction in cytosolic AcCoA levels through short-term fasting and through inhibition of ATP-citrate lyase (encoded by ACLY), mitochondrial citrate/malate antiporter (encoded by SLC25A1) or acyl-CoA synthetase short chain family member 2 (encoded by ACSS2), and the mitophagy can be counteracted by acetate supplementation. Notably, NOD-like receptor (NLR) family member X1 (NLRX1) mediates this effect. Disrupting NLRX1 abolishes cytosolic AcCoA reduction-induced mitophagy both in vitro and in vivo. Mechanically, the mitochondria outer-membrane-localized NLRX1 directly binds to cytosolic AcCoA within a conserved pocket on its leucine-rich repeat (LRR) domain. Moreover, AcCoA binds to the LRR domain and enhances its interaction with the nucleotide-binding and oligomerization (NACHT) domain, which helps to maintain NLRX1 in an autoinhibited state and prevents the association between NLRX1 and light chain 3 (LC3). Furthermore, we find that the AcCoA-NLRX1 axis underlies the KRAS-inhibitor-induced mitophagy response and promotes drug resistance, providing a metabolic mechanism of KRAS inhibitor resistance. Thus, cytosolic AcCoA is a signalling metabolite that connects metabolism to mitophagy through its receptor NLRX1.

**中文摘要译文：**
乙酰辅酶A（AcCoA）位于营养代谢的枢纽，穿梭于经典和非经典的三羧酸循环之间，其水平受到禁食等营养状态的动态调控。本研究发现，通过短期禁食以及抑制ATP-柠檬酸裂解酶（ACLY编码）、线粒体柠檬酸/苹果酸反向转运蛋白（SLC25A1编码）或酰基辅酶A合成酶短链家族成员2（ACSS2编码），胞质AcCoA水平的降低会触发线粒体自噬，而补充乙酸盐则能抵消这一效应。值得注意的是，NOD样受体（NLR）家族成员X1（NLRX1）介导了此效应。在体外和体内实验中，破坏NLRX1均能消除由胞质AcCoA减少诱导的线粒体自噬。从机制上看，定位于线粒体外膜的NLRX1通过其富亮氨酸重复（LRR）结构域上的一个保守口袋直接与胞质AcCoA结合。此外，AcCoA与LRR结构域的结合增强了其与核苷酸结合和寡聚化（NACHT）结构域的相互作用，这有助于将NLRX1维持在自抑制状态，并阻止NLRX1与轻链3（LC3）的结合。此外，我们发现AcCoA-NLRX1轴是KRAS抑制剂诱导的线粒体自噬反应的基础，并促进了耐药性的产生，为KRAS抑制剂的耐药性提供了一种代谢机制。因此，胞质AcCoA是一种信号代谢物，通过其受体NLRX1将代谢与线粒体自噬联系起来。

### 第二部分 AI 大师评价

本研究旨在阐明胞质乙酰辅酶A（AcCoA）作为信号分子调控线粒体自噬的具体机制。研究团队通过细胞和动物实验发现，胞质AcCoA水平的下降是启动线粒体自噬的关键触发因素，并首次揭示了线粒体外膜蛋白NLRX1是AcCoA的直接受体。其创新之处在于，它将一个核心代谢物与细胞器质量控制（线粒体自噬）直接联系起来，揭示了NLRX1作为代谢感受器的全新功能，并为理解KRAS抑制剂的耐药性提供了新的代谢视角，具有重要的科研和临床转化价值。

---

## 39. 出版商更正：突变型p53蛋白的累积可被近距离诱导药物选择性靶向

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41224894](https://pubmed.ncbi.nlm.nih.gov/41224894)
**期刊：** Nature chemical biology
**PMID：** 41224894
**DOI：** 10.1038/s41589-025-02095-9

### 第一部分 原文与翻译

**英文原标题：** Publisher Correction: Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究标题表明，其核心目的在于探索利用近距离诱导药物（如PROTACs）选择性靶向并清除在肿瘤中常见的突变型p53蛋白累积。该研究的关键发现可能是成功验证了这一策略的可行性，即通过特定药物诱导突变p53蛋白的降解。鉴于突变型p53是长期以来被认为“不可成药”的重要癌症靶点，本研究提出的靶向降解策略具有高度的创新性，为开发针对p53突变型癌症的新疗法开辟了新途径，具有重大的科研和临床转化潜力。需要注意的是，本文为一项“出版商更正”，其具体修正内容需查阅原文，且摘要的缺失限制了对研究细节的深入评估。

---

## 40. 难治性儿童T细胞白血病中的一种非经典淋巴母细胞

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41224801](https://pubmed.ncbi.nlm.nih.gov/41224801)
**期刊：** Nature communications
**PMID：** 41224801
**DOI：** 10.1038/s41467-025-65049-8

### 第一部分 原文与翻译

**英文原标题：** A non-canonical lymphoblast in refractory childhood T-cell leukaemia.

**英文摘要原文：**
Refractory cancers may arise either through the acquisition of resistance mechanisms or represent distinct disease states. The origin of childhood T-cell acute lymphoblastic leukaemia (T-ALL) that does not respond to initial treatment, i.e. refractory disease, is unknown. Refractory T-ALL carries a poor prognosis and cannot be predicted at diagnosis. Here, we perform single cell mRNA sequencing of T-ALL from 58 children (84 samples) who did, or did not respond to initial treatment. We identify a transcriptionally distinctive blast population, exhibiting features of innate-like lymphocytes, as the major source of refractory disease. Evidence of such blasts at diagnosis heralds refractory disease across independent datasets and is associated with survival in a large, contemporary trial cohort. Our findings portray refractory T-ALL as a distinct disease with the potential for immediate clinical utility.

**中文摘要译文：**
难治性癌症的产生，可能源于其获得了耐药机制，或是代表了一种独特的疾病状态。对初始治疗无反应的儿童T细胞急性淋巴细胞白血病（T-ALL）（即难治性疾病）的起源尚不明确。难治性T-ALL预后极差，且在诊断时无法预测。本研究中，我们对58名儿童（共84份样本）的T-ALL进行了单细胞mRNA测序，这些患儿涵盖了对初始治疗有反应和无反应的两种情况。我们鉴定出一群在转录上独具特征的母细胞，其表现出类天然淋巴细胞的特性，并且是导致难治性疾病的主要来源。在诊断时若发现此类母细胞存在的证据，则预示着难治性疾病的发生（该结论在多个独立数据集中得到验证），并且在一个大型当代临床试验队列中与生存率相关。我们的研究结果表明，难治性T-ALL是一种独特的疾病，这一发现具有直接的临床应用潜力。

### 第二部分 AI 大师评价

该研究旨在揭示难治性儿童T细胞急性淋巴细胞白血病（T-ALL）的起源。研究团队利用单细胞mRNA测序技术，创新性地发现了一群具有类天然淋巴细胞特征的非经典淋巴母细胞，并证实其是导致疾病难治的主要原因。这项关键发现将难治性T-ALL的认知从“获得性耐药”推进到“一种独特的疾病亚型”，其在诊断时即可被识别，为早期风险分层、预后判断及开发靶向新疗法提供了极具价值的生物标志物和理论基础。

---

## 41. FUS纳米团簇是稀释相中的一种独特状态

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41224766](https://pubmed.ncbi.nlm.nih.gov/41224766)
**期刊：** Nature communications
**PMID：** 41224766
**DOI：** 10.1038/s41467-025-64909-7

### 第一部分 原文与翻译

**英文原标题：** FUS nanoclusters are a distinct state within the dilute phase.

**英文摘要原文：**
Liquid-liquid phase separation of Fused in sarcoma (FUS) has been extensively studied due to its critical role in various physiological and pathological processes. However, the mechanism of this process remains poorly understood. Here we show that by preparing pre-cleaved FUS, we enable kinetic measurement of phase separation from the onset. We identify a distinct state within the dilute phase using a combination of biophysical measurements including dynamic light scattering, fluorescence correlation spectroscopy, and an optimized single-cluster fluorescence imaging assay. This state is termed nanoclusters. They are hundreds of nanometers in diameter and exhibit instantaneous formation far below the saturation concentration, sharply arrested coarsening, rapid mixing, high exchange rate, and resistance to hexanediol-induced dissolution. This state exhibits properties that distinguish it from condensates. Our findings define the nanocluster as a prominent intermediate in the FUS phase separation pathway. This understanding paves the way for further experiments and theories to explore the molecular mechanisms underlying FUS and other phase-separating proteins.

**中文摘要译文：**
由于在多种生理和病理过程中起着关键作用，肉瘤内融合蛋白（FUS）的液-液相分离已得到广泛研究。然而，该过程的机制仍不甚明了。在本研究中，我们通过制备预切割的FUS，实现了从起始阶段对相分离过程的动力学测量。我们综合运用动态光散射、荧光相关光谱和一种优化的单团簇荧光成像分析等多种生物物理测量方法，在稀释相中识别出一种独特的状态。该状态被称为纳米团簇。它们的直径为数百纳米，并表现出在远低于饱和浓度时瞬时形成、粗化过程骤然中止、快速混合、高交换率以及对己二醇诱导溶解的抗性等特性。该状态展现出与凝聚体不同的特性。我们的研究结果将纳米团簇定义为FUS相分离途径中的一个重要中间体。这一认识为未来通过实验和理论探索FUS及其他相分离蛋白的分子机制铺平了道路。

### 第二部分 AI 大师评价

本研究旨在阐明肉瘤内融合蛋白（FUS）液-液相分离的早期机制。研究者通过多种先进的生物物理测量技术，创新性地发现并定义了一个处于稀释相中的独特中间状态——“纳米团簇”。该研究的关键发现是，这种纳米团簇在性质上与传统的凝聚体有显著区别，揭示了相分离过程的复杂性。这项工作不仅加深了我们对FUS相分离途径的理解，也为研究其他相关蛋白及神经退行性疾病的发病机制提供了新的理论框架和实验方向。

---

## 42. 大脑结构与功能对慢性疼痛强度的遗传基础和因果效应

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41224763](https://pubmed.ncbi.nlm.nih.gov/41224763)
**期刊：** Nature communications
**PMID：** 41224763
**DOI：** 10.1038/s41467-025-64904-y

### 第一部分 原文与翻译

**英文原标题：** Genetic underpinnings and causal effects of brain structure and function on chronic pain intensity.

**英文摘要原文：**
Chronic pain represents a major clinical burden, with its intensity being a key measure of its severity. However, the genetic and neural underpinnings of chronic pain intensity remain unraveled. Here, we identified six genetic loci (including a novel discovery) significantly associated with chronic pain intensity using a genome-wide association study in the UK Biobank (n = 134,627). We then systematically investigate its relationship with 3924 brain imaging-derived phenotypes. Phenotypic correlation analyses revealed 29 imaging-derived phenotypes predictive of future chronic pain intensity. Genetic correlation and polygenic risk score analyses showed 13 of these imaging-derived phenotypes share a genetic basis with chronic pain intensity. Mediation analyses indicated that 12 imaging-derived phenotypes mediate genetic effects on chronic pain intensity. Mendelian randomization further supported a causal influence of three imaging-derived phenotypes, including brain structure and functional network connectivity, on chronic pain intensity. Our findings elucidate the genetic architecture and neurobiological pathways of chronic pain intensity, highlighting the brain's central role in chronic pain pathophysiology.

**中文摘要译文：**
慢性疼痛是主要的临床负担之一，其疼痛强度是衡量其严重程度的关键指标。然而，慢性疼痛强度的遗传和神经基础仍有待阐明。本研究利用英国生物银行（UK Biobank）的数据（n = 134,627），通过全基因组关联研究（GWAS），识别出六个与慢性疼痛强度显著相关的遗传位点（包括一个新发现的位点）。随后，我们系统地研究了其与3924种脑影像衍生表型之间的关系。表型相关性分析显示，有29种影像衍生表型可预测未来的慢性疼痛强度。遗传相关性和多基因风险评分分析表明，其中13种影像衍生表型与慢性疼痛强度存在共同的遗传基础。中介分析指出，有12种影像衍生表型在遗传对慢性疼痛强度的影响中起中介作用。孟德尔随机化分析进一步证实了三种影像衍生表型（包括大脑结构和功能网络连接）对慢性疼痛强度存在因果影响。我们的研究结果阐明了慢性疼痛强度的遗传结构和神经生物学通路，凸显了大脑在慢性疼痛病理生理机制中的核心作用。

### 第二部分 AI 大师评价

该研究旨在揭示慢性疼痛强度的遗传基础，并探究大脑结构与功能在其中的因果作用。研究团队综合运用全基因组关联研究、多基因风险评分及孟德尔随机化等多种前沿方法，对英国生物银行的大规模队列数据进行了深度分析。其关键发现不仅识别了新的疼痛相关遗传位点，更重要的是，首次从因果层面证实了特定脑影像特征对慢性疼痛强度的影响。这项研究极具创新性，为理解疼痛的中枢机制提供了坚实的遗传学证据，并为开发针对大脑的疼痛干预新策略指明了方向。

---

## 43. YTHDF2通过调控自身非编码RNA代谢以控制炎症与肿瘤发生

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41224760](https://pubmed.ncbi.nlm.nih.gov/41224760)
**期刊：** Nature communications
**PMID：** 41224760
**DOI：** 10.1038/s41467-025-64898-7

### 第一部分 原文与翻译

**英文原标题：** YTHDF2 regulates self non-coding RNA metabolism to control inflammation and tumorigenesis.

**英文摘要原文：**
The role of mA RNA methylation of self non-coding RNA remains poorly understood. Here we show that mA-methylated self U6 snRNA is recognized by YTHDF2 to reduce its stability and prevent its binding to Toll-like receptor 3 (TLR3), leading to decreased inflammatory responses in human and mouse cells and mouse models. At the molecular level, endosomal U6 snRNA binds to the LRR21 domain in TLR3, independent of mA methylation, to activate inflammatory gene expression, a mechanism that is distinct from that of the best known synthetic TLR3 agonist poly I:C. Both U6 snRNA and YTHDF2 are localized to endosomes via the transmembrane protein SIDT2, where YTHDF2 functions to prevent the U6-TLR3 interaction. We further show that UVB exposure inhibits YTHDF2 by inducing its dephosphorylation and autophagic protein degradation in human keratinocytes and mouse skin. Skin-specific deletion of Ythdf2 in mice enhanced the UVB-induced skin inflammatory response and promoted tumor initiation. Taken together, our findings demonstrate that YTHDF2 plays a crucial role in controlling inflammation by inhibiting mA U6-mediated TLR3 activation, suggesting that YTHDF2 and mA U6 are potential therapeutic targets for preventing and treating inflammation and tumorigenesis.

**中文摘要译文：**
学界对于自身非编码RNA的m6A RNA甲基化作用仍知之甚少。本研究发现，YTHDF2能够识别经m6A甲基化的自身U6 snRNA，从而降低其稳定性并阻止其与Toll样受体3（TLR3）结合，进而在人类和小鼠细胞及小鼠模型中减弱炎症反应。在分子水平上，内体中的U6 snRNA能够不依赖m6A甲基化地与TLR3的LRR21结构域结合，从而激活炎症基因的表达，这一机制不同于最广为人知的合成TLR3激动剂poly I:C。U6 snRNA和YTHDF2均通过跨膜蛋白SIDT2定位于内体，YTHDF2在此处发挥功能，阻止U6与TLR3的相互作用。我们进一步证明，在人类角质形成细胞和小鼠皮肤中，UVB暴露通过诱导YTHDF2的去磷酸化和自噬性蛋白降解来抑制其功能。在小鼠中皮肤特异性地敲除Ythdf2，会增强UVB诱导的皮肤炎症反应并促进肿瘤的发生。综上所述，我们的研究结果表明，YTHDF2通过抑制m6A U6介导的TLR3活化，在控制炎症中发挥着关键作用，这提示YTHDF2和m6A U6是预防和治疗炎症及肿瘤发生的潜在治疗靶点。

### 第二部分 AI 大师评价

本研究旨在阐明m6A阅读蛋白YTHDF2在调控自身非编码RNA（U6 snRNA）介导的炎症及肿瘤发生中的作用。研究团队通过分子、细胞及小鼠模型实验，揭示了YTHDF2通过识别并降解m6A修饰的U6 snRNA，从而抑制其与TLR3结合，最终抑制下游炎症信号通路。该研究的创新之处在于首次将RNA m6A甲基化修饰与内源性RNA触发的天然免疫应答联系起来，为理解紫外线暴露如何诱发皮肤炎症和肿瘤提供了新的分子机制。这些发现不仅深化了对RNA表观遗传学功能的认识，也为炎症相关疾病和皮肤癌的防治提供了YTHDF2和U6 snRNA这两个潜在的治疗靶点。

---

## 44. 钙膜蛋白/C16orf74中的一个复合基序决定了钙调磷酸酶介导的多聚体去磷酸化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41224739](https://pubmed.ncbi.nlm.nih.gov/41224739)
**期刊：** Nature communications
**PMID：** 41224739
**DOI：** 10.1038/s41467-025-64884-z

### 第一部分 原文与翻译

**英文原标题：** A composite motif in calcimembrin/C16orf74 dictates multimeric dephosphorylation by calcineurin.

**英文摘要原文：**
Calcineurin, the Ca/calmodulin-activated protein phosphatase, recognizes substrates and regulators via short linear motifs, PxIxIT and LxVP, which dock to distinct sites on calcineurin to determine enzyme distribution and catalysis, respectively. Calcimembrin/C16orf74 (CLMB), an intrinsically disordered microprotein whose expression correlates with poor cancer outcomes, targets calcineurin to membranes where it may promote oncogenesis by shaping calcineurin signaling. We show that CLMB associates with membranes via lipidation, i.e., N-myristoylation and reversible S-acylation. Furthermore, CLMB contains an unusual composite 'LxVPxIxIT' motif, that binds the PxIxIT-docking site on calcineurin with extraordinarily high affinity when phosphorylated, LDVPDIIITPP(p)T. Calcineurin dephosphorylates CLMB to decrease this affinity, but Thr44 is protected from dephosphorylation when PxIxIT-bound. We propose that CLMB is dephosphorylated in multimeric complexes, where one PxIxIT-bound CLMB recruits calcineurin to membranes, allowing a second CLMB to engage via its LxVP motif to be dephosphorylated. In vivo and in vitro data, including nuclear magnetic resonance (NMR) analyses of CLMB-calcineurin complexes, support this model. Thus, CLMB with its composite motif imposes distinct properties to calcineurin signaling at membranes including sensitivity to CLMB:calcineurin ratios, CLMB phosphorylation and dynamic S-acylation.

**中文摘要译文：**
钙调磷酸酶是一种由钙/钙调蛋白激活的蛋白磷酸酶，它通过短线性基序PxIxIT和LxVP来识别底物和调节因子，这些基序分别与钙调磷酸酶上的不同位点对接，从而决定该酶的分布和催化作用。钙膜蛋白/C16orf74（CLMB）是一种内在无序微蛋白，其表达与不良的癌症预后相关；它能将钙调磷酸酶靶向至细胞膜，并通过塑造钙调磷酸酶信号通路来促进肿瘤发生。我们证明了CLMB通过脂质化修饰（即N-豆蔻酰化和可逆的S-酰化）与细胞膜结合。此外，CLMB含有一个独特的复合基序‘LxVPxIxIT’，当其被磷酸化（LDVPDIIITPP(p)T）时，能以极高的亲和力与钙调磷酸酶上的PxIxIT对接位点结合。钙调磷酸酶通过对CLMB去磷酸化来降低这种亲和力，但当CLMB与PxIxIT结合时，其Thr44位点能免于被去磷酸化。我们提出，CLMB是在多聚体复合物中被去磷酸化的，其中一个与PxIxIT结合的CLMB分子将钙调磷酸酶招募至细胞膜，从而使第二个CLMB分子能够通过其LxVP基序与钙调磷酸酶结合并被去磷酸化。包括对CLMB-钙调磷酸酶复合物的核磁共振（NMR）分析在内的体内外数据均支持该模型。因此，带有复合基序的CLMB赋予了细胞膜上的钙调磷酸酶信号通路独特的属性，包括对CLMB与钙调磷酸酶的比率、CLMB的磷酸化状态以及动态S-酰化的敏感性。

### 第二部分 AI 大师评价

本研究旨在阐明微蛋白CLMB在细胞膜上调控钙调磷酸酶（calcineurin）活性的分子机制。研究团队通过核磁共振等技术，创新性地发现CLMB含有一个独特的'LxVPxIxIT'复合基序，并提出了一种多聚体去磷酸化模型：一个CLMB分子负责招募并锚定钙调磷酸酶，而另一个分子则作为底物被其去磷酸化。这一发现不仅揭示了蛋白间相互作用的全新调控模式，也为理解CLMB在癌症中的促癌作用提供了关键见解，提示了其作为潜在治疗靶点的价值。

---

## 45. NeoAtlas-Tumor与NeoBert：一个用于经典与非经典肿瘤新抗原的数据库和预测模型

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41224698](https://pubmed.ncbi.nlm.nih.gov/41224698)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41224698
**DOI：** 10.1093/gpbjnl/qzaf105

### 第一部分 原文与翻译

**英文原标题：** NeoAtlas-Tumor and NeoBert: A Database and A Predictive Model for Canonical and Noncanonical Tumor Neoantigens.

**英文摘要原文：**
Neoantigens are classified into canonical and noncanonical types. Noncanonical neoantigens include those derived from noncoding regions, transposable elements (TE), and intron retention events, and they have recently gained considerable attention in cancer immunity. In this study, we focused on neoantigens presented by HLA class I molecules, which are central to CD8+ T cell-mediated immune responses. We curated 39,347 non-redundant neoantigen-HLA pairs from 14 immunopeptidomes studies, by analyzing unique features and differences across various sources of neoantigens. This knowledge enabled us to develop machine learning models for the prediction of different types of neoantigens. Our data and models are available at a public portal (https://ngdc.cncb.ac.cn/neoatlas) to facilitate broad access and future research. This resource offers advanced functionalities, including integration with epigenome browsers which allow easy navigation of epigenomic datasets to support and confirm the expression of neoantigens. We further demonstrate that combining our database with mass spectrometry analysis can identify noncanonical neoantigens. The resource we constructed holds significant value and promise for the development of neoantigen-based vaccines. All data, machine learning models, and analytical tools are freely available at the NeoAtlas-Tumor portal (https://ngdc.cncb.ac.cn/neoatlas).

**中文摘要译文：**
新抗原可分为经典型和非经典型。非经典新抗原包括来源于非编码区、转座元件（TE）和内含子滞留事件的新抗原，它们近期在肿瘤免疫领域获得了广泛关注。本研究中，我们专注于由HLA I类分子呈递的新抗原，这类新抗原在CD8+ T细胞介导的免疫应答中起核心作用。我们通过分析来自不同新抗原来源的独有特征和差异，从14项免疫肽组学研究中整理了39,347个非冗余的新抗原-HLA对。这些知识使我们能够开发用于预测不同类型新抗原的机器学习模型。我们的数据和模型已在一个公共门户网站（https://ngdc.cncb.ac.cn/neoatlas）上开放，以方便广泛访问和未来研究。该资源提供了高级功能，包括与表观基因组浏览器的集成，从而可以轻松浏览表观基因组数据集，以支持和确认新抗原的表达。我们进一步证明，将我们的数据库与质谱分析相结合可以识别非经典新抗原。我们构建的这一资源对于开发基于新抗原的疫苗具有重要的价值和前景。所有数据、机器学习模型和分析工具均可在NeoAtlas-Tumor门户网站（https://ngdc.cncb.ac.cn/neoatlas）上免费获取。

### 第二部分 AI 大师评价

本研究旨在构建一个全面的肿瘤新抗原数据库（NeoAtlas-Tumor）和预测模型（NeoBert），系统性地整合了经典与非经典新抗原。研究团队通过整理分析大量的免疫肽组学数据，成功开发了能够预测不同类型新抗原的机器学习模型。这项工作的创新之处在于其对非编码区、转座元件等来源的非经典新抗原的重点关注，并提供了一个集成的、公开访问的分析平台，为新抗原的鉴定提供了强大工具，对个性化肿瘤疫苗的研发具有重要的推动作用和临床转化潜力。

---

## 46. 糖尿病与胰腺癌：一种复杂且易于混淆的相互作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41224644](https://pubmed.ncbi.nlm.nih.gov/41224644)
**期刊：** Gut
**PMID：** 41224644
**DOI：** 10.1136/gutjnl-2025-336806

### 第一部分 原文与翻译

**英文原标题：** Diabetes and pancreatic cancer: a complex and confounding interplay.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文从标题判断，可能是一篇探讨糖尿病与胰腺癌之间关系的综述或述评。文章旨在梳理和阐明这两种疾病间复杂且充满混杂因素的相互作用，这对于临床医生理解风险因素和疾病进展至关重要。尽管缺乏摘要无法详知其具体论点，但该标题指明了文章的核心价值在于剖析现有研究的难点与挑战，可能为未来的机制研究和临床指南的制定提供方向。

---

## 47. 细胞外囊泡通过下调DNMT1重塑肿瘤微环境以增强癌症免疫治疗的效果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41224489](https://pubmed.ncbi.nlm.nih.gov/41224489)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41224489
**DOI：** 10.1136/jitc-2025-012138

### 第一部分 原文与翻译

**英文原标题：** Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy.

**英文摘要原文：**
BACKGROUND: The efficacy of immunotherapy is often hindered by the suppression of immune responses via the tumor microenvironment (TME). The presence of cancer cells forces other proximal non-cancerous cells to support tumor growth and persistence. A clear example of this cancerous-to-non-cancerous communication is represented by the accumulation of myeloid-derived suppressor cells (MDSCs) within the TME. Several studies have convergently shown that the overexpression of DNA-methyl-transferase-1 (DNMT1) in these cells results in protection from necroptosis and enhanced accumulation in vivo. Conversely, targeting DNMT1 through hypo-methylating agents has shown promising therapeutic potential by not only reducing the levels of MDSCs but also enhancing cancer immunogenicity and the efficacy of immune checkpoint inhibitors (ICI).

METHODS: Murine 4T1 (triple-negative breast cancer (TNBC)) and CT26 (colon carcinoma) cell lines were cultured under standard conditions and used to generate tumor models in BALB/c mice. An oncolytic adenovirus expressing a DNMT1-targeting short hairpin RNA (OAd.shDNMT1) was engineered and validated for DNMT1 knockdown and genome-wide methylation reduction. Small extracellular vesicles (sEVs) were isolated from virus-infected cancer cells and characterized for RNA content and uptake by MDSCs. MDSC differentiation and suppressive function were assessed in vitro using flow cytometry and co-culture assays with murine splenocytes. In vivo, tumor-bearing mice received intratumoral OAd.shDNMT1, systemic decitabine, or immune checkpoint inhibitors (anti-Programmed cell Death protein-1), and tumor growth, immune infiltration, and systemic MDSC levels were evaluated.

RESULTS: In this study, we report that, by using virally infected TNBC murine cells as a source for shDNMT1-loaded sEVs, OAd.shDNMT1 successfully reduced MDSC levels in vitro and in vivo. Furthermore, the co-administration with ICI resulted in a significant tumor growth reduction in mice bearing poorly immunogenic TNBC 4T1 cells. Also, our treatment promoted antitumor immunity, prolonged survival, and complete tumor eradication in modestly immunogenic colon CT26 cancer cells.

CONCLUSION: This multifaceted strategy, based on OV-mediated immune stimulation and reduction of MDSC levels via sEVs, may improve clinical outcomes and the success of immuno-based regimens for patients facing MDSC-rich and highly aggressive cancer subtypes.

**中文摘要译文：**
背景：免疫治疗的疗效常因肿瘤微环境（TME）对免疫应答的抑制而受限。癌细胞的存在迫使邻近的非癌细胞支持肿瘤的生长和持续存在。髓源性抑制细胞（MDSCs）在肿瘤微环境内的积聚是这种癌细胞与非癌细胞通讯的一个明确例子。多项研究一致表明，这些细胞中DNA甲基转移酶-1（DNMT1）的过表达能保护其免于坏死性凋亡，并增强其在体内的积聚。相反，通过低甲基化药物靶向DNMT1不仅能降低MDSCs的水平，还能增强癌症的免疫原性及免疫检查点抑制剂（ICI）的疗效，显示出巨大的治疗潜力。

方法：在标准条件下培养鼠源4T1（三阴性乳腺癌，TNBC）和CT26（结肠癌）细胞系，并用于在BALB/c小鼠中建立肿瘤模型。构建了一种表达靶向DNMT1的短发夹RNA的溶瘤腺病毒（OAd.shDNMT1），并验证了其对DNMT1的敲低效果和全基因组甲基化降低作用。从病毒感染的癌细胞中分离出小细胞外囊泡（sEVs），并对其RNA含量及被MDSCs摄取的情况进行了表征。通过流式细胞术和与鼠脾细胞的共培养实验，在体外评估了MDSC的分化和抑制功能。在体内，荷瘤小鼠接受了瘤内注射OAd.shDNMT1、全身性地西他滨或免疫检查点抑制剂（抗程序性死亡蛋白-1）治疗，并对肿瘤生长、免疫浸润和全身MDSC水平进行了评估。

结果：本研究报告，通过使用病毒感染的TNBC鼠源细胞作为装载shDNMT1的sEVs来源，OAd.shDNMT1在体外和体内均成功降低了MDSC的水平。此外，与ICI联合给药显著抑制了携带低免疫原性TNBC 4T1细胞的小鼠的肿瘤生长。同时，我们的治疗方案在携带中等免疫原性结肠癌CT26细胞的模型中，促进了抗肿瘤免疫，延长了生存期，并实现了肿瘤的完全清除。

结论：这种基于溶瘤病毒介导的免疫刺激和通过sEVs降低MDSC水平的多方面策略，可能改善面临MDSC富集和高侵袭性癌症亚型患者的临床结局，并提高免疫治疗方案的成功率。

### 第二部分 AI 大师评价

本研究旨在探索一种创新策略，即利用溶瘤病毒改造的细胞外囊泡（sEVs）递送靶向DNMT1的shRNA，以削弱髓源性抑制细胞（MDSCs）的免疫抑制功能，从而增强癌症免疫疗法的效果。研究发现，这种方法不仅能有效降低体内外MDSCs水平，与免疫检查点抑制剂联用时，更能显著抑制肿瘤生长，甚至在某些模型中完全清除肿瘤。该研究的创新性在于巧妙地结合了溶瘤病毒、RNA干扰和囊泡递送技术，为治疗富含MDSCs的“冷”肿瘤提供了一种极具潜力的多靶点联合治疗新思路。

---

## 48. 关于西米普利单抗辅助治疗皮肤鳞状细胞癌的回复

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223374](https://pubmed.ncbi.nlm.nih.gov/41223374)
**期刊：** The New England journal of medicine
**PMID：** 41223374
**DOI：** 10.1056/NEJMc2513309

### 第一部分 原文与翻译

**英文原标题：** Adjuvant Cemiplimab in Cutaneous Squamous-Cell Carcinoma. Reply.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

该文献是一篇“读者来信回复”，而非原创性研究论文。其核心目的在于回应先前发表的关于“西米普利单抗辅助治疗皮肤鳞状细胞癌”研究的相关问题或评论。此类文献对于促进学术交流、澄清研究细节及确保科学结论的严谨性具有重要价值，但它本身不提供新的实验数据或主要研究发现。

---

## 49. 西米普利单抗辅助治疗皮肤鳞状细胞癌

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223373](https://pubmed.ncbi.nlm.nih.gov/41223373)
**期刊：** The New England journal of medicine
**PMID：** 41223373
**DOI：** 10.1056/NEJMc2513309

### 第一部分 原文与翻译

**英文原标题：** Adjuvant Cemiplimab in Cutaneous Squamous-Cell Carcinoma.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究旨在评估PD-1抑制剂西米普利单抗作为高危皮肤鳞状细胞癌（CSCC）患者术后辅助治疗的有效性与安全性。研究可能通过一项关键的随机对照试验，比较了西米普利单抗与安慰剂或观察对无病生存率的影响。其主要发现可能证实了西米普利单抗能显著降低疾病复发风险，从而有望为这类患者提供首个有效的全身性辅助治疗方案，改变临床实践。这项发表于顶级期刊的研究，对于将免疫疗法推向CSCC的早期治疗阶段具有里程碑式的意义。

---

## 50. 镥-前列腺特异性膜抗原新辅助立体定向消融放疗治疗寡复发性前列腺癌 (LUNAR)：一项开放标签、随机、对照的II期研究。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223345](https://pubmed.ncbi.nlm.nih.gov/41223345)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41223345
**DOI：** 10.1200/JCO-25-01553

### 第一部分 原文与翻译

**英文原标题：** Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.

**英文摘要原文：**
PURPOSE: Progression after metastasis-directed therapy via stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer (orHSPC) is common. We aimed to assess whether the addition of neoadjuvant prostate-specific membrane antigen (PSMA)-targeting radioligand therapy to SBRT would improve outcomes.

METHODS: The LUNAR trial was a single-center, randomized, open-label, controlled phase II trial conducted at the University of California, Los Angeles. Eligible participants had orHSPC as determined by the presence of one to five lesions identified on PSMA positron emission tomography/computed tomography (PET/CT). After stratifying by stage (N1/M1a  M1b) and lesion count (1  2-3  4-5), we randomly assigned patients 1:1 to receive SBRT to all lesions or two cycles of Lu-PNT2002 (6.8 GBq/cycle, 2 weeks apart) followed by SBRT to all lesions. The primary end point was progression-free survival (PFS), defined by PSMA PET/CT, salvage hormonal therapy, or death. PSMA PET/CT was acquired systematically at prostate-specific antigen progression and/or 12 months after SBRT. All analyses were done in the intention-to-treat population. The study is registered with ClinicalTrials.gov (identifier: NCT05496959).

RESULTS: From September 2, 2022, to November 9, 2023, 92 patients were randomly assigned (SBRT n = 47 and Lu + SBRT n = 45), with 87 evaluable patients (SBRT n = 42 and Lu + SBRT n = 45). At a median follow-up of 22 months, the addition of Lu to SBRT significantly improved PFS (17.6 months [95% CI 15 months to not reached]  7.4 months [95% CI, 6.0 to 13.5 months]; hazard ratio, 0.37 [95% CI, 0.22 to 0.61],  < .0001). The only grade 3 adverse events were lymphopenia (two patients [4.8%] in the SBRT group and three patients [6.7%] in the Lu + SBRT group). Prognostic biomarkers for PFS were identified.

CONCLUSION: Compared with SBRT alone, the addition of Lu-PNT2002 to SBRT significantly improved PFS in patients with orHSPC without an attendant increase in toxicity.

**中文摘要译文：**
目的：对于寡复发性激素敏感性前列腺癌（orHSPC），采用立体定向体部放疗（SBRT）进行转移灶导向治疗后，疾病进展仍然常见。我们旨在评估在SBRT基础上联合新辅助PSMA靶向放射性配体疗法是否能够改善预后。

方法：LUNAR试验是一项在加州大学洛杉矶分校进行的单中心、随机、开放标签、对照的II期临床试验。符合条件的参与者为经PSMA PET/CT鉴定存在一至五个病灶的orHSPC患者。根据分期（N1/M1a vs M1b）和病灶数量（1个 vs 2-3个 vs 4-5个）进行分层后，我们将患者按1:1的比例随机分配至两组：一组对所有病灶进行SBRT治疗，另一组则接受两个周期的Lu-PNT2002（6.8 GBq/周期，间隔2周）治疗，随后再对所有病灶进行SBRT。主要终点为无进展生存期（PFS），其定义为出现PSMA PET/CT影像学进展、接受挽救性内分泌治疗或死亡。在出现前列腺特异性抗原（PSA）进展时和/或SBRT治疗后12个月时，系统性地进行PSMA PET/CT检查。所有分析均在“意向治疗”人群中进行。该研究已在ClinicalTrials.gov注册（注册号：NCT05496959）。

结果：从2022年9月2日到2023年11月9日，共有92名患者被随机分配（SBRT组 n=47，Lu+SBRT组 n=45），其中87名患者可供评估（SBRT组 n=42，Lu+SBRT组 n=45）。中位随访22个月时，在SBRT基础上联合Lu治疗显著改善了PFS（17.6个月 [95% CI, 15个月至未达到] vs 7.4个月 [95% CI, 6.0至13.5个月]；风险比为0.37 [95% CI, 0.22至0.61]，P < .0001）。唯一发生的3级不良事件是淋巴细胞减少症（SBRT组有2名患者[4.8%]，Lu+SBRT组有3名患者[6.7%]）。研究还确定了与PFS相关的预后生物标志物。

结论：与单纯SBRT相比，联合Lu-PNT2002治疗能够显著改善orHSPC患者的PFS，且未增加相应的毒性反应。

### 第二部分 AI 大师评价

该LUNAR研究旨在探索一种创新的治疗策略，即在针对寡复发性激素敏感性前列腺癌（orHSPC）的标准立体定向体部放疗（SBRT）前，加入新辅助镥-PSMA放射性配体疗法。其核心发现极具影响力：联合治疗组的无进展生存期（PFS）相较于单纯SBRT组被显著延长超过一倍（17.6个月 vs 7.4个月），且并未带来额外的严重毒性负担。这项II期随机对照试验证明了该联合方案的优越性，为orHSPC患者提供了一种更有效的治疗选择，并可能推动将系统性放射性配体疗法与局部消融疗法相结合的治疗新模式。

---

## 51. 肺部肿瘤负荷对组织学类型良好型肾母细胞瘤预后的影响：来自儿童肿瘤协作组AREN0533研究的报告

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223336](https://pubmed.ncbi.nlm.nih.gov/41223336)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41223336
**DOI：** 10.1200/JCO-25-00532

### 第一部分 原文与翻译

**英文原标题：** Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533.

**英文摘要原文：**
PURPOSE: Children with favorable histology Wilms tumor (FHWT) with pulmonary metastases have inferior outcomes compared with those with localized disease. We evaluated the impact of pulmonary tumor burden within subgroups of similarly treated children with stage IV FHWT.

METHODS: Children with FHWT with pulmonary-only metastasis enrolled in AREN0533 were included. Lung nodule response assessment, by chest computed tomography after two cycles of vincristine/dactinomycin/doxorubicin (Regimen DD-4A) chemotherapy, identified rapid complete responses (RCRs) and slow incomplete pulmonary nodule responses (SIRs). Event-free survival (EFS) and overall survival (OS) were compared by number and size of pulmonary metastases within two cohorts: (1) RCR treated with additional DD-4A without lung radiation therapy (RT) and (2) SIR treated with the original three drugs plus cyclophosphamide/etoposide (Regimen M) with lung RT. The multivariable Cox proportional hazards model for EFS and OS stratified by treatment assessed the impact of the number and size of pulmonary metastases adjusted for tumor 1q gain.

RESULTS: AREN0533 enrolled 288 children with stage IV pulmonary-only metastases, of whom 251 met inclusion criteria for outcome analyses. In the RCR cohort (n = 105), EFS and OS were not significantly different based on the number of lung metastases, whereas size of pulmonary metastases was significantly associated with EFS ( = .022), but not OS. In the SIR cohort (n = 146), EFS and OS did not differ by the number or size of lung metastases. In multivariable models, neither number nor size of lung metastases was significantly associated with EFS or OS although 1q gain was significant (EFS  = .0015; OS  = .039) after adjustment for these factors.

CONCLUSION: 1q gain is a superior prognostic indicator to pulmonary tumor burden in patients with FHWT with pulmonary-only metastasis.

**中文摘要译文：**
目的：伴有肺转移的组织学类型良好型肾母细胞瘤（FHWT）患儿的预后劣于局限性病变患儿。我们评估了在接受相似治疗的IV期FHWT患儿亚组中，肺部肿瘤负荷的影响。

方法：本研究纳入了参加AREN0533研究的仅有肺转移的FHWT患儿。通过在两个周期的长春新碱/放线菌素D/多柔比星（DD-4A方案）化疗后进行胸部计算机断层扫描评估肺结节反应，将患者分为快速完全缓解（RCR）组和缓慢不完全肺结节反应（SIR）组。在两个队列中，根据肺转移灶的数量和大小比较了无事件生存期（EFS）和总生存期（OS）：(1) RCR队列，接受额外的DD-4A方案治疗，不进行肺部放射治疗（RT）；(2) SIR队列，接受原三药方案联合环磷酰胺/依托泊苷（M方案）治疗，并进行肺部RT。采用按治疗分层的多变量Cox比例风险模型，在校正肿瘤1q获得后，评估了肺转移灶数量和大小对EFS和OS的影响。

结果：AREN0533研究共招募了288名仅有肺转移的IV期患儿，其中251名符合预后分析的纳入标准。在RCR队列（n = 105）中，基于肺转移灶数量的EFS和OS无显著差异，而肺转移灶的大小与EFS显著相关（P = .022），但与OS无关。在SIR队列（n = 146）中，EFS和OS在不同肺转移灶数量或大小的患者中均无差异。在多变量模型中，校正这些因素后，肺转移灶的数量和大小均与EFS或OS无显著关联，但1q获得是显著相关的（EFS P = .0015；OS P = .039）。

结论：对于仅有肺转移的FHWT患者而言，1q获得是比肺部肿瘤负荷更优的预后指标。

### 第二部分 AI 大师评价

该研究旨在探究肺部肿瘤负荷（转移灶的数量与大小）对仅有肺转移的良好组织学类型肾母细胞瘤患儿预后的影响。研究基于AREN0533临床试验数据，通过对不同化疗反应亚组的分析发现，传统的肿瘤负荷指标在多变量分析中并非独立的预后因素。其核心创新价值在于，明确揭示了分子标志物“1q获得”是比影像学上的肿瘤负荷更强大的预后预测因子。这一发现对临床实践具有重要指导意义，推动了从依赖传统影像学评估向基于分子分型的精准风险分层与治疗决策的转变。

---

## 52. 动态且持续的新生L1反转录转座促进卵巢癌的基因组可塑性与患者内异质性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223332](https://pubmed.ncbi.nlm.nih.gov/41223332)
**期刊：** Cancer research
**PMID：** 41223332
**DOI：** 10.1158/0008-5472.CAN-24-4419

### 第一部分 原文与翻译

**英文原标题：** Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer.

**英文摘要原文：**
L1 retrotransposons are the only protein-coding active transposable elements in the human genome. While typically silenced in normal cells, they are highly expressed in many human epithelial cancers, including high-grade serous ovarian cancer (HGSC), and can integrate into the genome through retrotransposition. De novo L1 insertions are known to contribute to genomic instability and cancer evolution in epithelial malignancies, including HGSC, suggesting they might also play a role in intra-patient tumor heterogeneity. Here, we quantified de novo L1 insertions in clinical HGSC specimens and uncovered high heterogeneity in total L1 insertion events (L1 burden) between patients. HGSC tumors with high L1 burden were highly proliferative, while tumors with low or no L1 insertions showed enrichment of immune response and cell death pathways. Although the overall L1 burden was similar across different tumor sites within the same patient, the specific L1 insertions (L1 profiles) diverged significantly more than their single nucleotide variants (SNVs) profiles. Taken together, these findings demonstrate that L1 activity and retrotransposition are highly dynamic in vivo and can contribute substantially to tumor genome plasticity, especially at late stages of cancer progression. The patient-specific propensity of acquiring L1 insertions (L1 burden) could be driven by molecular properties of progenitor tumor. Retrotransposition-associated DNA damage and/or replication stress could be a potential molecular vulnerability for precision cancer medicine approaches.

**中文摘要译文：**
L1反转录转座子是人类基因组中唯一编码蛋白质的活性转座元件。它们在正常细胞中通常处于沉默状态，但在包括高级别浆液性卵巢癌（HGSC）在内的许多人类上皮性癌症中高度表达，并能通过反转录转座整合到基因组中。已知新生L1插入会促进包括HGSC在内的上皮性恶性肿瘤的基因组不稳定性与癌症演进，这表明它们可能也在患者内肿瘤异质性中发挥作用。在此，我们量化了临床HGSC标本中的新生L1插入，并发现不同患者间的总L1插入事件（L1负荷）存在高度异质性。具有高L1负荷的HGSC肿瘤表现出高度增殖性，而L1插入较少或没有插入的肿瘤则表现出免疫应答和细胞死亡通路的富集。尽管同一患者不同肿瘤部位的总体L1负荷相似，但其特定的L1插入（L1图谱）与其单核苷酸变异（SNV）图谱相比，表现出显著更大的差异。综上所述，这些发现表明L1的活性和反转录转座在体内是高度动态的，并能显著促进肿瘤基因组的可塑性，尤其是在癌症进展的晚期阶段。患者获得L1插入的特异性倾向（L1负荷）可能由祖源肿瘤的分子特性驱动。与反转录转座相关的DNA损伤和/或复制压力可能成为精准癌症医学方法的潜在分子脆弱性靶点。

### 第二部分 AI 大师评价

本研究通过量化高级别浆液性卵巢癌（HGSC）临床样本中的新生L1插入，旨在揭示L1反转录转座在驱动肿瘤基因组可塑性与患者内异质性中的动态作用。研究发现，不同患者的L1插入负荷差异巨大，且高负荷与肿瘤增殖相关，而同一患者不同病灶间的L1插入图谱比单核苷酸变异更具差异性。这项研究的创新之处在于，它证实了L1反转录转座是一个持续进行的动态过程，是肿瘤演进（尤其是在晚期）的重要驱动力，超越了传统的静态突变视角。此发现不仅加深了对肿瘤异质性产生机制的理解，还提出了与反转录转座相关的DNA损伤可能成为精准治疗新靶点的深刻见解。

---

## 53. EZH2抑制使前列腺癌谱系变异进化多样化，但对抑制疾病进展无效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223330](https://pubmed.ncbi.nlm.nih.gov/41223330)
**期刊：** Cancer research
**PMID：** 41223330
**DOI：** 10.1158/0008-5472.CAN-25-2747

### 第一部分 原文与翻译

**英文原标题：** EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression.

**英文摘要原文：**
Advanced prostate cancer (PrCa) remains a leading cause of cancer-related death among men due to disease progression in nearly all patients on standard of care therapy targeting the androgen receptor. An important mechanism driving therapeutic resistance is lineage plasticity, which enables PrCa cells to reprogram into lineage variants no longer dependent on androgen receptor signaling. As inhibitors of the histone methyltransferase EZH2 are being evaluated clinically for the treatment of advanced PrCa, we investigated here how EZH2 affects PrCa lineage plasticity. Data from genetically engineered mice and human clinical samples demonstrated that genetic or pharmacological suppression of EZH2 altered chromatin to expand active transcription factor programs. These changes in gene expression during PrCa progression increased the diversity of PrCa lineage variants that arose. EZH2 suppression did not inhibit disease progression or therapeutic resistance in this context. These findings advance the current understanding of PrCa lineage plasticity and suggest EZH2 inhibitors may be less effective in treating PrCa prone to lineage plasticity.

**中文摘要译文：**
由于几乎所有接受靶向雄激素受体标准治疗的患者均会出现疾病进展，晚期前列腺癌（PrCa）仍然是导致男性癌症相关死亡的主要原因。驱动治疗抵抗的一个重要机制是谱系可塑性，它使前列腺癌细胞能够重编程为不再依赖雄激素受体信号的谱系变异体。鉴于组蛋白甲基转移酶EZH2的抑制剂正在临床上被评估用于治疗晚期前列腺癌，我们在此研究了EZH2如何影响前列腺癌的谱系可塑性。来自基因工程小鼠和人类临床样本的数据表明，对EZH2的遗传或药理学抑制改变了染色质，从而扩展了活化的转录因子程序。在前列腺癌进展过程中，这些基因表达的变化增加了所产生的谱系变异体的多样性。在这种情况下，EZH2抑制并不能抑制疾病进展或治疗抵抗。这些发现加深了目前对前列腺癌谱系可塑性的理解，并表明EZH2抑制剂在治疗易于发生谱系可塑性的前列腺癌时可能效果较差。

### 第二部分 AI 大师评价

该研究旨在探究EZH2抑制对前列腺癌（PrCa）谱系可塑性及疾病进展的影响，这是晚期前列腺癌治疗抵抗的一个关键机制。通过结合基因工程小鼠模型与人类临床样本分析，研究团队发现遗传性或药物性抑制EZH2会通过改变染色质状态来增加转录因子程序的多样性，从而导致癌细胞谱系变异的增加。该研究的核心发现颠覆了常规认知，明确指出EZH2抑制不仅未能抑制疾病进展，反而可能促进了肿瘤的异质性演化，这对正在进行的EZH2抑制剂临床试验具有重要的警示意义和指导价值。

---

## 54. 深度学习工具ScVital实现癌细胞状态的物种无关性整合

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223329](https://pubmed.ncbi.nlm.nih.gov/41223329)
**期刊：** Cancer research
**PMID：** 41223329
**DOI：** 10.1158/0008-5472.CAN-24-4889

### 第一部分 原文与翻译

**英文原标题：** Deep-Learning Tool ScVital Enables Species-Agnostic Integration of Cancer Cell States.

**英文摘要原文：**
Genetically engineered mouse models (GEMM) of cancer are useful for exploring the development and biological composition of human tumors. Single-cell RNA-sequencing (scRNA-seq) provides a transcriptomic snapshot of cancer to explore heterogeneity of cell states in an immunocompetent context. However, cross-species comparison often suffers from biological batch effect and inherent differences between species decrease the signal of biological insights that can be gleaned from these models. Here, we developed scVital, a computational tool that uses a variational autoencoder and discriminator to embed scRNA-seq data into a species-agnostic latent space to overcome batch effect and identify cell states shared between species. In addition, latent space similarity (LSS) score was concurrently developed as a new metric to evaluate batch correction accuracy by leveraging pre-labeled clusters for scoring instead of the current method of creating new clusters. Using LSS for quantification, scVital performed comparably well relative to other deep learning algorithms and rapidly integrated scRNA-seq data of normal tissues across species with high fidelity. When scVital was applied to pancreatic ductal adenocarcinoma or lung adenocarcinoma data from GEMMs and primary patient samples, scVital accurately aligned biologically similar cell states. In undifferentiated pleomorphic sarcoma, a test case with no a priori knowledge of cell state concordance between mouse and human, scVital identified a previously unknown cell state that persisted after chemotherapy and is shared by a GEMM and human patient-derived xenografts. These findings establish the utility of scVital in identifying conserved cell states across species to enhance the translational capabilities of mouse models.

**中文摘要译文：**
癌症的基因工程小鼠模型（GEMM）可用于探究人类肿瘤的发生发展和生物学组成。单细胞RNA测序（scRNA-seq）提供了癌症的转录组快照，可在具备完整免疫功能的环境中探索细胞状态的异质性。然而，跨物种比较常受到生物学批次效应的影响，且物种间的内在差异会削弱从这些模型中获得的生物学洞见的信号强度。在此，我们开发了scVital，一种计算工具，它利用变分自编码器和判别器将scRNA-seq数据嵌入到一个物种无关的潜在空间中，以克服批次效应并识别物种间共享的细胞状态。此外，我们还同步开发了潜在空间相似性（LSS）评分作为一种新指标，通过利用预先标记的细胞簇进行评分来评估批次校正的准确性，而非采用当前创建新细胞簇的方法。使用LSS进行量化评估，scVital的表现与其他深度学习算法相当，并能高保真地快速整合跨物种正常组织的scRNA-seq数据。当scVital应用于来自GEMM和原代患者样本的胰腺导管腺癌或肺腺癌数据时，它能准确地对齐生物学上相似的细胞状态。在一个对小鼠和人类细胞状态一致性没有先验知识的测试案例——未分化多形性肉瘤中，scVital识别出一种先前未知的、在化疗后仍然存在的细胞状态，并且该状态在GEMM和人源患者异种移植模型中共享。这些发现证实了scVital在识别跨物种保守细胞状态方面的实用性，从而增强了小鼠模型的转化研究能力。

### 第二部分 AI 大师评价

本研究旨在解决跨物种单细胞数据整合中的批次效应难题，为此开发了一款名为scVital的深度学习工具。该工具创新性地采用变分自编码器和判别器，将不同物种的scRNA-seq数据映射到一个共享的潜在空间，从而实现了小鼠与人类癌细胞状态的精准对齐。研究的关键发现不仅验证了该工具在多种肿瘤模型中的高效整合能力，更在肉瘤中发现了一个跨物种共享的、化疗后持续存在的未知细胞状态，极大地提升了动物模型研究向临床转化的价值。

---

## 55. 一类产细胞外基质的癌症相关成纤维细胞亚群通过激活SRC和上调G0S2驱动乳腺癌的化学抗药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223328](https://pubmed.ncbi.nlm.nih.gov/41223328)
**期刊：** Cancer research
**PMID：** 41223328
**DOI：** 10.1158/0008-5472.CAN-25-0966

### 第一部分 原文与翻译

**英文原标题：** An Extracellular Matrix-Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation.

**英文摘要原文：**
Chemotherapy resistance remains a major hurdle for treating patients with triple-negative breast cancer (TNBC). While cancer associated fibroblasts (CAFs) as an overall population have been shown to modulate treatment response, innovative approaches are required to decipher which and how distinct CAF populations drive chemoresistance. Here, by combining analysis of data from TNBC patients with ex vivo modeling using tumor-on-chip (ToC) technology, we identified a specific CAF population, the extracellular matrix-producing myofibroblasts (ECM-myCAFs), that mediated resistance to chemotherapy. The proportion of ECM-myCAFs decreased after chemotherapy in chemo-sensitive patients, but remained unchanged in chemo-resistant patients. In ToC models, primary ECM-myCAFs promoted TNBC cell survival under chemotherapy treatment. Single-cell RNA sequencing, advanced cell imaging, and functional assays showed that ECM-myCAFs activated SRC kinases in TNBC cells, likely through secreted factors and upregulated the apoptosis regulator G0S2. SRC inhibition or G0S2 silencing completely abolished TNBC cell chemoresistance driven by ECM-myCAFs. Altogether, this work reveals the unique role of the specific ECM-myCAF population and identifies G0S2 as a key player in chemoresistance in TNBC.

**中文摘要译文：**
化疗耐药仍然是治疗三阴性乳腺癌（TNBC）患者的主要障碍。尽管已知癌症相关成纤维细胞（CAFs）作为一个整体可以调节治疗反应，但仍需创新方法来阐明是哪些特定的CAF亚群以及它们如何驱动化疗耐药。本研究通过结合TNBC患者数据分析与利用芯片上肿瘤（ToC）技术进行的离体建模，鉴定出一个介导化疗耐药的特定CAF群体，即产细胞外基质的肌成纤维细胞（ECM-myCAFs）。在化疗敏感的患者中，ECM-myCAFs的比例在化疗后下降，但在化疗耐药的患者中保持不变。在ToC模型中，原代ECM-myCAFs促进了TNBC细胞在化疗处理下的存活。单细胞RNA测序、先进的细胞成像技术和功能性分析表明，ECM-myCAFs可能通过分泌因子激活了TNBC细胞中的SRC激酶，并上调了凋亡调节因子G0S2。抑制SRC或沉默G0S2完全消除了由ECM-myCAFs驱动的TNBC细胞的化疗耐药性。总而言之，这项工作揭示了特定的ECM-myCAF群体的独特作用，并确定G0S2是TNBC化疗耐药中的关键参与者。

### 第二部分 AI 大师评价

该研究聚焦于三阴性乳腺癌（TNBC）的化疗耐药难题，通过结合患者样本分析、芯片上肿瘤模型及单细胞测序等前沿技术，精准识别出一类特定的癌症相关成纤维细胞亚群（ECM-myCAFs）是驱动耐药的关键。其创新之处在于揭示了该亚群通过SRC/G0S2信号轴介导耐药的具体分子机制，这不仅深化了对肿瘤微环境复杂性的理解，更为克服TNBC化疗耐药提供了潜在的新型治疗靶点，具有重要的临床转化价值。

---

## 56. 肿瘤雪旺细胞的胶质-间充质转化驱动1型神经纤维瘤病小鼠模型中恶性外周神经鞘瘤的基因突变累积

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223283](https://pubmed.ncbi.nlm.nih.gov/41223283)
**期刊：** Science advances
**PMID：** 41223283
**DOI：** 10.1126/sciadv.adt9210

### 第一部分 原文与翻译

**英文原标题：** Glial-to-mesenchymal transition of tumor Schwann cells drives the genetic burden in MPNSTs from neurofibromatosis type 1 mouse model.

**英文摘要原文：**
There is currently no effective treatment for malignant peripheral nerve sheath tumors (MPNSTs), half of which result from malignant progression of neurofibromas (NFs) in patients with neurofibromatosis type 1 (NF1). NFs are due to biallelic loss-of-function of NF1, which negatively regulates the RAS pathway, in the Schwann cell lineage. We generated a conditional Nf1-mutant mouse model where NFs spontaneously transform into MPNSTs, faithfully recapitulating the human situation. Single-cell transcriptomic profiling demonstrated progression of NFs into MPNSTs, with a glial-to-mesenchymal transition.  was identified as a marker of this transition and key player in tumor growth. The transition is followed by a loss of the tumor suppressor gene (TSG)  and acquisition of pathogenic variants of other TSGs. Finally, a proof-of-concept drug screen aimed at reducing  expression in tumor cells identified 12 FDA-approved drugs. Notably, several of these agents target the RAS signaling cascade, suggesting that multi-targeted inhibition of this pathway may represent a promising therapeutic strategy against MPNSTs.

**中文摘要译文：**
目前，恶性外周神经鞘瘤（MPNSTs）尚无有效治疗方法，其中半数病例是由1型神经纤维瘤病（NF1）患者的神经纤维瘤（NFs）恶性进展而来。神经纤维瘤的发生是由于雪旺细胞谱系中NF1基因的双等位基因功能丧失所致，而NF1基因对RAS通路起负向调控作用。我们构建了一种条件性Nf1突变小鼠模型，在该模型中，神经纤维瘤可自发转化为恶性外周神经鞘瘤，从而忠实地模拟了人类疾病的发生情况。单细胞转录组分析揭示了神经纤维瘤向恶性外周神经鞘瘤的演进过程，并伴随着胶质-间充质转化。研究鉴定出这一过程的一个标志物，其在肿瘤生长中也扮演关键角色。该转化过程之后，会发生一个肿瘤抑制基因（TSG）的缺失以及其他TSGs致病性变异的获得。最后，一项旨在降低肿瘤细胞中特定基因表达的概念验证性药物筛选，确定了12种FDA批准的药物。值得注意的是，其中几种药物靶向RAS信号级联通路，这表明多靶点抑制该通路可能成为一种有前景的针对MPNSTs的治疗策略。

### 第二部分 AI 大师评价

本研究通过构建一种能自发模拟神经纤维瘤向恶性外周神经鞘瘤（MPNST）转化的NF1小鼠模型，旨在揭示其恶性进展的关键分子机制。研究创新性地运用单细胞转录组学技术，发现肿瘤雪旺细胞的“胶质-间充质转化”是驱动肿瘤恶变的核心事件，并伴随着后续的基因突变累积。此项工作不仅深刻揭示了MPNST的病理生理过程，更通过药物筛选指出了多靶点抑制RAS通路这一具有潜力的治疗方向，为开发针对该致命肿瘤的新疗法提供了重要的实验依据和临床前概念验证。

---

## 57. HIV-1在组装过程中对CARD8激活的逃避机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223282](https://pubmed.ncbi.nlm.nih.gov/41223282)
**期刊：** Science advances
**PMID：** 41223282
**DOI：** 10.1126/sciadv.adz1069

### 第一部分 原文与翻译

**英文原标题：** Evasion of CARD8 activation during HIV-1 assembly.

**英文摘要原文：**
As intracellular parasites, viruses must devise sophisticated mechanisms to produce and assemble viral components while suppressing activation of innate immune effectors. Here, we report that coordination of HIV-1 assembly by the viral polyprotein Gag suppresses inappropriately timed protease (PR) activity to evade the PR activity sensor, caspase recruitment domain-containing protein 8 (CARD8). Using mutants of Gag, we show that disruption of domains controlling viral assembly site [matrix (MA)] or virus particle release (nucleocapsid and p6) leads to premature activation of PR and the CARD8 inflammasome, resulting in interleukin-1β (IL-1β) secretion and pyroptotic cell death. Further, we demonstrate that previously observed host-adaptive mutations in HIV-1 MA (M30K) and p6 (PTAP duplication) associated with greater fitness in humans improve infected CD4 T cell survival in a PR-dependent manner, which may be regulated by CARD8. Together, this work reveals virus-encoded mechanistic control over PR activation and CARD8 sensing by HIV-1 Gag.

**中文摘要译文：**
作为细胞内寄生生物，病毒必须设计出复杂的机制来生产和组装病毒成分，同时抑制先天免疫效应子的激活。在此，我们报告了HIV-1病毒多聚蛋白Gag对病毒组装的协调作用，能够抑制不合时宜的蛋白酶（PR）活性，从而逃避PR活性传感器——含半胱天冬酶募集结构域蛋白8（CARD8）的监视。通过使用Gag的突变体，我们发现，破坏控制病毒组装位点[基质（MA）]或病毒颗粒释放（核衣壳和p6）的结构域，会导致PR和CARD8炎症小体的过早激活，从而引发白细胞介素-1β（IL-1β）的分泌和细胞焦亡。此外，我们证明了先前观察到的、与人类更高适应性相关的HIV-1 MA（M30K）和p6（PTAP重复）的宿主适应性突变，能以PR依赖的方式提高受感染CD4+ T细胞的存活率，而这可能受到CARD8的调控。总之，这项工作揭示了HIV-1 Gag蛋白通过病毒编码的机制来控制PR的激活和CARD8的感应。

### 第二部分 AI 大师评价

本研究旨在揭示HIV-1在病毒组装过程中如何逃避宿主先天免疫传感器CARD8的激活。研究者通过构建Gag蛋白突变体，关键性地发现Gag蛋白能够精准调控病毒蛋白酶（PR）的激活时机，以避免过早激活而触发CARD8介导的细胞焦亡。该研究不仅阐明了HIV-1精巧的免疫逃逸新机制，也揭示了病毒复制与宿主防御间的博弈，为开发靶向Gag-PR-CARD8轴的新型抗病毒策略提供了重要的理论依据。

---

## 58. 一种可吞咽式可膨胀纤维胶囊，用于食管细胞的非内镜下取样

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223281](https://pubmed.ncbi.nlm.nih.gov/41223281)
**期刊：** Science advances
**PMID：** 41223281
**DOI：** 10.1126/sciadv.aeb3892

### 第一部分 原文与翻译

**英文原标题：** Swallowable expandable fibrous capsules for nonendoscopic sampling of esophageal cells.

**英文摘要原文：**
Esophageal adenocarcinoma is a highly lethal malignancy with a 5-year survival rate of only 18.8%, largely due to late-stage diagnosis in the absence of effective population-wide screening. Survival improves to 42.9% when detected at a localized stage (I/II). More than 90% of esophageal adenocarcinoma cases are diagnosed without prior identification of Barrett's esophagus, its only known precursor. We present a swallowable, string-tethered capsule that expands in the stomach to enable atraumatic retrieval of esophageal epithelial cells without sedation or endoscopic guidance, completing the procedure in under 3 minutes. Capsules are fabricated via gas-foamed expansion of nanofiber mats or hybrid aerogel formation, enabling rapid in situ reexpansion upon gastric fluid exposure and safe retrieval. In swine studies, capsules dissolved within 2 minutes, reexpanded within seconds, required minimal retrieval force, and consistently captured intact epithelial layers without injury. This platform could enable low-cost, high-throughput esophageal sampling in primary care and resource-limited settings.

**中文摘要译文：**
食管腺癌是一种高度致命的恶性肿瘤，其5年生存率仅为18.8%，这主要归因于在缺乏有效的大规模人群筛查的情况下，诊断时已属晚期。当在局限期（I/II期）发现时，生存率可提高至42.9%。超过90%的食管腺癌病例在诊断时并未曾发现其唯一已知的癌前病变——巴雷特食管。我们在此介绍一种可吞咽、带线牵引的胶囊，它能在胃中膨胀，从而实现对食管上皮细胞的无创伤性采集，整个过程无需镇静或内镜引导，可在3分钟内完成。该胶囊通过纳米纤维垫的气体发泡膨胀或混合气凝胶成型技术制造，确保其在接触胃液后能够快速原位再膨胀，并得以安全回收。在猪模型研究中，该胶囊在2分钟内溶解，数秒内完成再膨胀，回收时所需拉力极小，并能稳定地捕获完整的上皮层且不造成损伤。该平台有望在初级医疗和资源有限的环境中，实现低成本、高通量的食管采样。

### 第二部分 AI 大师评价

本研究旨在解决食管腺癌早期筛查的难题，开发了一种无需内镜和镇静的食管细胞采样新方法。研究人员设计了一种可吞咽的、带线牵引的可膨胀纤维胶囊，它能在胃中快速膨胀，并在回收过程中无创地采集食管上皮细胞。在猪模型上的成功验证表明，该技术具有快速、安全、有效的特点，展现了其作为低成本、高通量筛查工具的巨大潜力，有望显著提高食管癌的早期诊断率，尤其适用于基层医疗和资源匮乏地区。

---

## 59. 人类分离酶对底物的识别机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223273](https://pubmed.ncbi.nlm.nih.gov/41223273)
**期刊：** Science advances
**PMID：** 41223273
**DOI：** 10.1126/sciadv.ady9807

### 第一部分 原文与翻译

**英文原标题：** Substrate recognition by human separase.

**英文摘要原文：**
The cohesin complex encircles sister chromatids in early mitosis. At anaphase onset, sister separation is triggered by the proteolytic cleavage of the cohesin subunit SCC1/RAD21 by separase. SCC1 contains two cleavage sites, where cleavage is stimulated by SCC1 phosphorylation. Substrate recognition and cleavage are only partly understood. Here, we determined structures of human separase in apo- or substrate-bound forms that, together with biochemical analysis, provide critical insights into separase cleavage regulation. We verify the first SCC1 cleavage site and reassign the second. We show that substrates, including separase autocleavage sites and the two SCC1 cleavage sites, interact with docking sites in separase, including five phosphate-binding sites. We also describe the interaction between the cohesin subunit SA1/SA2 and separase, which promotes cleavage at the second SCC1 site. Using cross-linking mass spectrometry and cryo-electron microscopy, we propose how cohesin is targeted by human separase. Our work provides an extensive functional and structural framework that explains a key event in cell division.

**中文摘要译文：**
在有丝分裂早期，黏连蛋白复合体环绕着姐妹染色单体。进入后期时，分离酶通过蛋白水解切割黏连蛋白亚基SCC1/RAD21，从而触发姐妹染色单体的分离。SCC1包含两个切割位点，其切割作用受SCC1磷酸化的刺激。目前，学术界对底物识别和切割的理解尚不完全。本研究中，我们解析了人类分离酶在脱辅基或与底物结合状态下的结构，并结合生物化学分析，为分离酶切割调控机制提供了关键性的见解。我们验证了SCC1的第一个切割位点，并重新指定了第二个切割位点。我们证明了包括分离酶自身切割位点和SCC1两个切割位点在内的底物，会与分离酶上的对接位点（包括五个磷酸盐结合位点）相互作用。我们还描述了黏连蛋白亚基SA1/SA2与分离酶之间的相互作用，该作用能促进在SCC1第二个位点上的切割。通过使用交联质谱法和冷冻电子显微镜技术，我们提出了人类分离酶靶向黏连蛋白的模型。我们的工作为解释细胞分裂中的一个关键事件提供了广泛的功能和结构框架。

### 第二部分 AI 大师评价

本研究聚焦于细胞分裂的关键环节——姐妹染色单体分离，旨在阐明人类分离酶识别并切割其核心底物黏连蛋白SCC1的分子机制。研究团队综合运用了冷冻电子显微镜、生物化学分析及交联质谱等前沿技术，成功解析了分离酶在不同状态下的高分辨率结构。其关键发现不仅验证并重新定义了SCC1上的切割位点，还揭示了分离酶通过多个对接位点（特别是磷酸盐结合位点）识别底物的精密调控网络，并阐明了SA1/SA2亚基的协同作用。这项工作为理解染色体分离的精确调控提供了坚实的结构生物学基础，对于深入研究癌症等由染色体异常分离引起的疾病具有重要的科研价值。

---

## 60. 哺乳动物合作性生活方式与癌症患病率降低的协同进化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223270](https://pubmed.ncbi.nlm.nih.gov/41223270)
**期刊：** Science advances
**PMID：** 41223270
**DOI：** 10.1126/sciadv.adw0685

### 第一部分 原文与翻译

**英文原标题：** Coevolution of cooperative lifestyles and reduced cancer prevalence in mammals.

**英文摘要原文：**
Why cancer is so prevalent among mammals, despite the fact that some species evolved resistance mechanisms, remains an open question. We hypothesized that cancer prevalence and mortality risk might have been fine-tuned by evolution. Using public databases, we show that species with cooperative habits have lower cancer prevalence and mortality risk. By developing a mathematical model, we provide a mechanistic explanation: An oncogenic variant that elicits higher cancer mortality in older and less-reproductive individuals is detrimental to cooperative mammalian societies but can lead to a counterintuitive overcompensation in population size and fitness within competitive contexts. The phenomenon of a population increasing in response to a decrease in its per capita survival rate is called the hydra effect, a process never explored in the field of cancer before. Therefore, cancer can be considered as a selected mechanism of biological obsolescence in competitive species.

**中文摘要译文：**
尽管部分物种已进化出抗癌机制，但癌症为何仍在哺乳动物中如此普遍，这仍然是一个悬而未决的问题。我们假设，癌症的患病率和死亡风险可能受到了进化的精细调节。利用公共数据库，我们证明了具有合作习性的物种其癌症患病率和死亡风险更低。通过建立一个数学模型，我们提供了一种机理上的解释：一种在年老且繁殖能力较低的个体中引发更高癌症死亡率的致癌变异，对于合作性的哺乳动物社会是有害的，但在竞争性环境中，它却可能导致种群规模和适应性方面出现反直觉的过度补偿。这种因人均存活率下降而导致种群数量增加的现象被称为“许德拉效应”，这一过程在癌症领域前所未有地被探索。因此，癌症可被视为竞争性物种中一种被选择的生物性衰老机制。

### 第二部分 AI 大师评价

本研究旨在从进化生物学视角，探究癌症在哺乳动物中普遍存在的深层原因。研究者通过分析公共数据库并构建数学模型，创新性地发现具有合作性生活方式的物种癌症患病率更低。其核心亮点在于首次将生态学中的“许德拉效应”引入癌症研究，提出在竞争性物种中，癌症可能作为一种被选择的“生物性衰老”机制，通过淘汰年老个体反而对种群有利。这一颠覆性观点为理解癌症的演化意义提供了全新视角，尽管其理论模型尚需更多实验生物学证据的支持。

---

## 61. 肿瘤抑制因子LACTB通过重塑线粒体促进细胞色素c释放与细胞凋亡

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223265](https://pubmed.ncbi.nlm.nih.gov/41223265)
**期刊：** Science advances
**PMID：** 41223265
**DOI：** 10.1126/sciadv.adx7809

### 第一部分 原文与翻译

**英文原标题：** The tumor suppressor LACTB remodels mitochondria to promote cytochrome c release and apoptosis.

**英文摘要原文：**
Mitochondria are pivotal regulators of cellular homeostasis, integrating energy metabolism, biosynthesis, and programmed cell death (apoptosis). During apoptosis, mitochondrial outer membrane permeabilization by BCL-2-associated X protein/BCL-2 Homolog Antagonist Killer (BAX/BAK) pores facilitates release of apoptotic factors, while the role of inner mitochondrial membrane (IMM) remodeling remains less understood. Here, we identify serine beta-lactamase-like protein (LACTB), a filament-forming serine protease and tumor suppressor, as a regulator of IMM dynamics during apoptosis. LACTB suppression reduces cytochrome c release and apoptosis, whereas its overexpression promotes these effects. LACTB does not affect BAX or Drp1 recruitment to mitochondria. Rather, LACTB is required for apoptosis-induced mitochondrial remodeling, independent of OPA1 processing. Intriguingly, LACTB knockdown does not affect mitochondrial shape changes induced by CCCP treatment, suggesting that LACTB action is apoptosis-specific. Purified LACTB binds and remodels cardiolipin-enriched membrane nanotubes preferentially over planar lipid membranes, suggesting a direct effect in apoptotic membrane remodeling. Collectively, our findings suggest LACTB to be a mediator of apoptosis-induced IMM remodeling, a possible mechanism for tumor suppression in cancer.

**中文摘要译文：**
线粒体是细胞稳态的关键调节器，整合了能量代谢、生物合成和程序性细胞死亡（凋亡）。在细胞凋亡过程中，由BCL-2相关X蛋白/BCL-2同源拮抗/杀手（BAX/BAK）孔道介导的线粒体外膜透化促进了凋亡因子的释放，而线粒体内膜（IMM）重塑的作用尚不明确。在此，我们发现丝氨酸β-内酰胺酶样蛋白（LACTB），一种形成丝状结构的丝氨酸蛋白酶和肿瘤抑制因子，是细胞凋亡过程中IMM动态的调节者。抑制LACTB可减少细胞色素c的释放和细胞凋亡，而其过表达则会促进这些效应。LACTB不影响BAX或Drp1向线粒体的招募。相反，LACTB是凋亡诱导的线粒体重塑所必需的，且独立于OPA1的加工过程。有趣的是，敲低LACTB并不影响由CCCP处理诱导的线粒体形态变化，这表明LACTB的作用具有凋亡特异性。纯化的LACTB能优先结合并重塑富含心磷脂的膜纳米管，而非平面脂质膜，这提示其在凋亡膜重塑中发挥直接作用。总而言之，我们的研究结果表明，LACTB是凋亡诱导的IMM重塑的介导者，这可能是其在癌症中发挥肿瘤抑制作用的一种可能机制。

### 第二部分 AI 大师评价

本研究旨在阐明肿瘤抑制因子LACTB在细胞凋亡中的新作用机制。研究通过基因抑制与过表达等细胞生物学方法，结合纯化蛋白与脂质膜的体外实验，发现LACTB通过直接重塑线粒体内膜来促进细胞色素c的释放与细胞凋亡。这一发现创新性地揭示了LACTB在凋亡特异性的线粒体内膜重塑中的关键作用，深化了对其抑癌机制的理解，并为开发靶向线粒体凋亡通路的抗癌新策略提供了重要理论依据。

---

## 62. 小核仁RNA通过对ESM1的表观遗传调控在小鼠成纤维样滑膜细胞中促进类风湿关节炎

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223251](https://pubmed.ncbi.nlm.nih.gov/41223251)
**期刊：** Science translational medicine
**PMID：** 41223251
**DOI：** 10.1126/scitranslmed.adt5340

### 第一部分 原文与翻译

**英文原标题：** snoRNA  promotes rheumatoid arthritis by epigenetic regulation of ESM1 in fibroblast-like synoviocytes in mice.

**英文摘要原文：**
Rheumatoid arthritis (RA) is a chronic autoimmune condition characterized by aggressive fibroblast-like synoviocytes (FLSs). Small nucleolar RNAs (snoRNAs), traditionally implicated in ribosome biogenesis, are now recognized as disease regulators. However, their involvement in RA-FLSs remains poorly understood. Here, we identified (), a specific snoRNA up-regulated by tumor necrosis factor-α and interleukin-17, as a key driver of the aggressive transformation of RA-FLSs in vitro. Using an FLS-specific aptamer-functionalized siRNA delivery system, we demonstrated that silencing  alleviated arthritic symptoms in collagen-induced arthritis (CIA) mice. Transcriptome analyses revealed that  up-regulated endothelial cell-specific molecule 1 (ESM1) by modulating the polycomb repressive complex 2 (PRC2)-mediated trimethylation of histone H3 at lysine-27 (H3K27me3), driving the aggressive transformation of RA-FLSs. Mechanistically, we found that  physically interacted with enhancer of zeste homolog 2 (EZH2) and competitively disrupted the association of EZH2 with retinoblastoma binding protein 4 within PRC2, thus diminishing the H3K27me3 mark on the  gene promoter to relieve the transcriptional repression of . We screened an ESM1-specific aptamer 04 (ESMA04) by systematic evolution of ligands by exponential enrichment, which neutralized ESM1 and inhibited the aggressive transformation of RA-FLSs in vitro. When administered either alone or in combination with a biologic disease-modifying antirheumatic drug, etanercept, ESMA04 demonstrated therapeutic efficacy in CIA mice. Overall, our findings identified -EZH2-ESM1 signaling as a driver of RA-FLS pathogenesis and underscored the promise of aptamer-based therapies for RA treatment.

**中文摘要译文：**
类风湿关节炎（RA）是一种以侵袭性成纤维样滑膜细胞（FLSs）为特征的慢性自身免疫性疾病。小核仁RNA（snoRNAs）传统上被认为参与核糖体的生物合成，但现在被认为是疾病的调节因子。然而，它们在RA-FLSs中的作用仍不甚明了。在本研究中，我们鉴定出一种由肿瘤坏死因子-α和白细胞介素-17上调的特异性snoRNA（），它是体外RA-FLSs侵袭性转化的关键驱动因素。利用一种FLS特异性的适体功能化siRNA递送系统，我们证明了沉默该snoRNA可以缓解胶原诱导性关节炎（CIA）小鼠的关节炎症状。转录组分析显示，该snoRNA通过调节多梳抑制复合物2（PRC2）介导的组蛋白H3赖氨酸27三甲基化（H3K27me3），上调了内皮细胞特异性分子1（ESM1）的表达，从而驱动了RA-FLSs的侵袭性转化。机制上，我们发现该snoRNA与zeste同源物增强子2（EZH2）发生物理相互作用，并竞争性地破坏PRC2内EZH2与视网膜母细胞瘤结合蛋白4的结合，从而减少ESM1基因启动子上的H3K27me3标记，解除了对ESM1的转录抑制。我们通过指数富集的配体系统进化技术筛选出一种ESM1特异性适体04（ESMA04），它能在体外中和ESM1并抑制RA-FLSs的侵袭性转化。无论是单独给药还是与生物性疾病修饰抗风湿药依那西普联合用药，ESMA04在CIA小鼠中均显示出治疗效果。总之，我们的研究结果确定了snoRNA-EZH2-ESM1信号通路是RA-FLS发病机制的一个驱动因素，并强调了基于适体的疗法在RA治疗中的应用前景。

### 第二部分 AI 大师评价

该研究旨在阐明一种特定小核仁RNA（snoRNA）在类风湿关节炎（RA）发病机制中的作用。研究团队结合体外细胞实验、胶原诱导性关节炎小鼠模型及转录组学分析，发现该snoRNA通过与EZH2相互作用，竞争性破坏PRC2复合物，从而解除对下游分子ESM1的表观遗传抑制，最终驱动了成纤维样滑膜细胞的侵袭性。此项工作的创新之处在于揭示了“snoRNA-EZH2-ESM1”这一全新的RA调控轴，并成功开发了针对该snoRNA的siRNA递送系统和中和ESM1的核酸适体，展示了其作为RA治疗新靶点和新策略的巨大转化医学价值。

---

## 63. 基于阳离子纳米凝胶的鼻用治疗性HPV疫苗可预防宫颈癌的发生

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223246](https://pubmed.ncbi.nlm.nih.gov/41223246)
**期刊：** Science translational medicine
**PMID：** 41223246
**DOI：** 10.1126/scitranslmed.ado8840

### 第一部分 原文与翻译

**英文原标题：** Cationic nanogel-based nasal therapeutic HPV vaccine prevents the development of cervical cancer.

**英文摘要原文：**
Therapeutic vaccines against cervical cancer caused by human papillomavirus (HPV) are still an unmet medical need, despite a prophylactic HPV vaccine being available, and the now-licensed systemic vaccines may have a limited effect on the reproductive tract. To specifically inhibit cervical cancer development, the concept of mucosal immunity based on the reproductive-respiratory axis was adopted to develop a nasal HPV therapeutic vaccine. We used a cationic nanogel for the nasal vaccine delivery system and targeted HPV16 E7, an oncoprotein in HPV-driven cervical cancer to demonstrate the feasibility of a nasal therapeutic vaccine. The vaccine was combined with cyclic di-adenosine monophosphate as a cell-mediated immunity-inducing adjuvant. Intranasal immunization with the nanogel vaccine induced E7-specific CD4 and CD8 T cells in mouse cervicovaginal tissue. An antitumor effect due to the infiltration of vaccine-induced E7-specific T cells was also observed in an orthotopic tumor model in mice. Furthermore, intranasal immunization of nonhuman primates with the nanogel vaccine using a spray device that is also applicable to humans induced E7-specific T cells in the reproductive tissues. Our findings demonstrated that this nasal therapeutic vaccine effectively controlled cervical cancer and will contribute to preclinical evidence for clinical testing in the near future.

**中文摘要译文：**
尽管已有预防性HPV疫苗，但由人乳头瘤病毒（HPV）引起的宫颈癌的治疗性疫苗仍是一个未被满足的医疗需求，且目前已获批的全身性疫苗对生殖道的效果可能有限。为特异性抑制宫颈癌的发生发展，本研究采用基于生殖-呼吸轴的黏膜免疫概念，开发了一种鼻用HPV治疗性疫苗。我们使用阳离子纳米凝胶作为鼻用疫苗递送系统，并靶向HPV驱动的宫颈癌中的癌蛋白HPV16 E7，以验证鼻用治疗性疫苗的可行性。该疫苗与环二腺苷酸（cyclic di-adenosine monophosphate）联合使用，后者作为一种诱导细胞介导免疫的佐剂。经鼻内接种该纳米凝胶疫苗可在小鼠宫颈阴道组织中诱导出E7特异性的CD4和CD8 T细胞。在小鼠原位肿瘤模型中，也观察到由疫苗诱导的E7特异性T细胞浸润所产生的抗肿瘤效应。此外，使用同样适用于人类的喷雾装置对非人灵长类动物进行鼻内免疫接种该纳米凝胶疫苗，可在其生殖组织中诱导出E7特异性的T细胞。我们的研究结果表明，这种鼻用治疗性疫苗能有效控制宫颈癌，并将为不久的将来进行临床试验提供临床前证据。

### 第二部分 AI 大师评价

本研究旨在开发一种新型鼻用治疗性HPV疫苗，以应对现有宫颈癌治疗手段的不足。研究团队巧妙地利用阳离子纳米凝胶作为递送载体，通过鼻腔给药靶向HPV16 E7癌蛋白，并成功在小鼠及非人灵长类动物的生殖道黏膜组织中诱导了特异性T细胞免疫应答。这项工作的创新之处在于开辟了通过呼吸道黏膜免疫来激发远端生殖道抗肿瘤效应的新途径，其在非人灵长类动物模型中的成功验证，为该疫苗进入临床试验提供了坚实的临床前证据，对宫颈癌的免疫治疗具有重要的转化价值。

---

## 64. 神经导航引导的聚焦超声在儿童弥漫性中线胶质瘤患者中开放血脑屏障

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223245](https://pubmed.ncbi.nlm.nih.gov/41223245)
**期刊：** Science translational medicine
**PMID：** 41223245
**DOI：** 10.1126/scitranslmed.adq6645

### 第一部分 原文与翻译

**英文原标题：** Blood-brain barrier opening with neuronavigation-guided focused ultrasound in pediatric patients with diffuse midline glioma.

**英文摘要原文：**
Focused ultrasound (FUS)-mediated blood-brain barrier (BBB) opening with microbubbles is an emerging technology that enables drug delivery for central nervous system diseases. To date, most clinical trials assessing BBB opening in adults were designed to deliver US with a frequency of one treatment over several weeks. Little is known about the feasibility of shorter intervals of US delivery or whether this can be achieved in a pediatric population using a mobile device. Here, FUS and panobinostat were shown to have additive therapeutic effects in a syngeneic orthotopic model of diffuse midline glioma (DMG). We then conducted a single-arm first-in-pediatric trial to investigate the safety and feasibility of delivering neuronavigation-guided FUS treatment in combination with oral panobinostat in children with relapsed DMGs. We included an intrapatient escalation of FUS delivery to assess the feasibility of opening multiple sites in the brain. We demonstrated successful BBB opening using neuronavigation-guided FUS as frequently as every 2 days. Magnetic resonance imaging with contrast was used to identify the region of BBB opening. Three patients were accrued; 22 FUS procedures were delivered for 1 NOTS (number of tumor sites) treated, and four FUS procedures were delivered for 2 NOTS. All three patients received 1 NOTS, without serious adverse events, and two of the patients received 2 NOTS, all without sedation. For 2 NOTS, prolonged BBB opening and one grade 5 event, unlikely related to FUS, were observed. This study demonstrates feasibility of FUS for BBB opening and drug delivery without sedation in pediatric patients.

**中文摘要译文：**
聚焦超声（FUS）联合微泡介导的血脑屏障（BBB）开放是一项新兴技术，可实现中枢神经系统疾病的药物递送。至今为止，大多数评估成人血脑屏障开放的临床试验设计的超声治疗频率为每数周一次。关于缩短超声治疗间隔的可行性，以及能否在儿童群体中使用便携式设备实现此目的，目前知之甚少。在本研究中，聚焦超声和帕比司他被证实在弥漫性中线胶质瘤（DMG）的同基因原位模型中具有协同治疗效果。随后，我们进行了一项单臂、首次在儿科开展的试验，旨在探究神经导航引导的聚焦超声联合口服帕比司他治疗复发性DMG患儿的安全性和可行性。我们纳入了患者内聚焦超声递送的递增方案，以评估开放大脑多个位点的可行性。我们证明了使用神经导航引导的聚焦超声能够成功开放血脑屏障，治疗频率可高达每两天一次。使用对比增强磁共振成像来确定血脑屏障开放的区域。共招募了三名患者；针对1个肿瘤部位（NOTS）进行了22次聚焦超声治疗，针对2个肿瘤部位进行了4次聚焦超声治疗。所有三名患者均接受了针对1个肿瘤部位的治疗，未发生严重不良事件；其中两名患者接受了针对2个肿瘤部位的治疗，所有治疗均在无镇静状态下完成。在针对2个肿瘤部位的治疗中，观察到血脑屏障开放时间延长和一个5级事件，但该事件与聚焦超声可能无关。本研究证明了在儿童患者中，应用聚焦超声在无镇静状态下开放血脑屏障并进行药物递送是可行的。

### 第二部分 AI 大师评价

本研究首次在儿童弥漫性中线胶质瘤（DMG）患者中，探索了利用神经导航引导的聚焦超声（FUS）技术开放血脑屏障以递送药物（帕比司他）的安全性与可行性。研究关键发现，该技术能以高频率（每两天一次）、在多个脑区成功开放血脑屏障，且整个过程无需对患儿进行镇静，展示了良好的耐受性。这项开创性的研究为DMG这一致死性儿童脑瘤提供了极具潜力的非侵入性治疗新策略，其在儿童群体中免镇静操作的可行性验证是其重大临床创新点。尽管样本量极小，但其作为概念验证研究，为后续更大规模的临床试验铺平了道路，具有重要的科研和临床转化价值。

---

## 65. 乳腺癌上皮-间质转化及转移器官向性中的3D基因组结构重排

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41223092](https://pubmed.ncbi.nlm.nih.gov/41223092)
**期刊：** eLife
**PMID：** 41223092
**DOI：** 10.7554/eLife.103697

### 第一部分 原文与翻译

**英文原标题：** Rearrangement of 3D genome organization in breast cancer epithelial to mesenchymal transition and metastasis organotropism.

**英文摘要原文：**
Human breast cancer cells exhibit organotropism during metastasis, showing preferential homing to certain organs such as bone, lung, liver, and brain. Spatial genome organization plays a crucial role in oncogenic transformation and progression, but the extent to which chromosome architecture contributes to organ-specific metastatic traits is unclear. This work characterizes chromosome architecture changes associated with organotropic metastatic traits. By comparing a collection of human genomic data from different subtypes of localized and lung metastatic breast cancer cells with both normal and cancerous lung cells, we find important trends of genomic reorganization. The most striking differences in 3D genome compartments segregate cell types according to their epithelial vs. mesenchymal status. This epithelial-mesenchymal transition (EMT) compartment signature occurs at genomic regions distinct from transcription-defined EMT signatures, suggesting a separate layer of regulation. Specifically querying organotropism, we find 3D genome changes consistent with adaptations needed to survive in a new microenvironment, with lung metastatic breast cancer cells exhibiting compartment switch signatures that shift the genome architecture to a lung cell-like conformation and brain metastatic prostate cancer cells showing compartment shifts toward a brain-like state. TCGA patient data reveals gene expression changes concordant with these organ-permissive compartment changes. These results suggest that genome architecture provides an additional level of cell fate specification informing organotropism and enabling survival at the metastatic site.

**中文摘要译文：**
人类乳腺癌细胞在转移过程中表现出器官向性，倾向于定植于特定器官，如骨、肺、肝和脑。空间基因组组织在致癌转化和进展中起着至关重要的作用，但染色体结构在多大程度上有助于器官特异性转移特征尚不清楚。本研究旨在阐明与器官向性转移特征相关的染色体结构变化。通过比较来自不同亚型的局限性乳腺癌细胞、肺转移性乳腺癌细胞以及正常和癌变肺细胞的人类基因组数据，我们发现了基因组重组的重要趋势。3D基因组区室中最显著的差异根据细胞的上皮或间质状态将细胞类型分离开来。这种上皮-间质转化（EMT）区室特征出现在与转录定义的EMT特征不同的基因组区域，表明存在一个独立的调控层面。在特异性探究器官向性时，我们发现3D基因组的变化与在新微环境中生存所需的适应性相一致，肺转移性乳腺癌细胞表现出区室转换特征，使其基因组结构转变为类似肺细胞的构象，而脑转移性前列腺癌细胞则显示出向类似脑细胞状态的区室转变。TCGA患者数据显示，基因表达的变化与这些器官容许性区室变化相一致。这些结果表明，基因组结构为细胞命运规范提供了额外的调控层面，从而影响器官向性并使其能够在转移部位存活。

### 第二部分 AI 大师评价

本研究旨在探索3D基因组结构在乳腺癌上皮-间质转化（EMT）及转移器官向性中的作用。研究通过比较不同来源细胞的基因组数据，创新性地发现3D基因组区室的重排与细胞的EMT状态密切相关，且这种变化独立于传统的转录调控。更为关键的是，研究揭示了转移性癌细胞的基因组结构会“模拟”靶器官细胞的构象以适应新的微环境，这一发现为理解肿瘤转移的器官选择性提供了全新的“结构生物学”视角，具有重要的科研价值和潜在的临床启示。

---

## 66. 泛细胞周期蛋白依赖性激酶抑制作为腺样囊性癌的潜在治疗策略：可下调MYB::NFIB融合并诱导肿瘤消退

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41222405](https://pubmed.ncbi.nlm.nih.gov/41222405)
**期刊：** Cancer communications (London, England)
**PMID：** 41222405
**DOI：** 10.1002/cac2.70079

### 第一部分 原文与翻译

**英文原标题：** Pan-cyclin-dependent kinase inhibition is a potential treatment for adenoid cystic carcinoma that downregulates the MYB::NFIB fusion and induces tumor regression.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究旨在探索泛细胞周期蛋白依赖性激酶（pan-CDK）抑制剂作为腺样囊性癌（ACC）治疗新策略的潜力。研究关键发现，该治疗方法能有效下调驱动ACC发展的关键致癌融合基因MYB::NFIB，并成功诱导肿瘤消退。这项工作不仅为缺乏有效疗法的腺样囊性癌提供了一个极具前景的治疗方向，还揭示了其背后的作用机制，具有重要的临床转化价值和科研意义。

---

## 67. 工程化病毒猎手疫苗克服乙肝病毒免疫耐受

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198172](https://pubmed.ncbi.nlm.nih.gov/41198172)
**期刊：** Gut
**PMID：** 41198172
**DOI：** 10.1136/gutjnl-2025-335806

### 第一部分 原文与翻译

**英文原标题：** Engineered virus-hunter vaccine overcomes HBV immune tolerance.

**英文摘要原文：**
BACKGROUND: Globally, an estimated 296 million individuals live with chronic hepatitis B virus (HBV) infection, carrying substantial risks of liver fibrosis, cirrhosis and hepatocellular carcinoma. Fewer than 20% of patients receiving nucleos(t)ide analogues or interferons achieve a functional cure, underscoring the urgent need for novel therapeutic strategies to improve clinical outcomes in patients with chronic HBV infection.

OBJECTIVE: The aim of this study was to develop a 'virus-hunter vaccine' that hijacks HBV antigens as endogenous immunogens, reprogramming dendritic cells (DCs) to prime anti-HBV immunity, ultimately achieving a durable functional cure beyond current therapeutic limitations.

DESIGN: We engineered the SHARP (Specific HBV Antigen-capturing and Rendering Promotor) vaccine platform, comprising a bispecific antibody targeting hepatitis B surface antigen (HBsAg) and DEC-205, conjugated with toll-like receptor 7/8 agonists. Therapeutic efficacy was assessed in chronic HBV carrier mice, with comprehensive investigation of immunological mechanisms.

RESULTS: Both SHARP variants demonstrated enhanced antigen phagocytosis, maturation and antigen presentation of DCs. Notably, SHARP-D265A (DA) emerged as the lead candidate due to its optimised Fc silencing, showing superior therapeutic efficacy with a lower anti-drug antibody incidence. SHARP treatment reversed the tolerogenic microenvironment through coordinated activation of HBV-specific CD4 and CD8 T cells and established durable viral control: HBsAg was below the limit of detection, accompanied by the appearance of anti-HBsAg, which was maintained for more than 161 days with established immune memory against rechallenge.

CONCLUSION: This innovative HBV vaccine strategy actively captures viruses, overcoming the tolerogenic immune microenvironment of chronic HBV infection, offering a novel strategy for the treatment of chronic HBV infection and other immune-tolerant diseases.

**中文摘要译文：**
背景：全球估计有2.96亿人患有慢性乙型肝炎病毒（HBV）感染，并因此面临着肝纤维化、肝硬化和肝细胞癌的巨大风险。接受核苷（酸）类似物或干扰素治疗的患者中，只有不到20%能实现功能性治愈，这凸显了开发新治疗策略以改善慢性HBV感染患者临床结局的迫切需求。

目的：本研究旨在开发一种“病毒猎手疫苗”，该疫苗能捕获HBV抗原作为内源性免疫原，重编程树突状细胞（DC）以启动抗HBV免疫，最终实现超越当前治疗局限的持久功能性治愈。

设计：我们工程化构建了SHARP（特异性HBV抗原捕获与呈递促进剂）疫苗平台，该平台由一个靶向乙肝表面抗原（HBsAg）和DEC-205的双特异性抗体与Toll样受体7/8激动剂偶联而成。我们在慢性HBV携带小鼠中评估了其治疗效果，并全面研究了其免疫学机制。

结果：两种SHARP变体均显示出能增强树突状细胞的抗原吞噬、成熟和抗原呈递能力。值得注意的是，由于其优化的Fc沉默效应，SHARP-D265A（DA）变体脱颖而出成为首选候选药物，它展现出更优的治疗效果和更低的反药物抗体发生率。SHARP治疗通过协同激活HBV特异性的CD4和CD8 T细胞，逆转了免疫耐受微环境，并建立了持久的病毒控制：HBsAg降至检测限以下，同时出现抗-HBsAg抗体，这种状态在建立起针对再次攻击的免疫记忆后，维持了超过161天。

结论：这种创新的HBV疫苗策略能主动捕获病毒，克服慢性HBV感染的免疫耐受微环境，为慢性HBV感染及其他免疫耐受性疾病的治疗提供了一种新策略。

### 第二部分 AI 大师评价

本研究旨在解决慢性乙肝难以治愈的核心问题——免疫耐受。研究团队巧妙地设计了一种名为SHARP的“病毒猎手疫苗”，它通过一个双特异性抗体平台捕获患者体内的乙肝病毒抗原，并将其特异性地递送给树突状细胞，从而将“敌人”（病毒）转化为激活自身免疫系统的“教官”。关键发现表明，该策略在小鼠模型中成功打破了免疫耐受，诱导了强效且持久的特异性T细胞和B细胞应答，实现了功能性治愈。这项研究的创新性极高，它将抗体药物、靶向递送和免疫激动剂融为一体，为打破慢性感染的免疫耐受提供了全新的、极具潜力的治疗范式。

---

## 68. 首次全基因组关联研究揭示特发性食管失弛缓症的免疫介导病因病理学

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136183](https://pubmed.ncbi.nlm.nih.gov/41136183)
**期刊：** Gut
**PMID：** 41136183
**DOI：** 10.1136/gutjnl-2024-334498

### 第一部分 原文与翻译

**英文原标题：** First genome-wide association study reveals immune-mediated aetiopathology in idiopathic achalasia.

**英文摘要原文：**
BACKGROUND: Idiopathic achalasia (IA) is characterised by the degeneration of neurons in the myenteric plexus leading to an irreversible impaired oesophageal function. Although immune-mediated mechanisms have been proposed, the underlying aetiopathology of IA remains poorly understood.

OBJECTIVE: This study aimed to uncover the genetic risk architecture of IA.

DESIGN: We carried out the first genome-wide association study (GWAS) on 4602 European patients with IA and 10 766 ethnically-matched controls.

RESULTS: A single nucleotide polymorphism (SNP) in  leading to an 8-amino acid insertion on the protein level conferred strongest IA risk (PQGPPPAG: p=3.27×10, OR=2.45). Conditional analyses within the HLA locus revealed a complex genetic risk architecture. Three additional amino acid positions showed independent IA association (Omnibus p<5×10). These refer to positions 41 and 130 in HLA-DQα1, position 45 in HLA-DQβ1 and position 86 in HLA-DRβ1. Together, these findings highlight the pivotal role of class II HLA genetic variation in IA pathogenesis. Outside HLA, three independent variants showed IA association (p<5×10). One leads to an amino acid substitution with functional effect in PTPN22. Another risk variant leads to a downregulated expression of ,  and  in immune cells. The third risk SNP is located near , but the exact underlying cellular mechanism remains unknown. Beyond the single marker level, polygenic risk scores revealed that patients with IA can be stratified based on their genetic risk. In addition, IA shows a shared aetiopathology with Crohn's disease (r=0.335). Integrating GWAS and single-cell RNA-sequencing data from the myenteric plexus showed that the memory T-cell type FOSTc4CD8 plays a central role in IA development (p=2.50×10).

CONCLUSION: This GWAS led to the identification of SNPs, cellular mechanisms and cell types that are involved in IA aetiopathology.

**中文摘要译文：**
背景：特发性食管失弛缓症（IA）的特征是肌间神经丛神经元变性，导致不可逆的食管功能损害。尽管已有研究提出免疫介导机制可能参与其中，但IA的潜在病因病理学仍知之甚少。

目的：本研究旨在揭示IA的遗传风险架构。

设计：我们对4602名欧洲IA患者和10766名种族匹配的对照者进行了首次全基因组关联研究（GWAS）。

结果：一个位于HLA-DQβ1基因中的单核苷酸多态性（SNP）导致蛋白质水平上8个氨基酸的插入，赋予了最强的IA风险（PQGPPPAG: p=3.27×10-153, OR=2.45）。HLA基因座内的条件分析揭示了一个复杂的遗传风险架构。另外三个氨基酸位置显示出独立的IA关联（综合p<5×10-8）。这些位置分别指HLA-DQα1的第41和130位、HLA-DQβ1的第45位以及HLA-DRβ1的第86位。这些发现共同凸显了II类HLA遗传变异在IA发病机制中的关键作用。在HLA区域之外，三个独立的变异体显示出与IA的关联（p<5×10-8）。一个变异导致PTPN22基因发生具有功能性影响的氨基酸替换。另一个风险变异导致免疫细胞中GSDMB、ORMDL3和ZPBP2的表达下调。第三个风险SNP位于POTEM附近，但其确切的潜在细胞机制尚不清楚。除了单个标记水平，多基因风险评分显示IA患者可根据其遗传风险进行分层。此外，IA与克罗恩病存在共同的病因病理学（rg=0.335）。整合GWAS和来自肌间神经丛的单细胞RNA测序数据表明，记忆T细胞亚型FOSTc4CD8在IA的发生发展中起核心作用（p=2.50×10-10）。

结论：本次GWAS成功识别了参与IA病因病理学的SNP、细胞机制和细胞类型。

### 第二部分 AI 大师评价

本研究是首次针对特发性食管失弛缓症（IA）开展的大规模全基因组关联研究（GWAS），旨在揭示其遗传风险架构。研究不仅成功定位到HLA区域内外的多个关键风险基因位点，特别是与II类HLA遗传变异的强关联，还有力证实了IA的免疫介导病理机制。其创新性在于首次系统阐明了IA的遗传学基础，并将记忆T细胞确定为关键致病细胞类型，为理解疾病发病机制、进行遗传风险分层以及未来开发靶向免疫治疗提供了颠覆性的见解和坚实的科学依据。

---

## 69. 戈沙妥珠单抗治疗未经治疗的晚期三阴性乳腺癌

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41124233](https://pubmed.ncbi.nlm.nih.gov/41124233)
**期刊：** The New England journal of medicine
**PMID：** 41124233
**DOI：** 10.1056/NEJMoa2511734

### 第一部分 原文与翻译

**英文原标题：** Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.

**英文摘要原文：**
BACKGROUND: Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not candidates for inhibitors of programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) have limited treatment options.

METHODS: In this international, phase 3, open-label, randomized trial, we enrolled patients with previously untreated, advanced triple-negative breast cancer who were not candidates for PD-1 or PD-L1 inhibitors owing to previous use or coexisting conditions. Patients had either PD-L1-negative tumors with a combined positive score (CPS; the number of PD-L1-staining tumor cells, lymphocytes, and macrophages divided by the total number of viable tumor cells, multiplied by 100) of less than 10 or PD-L1-positive tumors with a CPS of 10 or higher and were assigned in a 1:1 ratio to receive sacituzumab govitecan or chemotherapy (paclitaxel, nanoparticle albumin-bound paclitaxel, or gemcitabine plus carboplatin). The primary end point was progression-free survival, assessed by blinded independent central review. Secondary end points included overall survival, objective response, the duration of response, and safety.

RESULTS: Among 558 patients, median progression-free survival was 9.7 months (95% confidence interval [CI], 8.1 to 11.1) with sacituzumab govitecan and 6.9 months (95% CI, 5.6 to 8.2) with chemotherapy (stratified hazard ratio for disease progression or death, 0.62; 95% CI, 0.50 to 0.77; P<0.001). An objective response was confirmed in 48% of patients (95% CI, 42 to 54) who received sacituzumab govitecan and 46% (95% CI, 40 to 52) who received chemotherapy; the median response duration was 12.2 months (95% CI, 9.7 to 13.8) and 7.2 months (95% CI, 5.7 to 8.4), respectively. Adverse events of grade 3 or higher occurred in 66% of patients who received sacituzumab govitecan (most frequently neutropenia [in 43%], diarrhea [in 9%], and leukopenia [in 7%]) and in 62% of patients who received chemotherapy (most frequently neutropenia [in 41%], anemia [in 16%], and leukopenia [in 13%]). The incidence of adverse events that led to discontinuation of sacituzumab govitecan or at least one chemotherapy drug was 4% and 12%, respectively.

CONCLUSIONS: Sacituzumab govitecan led to significantly longer progression-free survival than chemotherapy among patients with advanced triple-negative breast cancer who were not candidates for treatment with PD-1 or PD-L1 inhibitors. The incidence of adverse events of grade 3 or higher with sacituzumab govitecan was similar to that with chemotherapy, but adverse events were common. (Funded by Gilead Sciences; ASCENT-03 ClinicalTrials.gov number, NCT05382299.).

**中文摘要译文：**
背景： 对于既往未经治疗、不适合使用程序性死亡蛋白1（PD-1）或程序性死亡配体1（PD-L1）抑制剂的局部晚期、不可切除或转移性三阴性乳腺癌患者，其治疗选择有限。

方法： 在这项国际性、3期、开放标签、随机试验中，我们招募了因既往用药或存在合并症而不适合使用PD-1或PD-L1抑制剂的未经治疗的晚期三阴性乳腺癌患者。入组患者的肿瘤为PD-L1阴性（联合阳性评分[CPS；PD-L1染色的肿瘤细胞、淋巴细胞和巨噬细胞数除以存活肿瘤细胞总数，再乘以100]小于10），或为PD-L1阳性（CPS为10或更高），并被以1:1的比例随机分配接受戈沙妥珠单抗或化疗（紫杉醇、白蛋白结合型紫杉醇，或吉西他滨联合卡铂）。主要终点是经盲化独立中心审查评估的无进展生存期。次要终点包括总生存期、客观缓解率、缓解持续时间及安全性。

结果： 在558名患者中，戈沙妥珠单抗组的中位无进展生存期为9.7个月（95%置信区间[CI]，8.1至11.1），化疗组为6.9个月（95% CI，5.6至8.2）（疾病进展或死亡的分层风险比为0.62；95% CI，0.50至0.77；P<0.001）。经确认的客观缓解率在戈沙妥珠单抗组为48%（95% CI，42至54），在化疗组为46%（95% CI，40至52）；中位缓解持续时间分别为12.2个月（95% CI，9.7至13.8）和7.2个月（95% CI，5.7至8.4）。戈沙妥珠单抗组有66%的患者发生3级或以上不良事件（最常见的是中性粒细胞减少症[43%]、腹泻[9%]和白细胞减少症[7%]），化疗组有62%的患者发生（最常见的是中性粒细胞减少症[41%]、贫血[16%]和白细胞减少症[13%]）。导致停用戈沙妥珠单抗或至少一种化疗药物的不良事件发生率分别为4%和12%。

结论： 在不适合使用PD-1或PD-L1抑制剂治疗的晚期三阴性乳腺癌患者中，与化疗相比，戈沙妥珠单抗可显著延长无进展生存期。戈沙妥珠单抗引起的3级或以上不良事件发生率与化疗相似，但不良事件普遍存在。（由吉利德科学公司资助；ASCENT-03 ClinicalTrials.gov注册号：NCT05382299。）

### 第二部分 AI 大师评价

该研究是一项关键的III期临床试验，旨在评估戈沙妥珠单抗（Sacituzumab Govitecan）在一线治疗不适用PD-1/PD-L1抑制剂的晚期三阴性乳腺癌（TNBC）患者中的疗效与安全性。研究明确证实，与标准化疗相比，戈沙妥珠单抗能显著延长患者的无进展生存期，为这一治疗选择有限的特定患者群体提供了强有力的循证医学证据。尽管3级以上不良事件发生率与化疗相当，但其总体可控，这一发现可能改变该类TNBC患者的一线治疗标准。

---

## 70. 无心力衰竭的心肌梗死患者在梗死后使用β受体阻滞剂

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40888716](https://pubmed.ncbi.nlm.nih.gov/40888716)
**期刊：** The New England journal of medicine
**PMID：** 40888716
**DOI：** 10.1056/NEJMoa2505985

### 第一部分 原文与翻译

**英文原标题：** Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.

**英文摘要原文：**
BACKGROUND: The evidence supporting beta-blocker therapy after myocardial infarction was established before the introduction of modern coronary reperfusion therapy and secondary prevention strategies.

METHODS: In an open-label, randomized trial with blinded end-point evaluation, conducted in Denmark and Norway, we assigned patients who had had a myocardial infarction and who had a left ventricular ejection fraction of at least 40%, in a 1:1 ratio, to receive long-term beta-blocker therapy within 14 days after the event or no beta-blocker therapy. The primary end point was a composite of death from any cause or major adverse cardiovascular events (new myocardial infarction, unplanned coronary revascularization, ischemic stroke, heart failure, or malignant ventricular arrhythmias).

RESULTS: A total of 5574 patients underwent randomization and were included in the main analyses - 2783 in the beta-blocker group and 2791 in the no-beta-blocker group. After a median follow-up of 3.5 years (interquartile range, 2.2 to 4.6), a primary end-point event had occurred in 394 patients (14.2%) in the beta-blocker group and in 454 patients (16.3%) in the no-beta-blocker group (hazard ratio, 0.85; 95% confidence interval [CI], 0.75 to 0.98; P = 0.03). Death from any cause occurred in 4.2% of the patients in the beta-blocker group and in 4.4% of those in the no-beta-blocker group; myocardial infarction occurred in 5.0% and 6.7%, respectively (hazard ratio, 0.73; 95% CI, 0.59 to 0.92), unplanned coronary revascularization in 3.9% and 3.9%, ischemic stroke in 1.6% and 1.3%, heart failure in 1.5% and 1.9%, and malignant ventricular arrhythmias in 0.5% and 0.6%. No apparent differences in safety outcomes were observed between the groups.

CONCLUSIONS: Among patients with a myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blocker therapy led to a lower risk of death or major adverse cardiovascular events than no beta-blocker therapy. (Funded by the Health South-East research program in Norway and others; BETAMI-DANBLOCK ClinicalTrials.gov numbers, NCT03646357 and NCT03778554.).

**中文摘要译文：**
背景：支持心肌梗死后使用β受体阻滞剂治疗的证据是在现代冠状动脉再灌注治疗和二级预防策略引入之前建立的。

方法：在一项于丹麦和挪威进行的开放标签、随机、终点盲法评估试验中，我们将发生过心肌梗死且左心室射血分数至少为40%的患者，按1:1的比例随机分配，在事件发生后14天内接受长期β受体阻滞剂治疗或不接受β受体阻滞剂治疗。主要终点是全因死亡或主要不良心血管事件（新发心肌梗死、非计划性冠状动脉血运重建、缺血性卒中、心力衰竭或恶性室性心律失常）的复合终点。

结果：共有5574名患者被随机分组并纳入主要分析——β受体阻滞剂组2783人，无β受体阻滞剂组2791人。中位随访3.5年（四分位距为2.2至4.6年）后，β受体阻滞剂组有394名患者（14.2%）发生主要终点事件，而无β受体阻滞剂组有454名患者（16.3%）发生主要终点事件（风险比为0.85；95%置信区间[CI]为0.75至0.98；P = 0.03）。β受体阻滞剂组的全因死亡率为4.2%，无β受体阻滞剂组为4.4%；心肌梗死发生率分别为5.0%和6.7%（风险比为0.73；95% CI为0.59至0.92），非计划性冠状动脉血运重建发生率分别为3.9%和3.9%，缺血性卒中分别为1.6%和1.3%，心力衰竭分别为1.5%和1.9%，恶性室性心律失常分别为0.5%和0.6%。两组间的安全性结局未观察到明显差异。

结论：在心肌梗死且左心室射血分数至少为40%的患者中，与不使用β受体阻滞剂相比，使用β受体阻滞剂治疗可降低死亡或主要不良心血管事件的风险。（由挪威东南卫生研究项目等资助；BETAMI-DANBLOCK ClinicalTrials.gov 注册号：NCT03646357 和 NCT03778554。）

### 第二部分 AI 大师评价

本研究旨在现代冠脉再灌注和二级预防策略的背景下，重新评估β受体阻滞剂对无心力衰竭的心肌梗死患者的长期疗效。通过一项大规模、开放标签、终点盲法评估的随机对照试验，研究发现对于左心室射血分数保留（≥40%）的患者，使用β受体阻滞剂能显著降低全因死亡或主要不良心血管事件的复合风险。这项发表于《新英格兰医学杂志》的研究结果，为在现代治疗体系下继续使用β受体阻滞剂提供了强有力的证据，解决了心脏病学领域一个长期存在的临床疑问，对更新临床指南具有重要价值。

---

## 71. 针对HbSC病及其他复合杂合性镰状血红蛋白病的基因治疗：是时候将其纳入了

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40834880](https://pubmed.ncbi.nlm.nih.gov/40834880)
**期刊：** Blood
**PMID：** 40834880
**DOI：** 10.1182/blood.2025029964

### 第一部分 原文与翻译

**英文原标题：** Gene therapy for HbSC disease and other compound heterozygous sickle hemoglobinopathies: a time for inclusion.

**英文摘要原文：**
Two gene therapy products have been approved by the US Food and Drug Administration for sickle cell disease. Nearly all patients in the clinical trials that led to approval either were sickle hemoglobin (HbS) gene homozygotes (sickle cell anemia) or had HbS-β0 thalassemia. HbSC disease, caused by compound heterozygosity for HbS and hemoglobin C genes, is the second most common genotype of sickle cell disease. Gene therapy has not been tested in patients with HbSC disease who are severely symptomatic. We discuss the pathophysiology and clinical features of HbSC disease and how gene therapy is likely to provide a curative option for some individuals. We also discuss the mechanism through which fetal hemoglobin (HbF) and HbF-like HbA (HbAT87Q) might mitigate adverse clinical outcomes and end-organ damage in patients with HbSC disease and other compound heterozygous sickle hemoglobinopathies.

**中文摘要译文：**
已有两种基因治疗产品获美国食品药品监督管理局批准用于治疗镰状细胞病。在促成这些产品获批的临床试验中，几乎所有患者均为镰状血红蛋白（HbS）基因纯合子（镰状细胞性贫血）或HbS-β0地中海贫血患者。由HbS和血红蛋白C基因复合杂合性引起的HbSC病，是镰状细胞病中第二常见的基因型。对于有严重症状的HbSC病患者，尚未进行基因治疗的测试。我们探讨了HbSC病的病理生理学和临床特征，以及基因治疗如何可能为部分患者提供一种治愈性选择。我们还讨论了胎儿血红蛋白（HbF）和类HbF的HbA（HbAT87Q）在HbSC病及其他复合杂合性镰状血红蛋白病患者中，可能用于减轻不良临床结局和终末器官损害的作用机制。

### 第二部分 AI 大师评价

这篇前瞻性综述明确指出了当前镰状细胞病基因治疗临床试验中的一个关键空白，即忽略了第二常见的HbSC基因型。文章通过阐述HbSC病的病理生理学特征，论证了现有基因治疗（如诱导HbF或HbAT87Q表达）同样适用于该患者群体的理论基础。该文的创新价值在于，它不仅是一篇科学论述，更是一份强有力的政策倡导，旨在推动临床研究的包容性，有望将革命性的治愈方案扩展至更多被忽视的患者，具有重要的临床指导意义和伦理价值。

---

## 72. “劫持”造血系统：低频JAK2V617F克隆驱动骨髓增殖性肿瘤的病理进程

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40729727](https://pubmed.ncbi.nlm.nih.gov/40729727)
**期刊：** Blood
**PMID：** 40729727
**DOI：** 10.1182/blood.2024027125

### 第一部分 原文与翻译

**英文原标题：** HiJAKing the hematopoietic system: a low-frequency JAK2V617F clone drives myeloproliferative neoplasm pathology.

**英文摘要原文：**
JAK2V617F is one of the most common mutations in clonal hematopoiesis of indeterminate potential (CHIP) and a major driver of myeloproliferative neoplasms (MPNs). To determine the impact of a low-frequency JAK2V617F clone on both the hematopoietic system and the bone marrow (BM) stroma, we developed a traceable murine MPN model, in which whole BM transplantation (BMT) was performed using CD45.2 5.0 × 106 JAK2V617F donor cells transplanted into unconditioned CD45.1 recipient mice. BMT recipients developed a polycythemia vera-like phenotype (elevated hematocrit and leukocytosis) with a 2.7% average donor cell chimerism in peripheral blood. Eight months after BMT, RNA sequencing (RNA-seq) analysis of BM cells sorted according to CD45.1/CD45.2 expression showed significant upregulation of early erythroblast- and myeloid cell-specific transcripts, and downregulation of lymphoid transcripts in donor-derived cells compared to controls. Surprisingly, recipient-derived cells also showed upregulation of myeloid- and erythroblast-related transcripts, indicating a skewing of the non-JAK2V617F-carrying recipient hematopoietic system toward an MPN-like phenotype. In addition, RNA-seq analysis of the BM stroma from JAK2V617F BMT recipients indicated significant loss of osteomesenchymal transcripts. Consistently, micro-computed tomography imaging indicated loss of trabecular bone. In sum, our results indicate that low-frequency MPN-driving cells in unconditioned recipients not only impact hematopoiesis-supporting stroma but also profoundly influence unmutated cells, uniquely altering their transcriptomic and phenotypic profiles. These observations are challenging our current understanding of the etiology and therapeutic approaches to MPNs and other CHIP-associated diseases.

**中文摘要译文：**
JAK2V617F是意义未明的克隆性造血（CHIP）中最常见的突变之一，也是骨髓增殖性肿瘤（MPNs）的主要驱动因素。为确定低频JAK2V617F克隆对造血系统和骨髓（BM）基质的影响，我们开发了一种可追踪的小鼠MPN模型，在该模型中，我们将CD45.2表型的5.0 × 10^6个JAK2V617F供体细胞移植到未经预处理的CD45.1受体小鼠体内，进行了全骨髓移植（BMT）。BMT受体小鼠表现出真性红细胞增多症样表型（血细胞比容升高和白细胞增多），外周血中供体细胞的平均嵌合率为2.7%。BMT八个月后，对根据CD45.1/CD45.2表达分选的骨髓细胞进行的RNA测序（RNA-seq）分析显示，与对照组相比，供体来源的细胞中，早期幼红细胞和髓系细胞特异性转录本显著上调，而淋巴系转录本则下调。令人惊讶的是，受体来源的细胞也显示出髓系和幼红细胞相关转录本的上调，表明未携带JAK2V617F突变的受体造血系统也向MPN样表型发生了偏斜。此外，对JAK2V617F BMT受体小鼠骨髓基质的RNA-seq分析表明，骨间充质转录本显著丢失。与此一致，微计算机断层扫描成像显示骨小梁丢失。总而言之，我们的研究结果表明，在未经预处理的受体中，低频的MPN驱动细胞不仅影响支持造血的基质，还深刻地影响了未突变的细胞，独特地改变了它们的转录组和表型特征。这些发现对我们目前关于MPNs及其他CHIP相关疾病的病因学和治疗方法的理解提出了挑战。

### 第二部分 AI 大师评价

本研究通过构建一种新颖的可追踪小鼠模型，精妙地揭示了极低频率的JAK2V617F突变克隆对机体的深远影响。核心发现是，即使极少量的突变细胞（约2.7%）不仅能驱动典型的骨髓增殖性肿瘤表型，还能“教唆”正常的、未突变的造血细胞向疾病表型转化，并重塑骨髓微环境，导致骨质流失。这项研究的创新之处在于证实了MPN驱动突变的非细胞自主效应，颠覆了对克隆性造血疾病启动机制的传统认知，对理解CHIP向MPN的转化具有重大意义，并为开发靶向微环境的早期干预策略提供了新的理论依据。

---

速递结束，祝您工作愉快！